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Abstract  
  
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown aetiology, characterised by 
the progressive and irreversible scarring of parenchymal lung tissue that leads to 
respiratory failure and death. The disease is understood to be driven by an impaired and 
aberrant wound healing response, with an inappropriate reactivation of developmental 
signalling. The greatest risk factor for the disease is age, which is a process intimately 
associated with an increase in the burden of senescent cells. Such cells acquire a unique 
secretory phenotype and are known to have a significant impact on their local 
microenvironment.   
  
It was hypothesised that an alteration in epithelial-mesenchymal secretory 
communication, due to senescent-like changes in the fibroblast phenotype, may 
detrimentally contribute to lung homeostasis.  An in vitro model of the lung airway was 
established in which primary human lung fibroblasts (HLFs) were co-cultured with 
human bronchial epithelial cells (HBECs). HBECs were cultured on a semi-permeable, 
transwell insert and co-cultured with either normal (NHLF), fibrotic (FHLF) or senescent 
fibroblasts. Over 72 hrs of co-culture, wound healing was assessed, via an epithelial 
scratch assay, and epithelial regeneration was measured, via trans-epithelial electrical 
resistance.   
  
Co-culture with NHLFs improves epithelial regeneration, however, FHLFs and senescent 
cells in co-culture show a diminished ability to promote epithelial regeneration and 
wound repair. The secretory repertoire of these cells contains elevated levels of IL-6, 
CXCL8, CXCL1 and GCSF (when assessed at both an RNA and protein level), factors 
strongly associated with the senescent phenotype. Targeting this secretome via 
treatment with the JAK 1/2 inhibitor Ruxolitinib attenuates these impairments and may 
point towards a new therapeutic strategy for the treatment of IPF.   
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HGF  Hepatocyte growth factor  
HLF  Human lung fibroblast  
HOPX  HOP homeobox  
HPLC  High-performance liquid chromatography  
HRCT  High-resolution computed tomography  
HSC  Hepatic stellate cells  
ID2  Inhibitor of DNA binding-2  
IIP  Idiopathic interstitial pneumonias  
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IL-1β  Interleukin 1-beta  
IL-6  Interleukin-6  
IPF  Idiopathic pulmonary fibrosis  
ITGA6  Integrin subunit alpha-6  
JAK  Janus Kinase  
KGF  Keratinocyte growth factor  
KRT14  Keratin-14  
KRT5  Keratin-5  
LN2  Liquid nitrogen  
LOXL2  Lysyl hydroxylase-2  
LPS  Lipopolysaccharide  
MAPK  Mitogen-activated protein kinase  
MDM2  E3 ubiquitin-protein ligase  
MFI  Median fluorescent intensity  
MMP  Matrix metalloproteinase  
mtDNA  Mitochondrial DNA  
mTOR  Mammalian target of Rapamycin  
MUC5AC  Mucin 5ac  
NF-κB  Nuclear factor kappa-B  
NGFR  Nerve growth factor receptor  
NHLF  Normal human lung fibroblast  
NK  Natural killer  
NKX2.1  NK2 homeobox-1   
NOX  NADPH oxidase  
OD  Optical density  
OIS  Oncogene-induced senescence  
OSKM  Oct4, Sox2, Klf4, cMyc  
PAI-1  Plasminogen activator inhibitor-1  
PDGFRA  Platelet derived growth factor receptor-alpha  
PDPN  Podoplanin  
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PFA  Paraformaldehyde  
PGE2  Prostaglandin E2  
PINK1  PTEN-induced putative kinase-1  
PMK  Primary mouse keratinocytes  
pSTAT-3  phosphorylated STAT-3  
PTGDS  Prostaglandin D synthase  
PZ  Progress zone  
RB  Retinoblastoma protein  
RCN  Relative cell number  
RCT  Randomised control trial  
RD&E  Royal Devon and Exeter Hospital  
ROS  Reactive oxygen species  
RTE  Trans-epithelial electrical resistance   
RT-qPCR  
Reverse transcription - quantitative polymerase chain 
reaction  
SADS  Senescence-associated distension of satellites  
SAHF  Senescence-associated heterochromatic foci  
SASP  Senescence-associated secretory phenotype  
SA-βgal  Senescence-associated beta-galactosidase   
SCGB1A1  Secretoglobin family 1A member 1  
SDS  Sodium dodecyl sulphate  
SDS  Standard deviation  
SEM  Standard error of mean  
SFTP  Surfactant protein  
SHH  Sonic hedgehog  
SIPS  Stress-induced premature senescence  
SMG  Submucosal glands  
SOX2  SRY-box 2  
SOX9  SRY-box 9  
SRY  Sex-determining region Y  
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STAT-3  Signal transducer and activator of transcription-3  
TAZ  Transcriptional coactivator with PDZ-binding motif  
TERT  Telomerase reverse transcriptase  
TGF-β  Transforming growth factor beta  
TMRE  Tetramethylrhodamine, ethyl ester   
TNF-α  Tumour necrosis factor-alpha  
TRP63  Transformation related protein-63  
TUBB6  Tubulin beta-6  
UIP  Usual interstitial pneumonia   
VEGF  Vascular endothelial growth factor  
VIM  Vimentin  
WNT  Wingless-type MMTV integration site family  
WISP1  WNT1-inducible signalling protein-1  
YAP  Yes-associated protein-1  
ZO-1  Zonula occludens-1  
αMEM  alpha-minimum essential medium  
αSMA  alpha-smooth muscle actin  
Δp  Proton motive force  
Δψm  Mitochondrial membrane potential   
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1. Introduction  
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Idiopathic pulmonary fibrosis (IPF) is a disease of unknown aetiology, characterised by 
progressive and irreversible scarring of the parenchymal lung tissue, leading to 
respiratory failure and death. The disease is understood to be driven by an inappropriate 
reactivation of developmental signalling and an impaired and aberrant wound healing 
response, set against the backdrop of an ageing lung. Fundamental to the processes of 
development, repair, and maintenance of tissue function, is the relationship between 
the epithelium and the mesenchyme. This relationship is thought to be key to the 
pathology of IPF and understanding it can help better elucidate some of the driving 
forces of the disease. This introduction aims to outline the numerous roles of 
epithelialmesenchymal crosstalk in basic lung physiology, covering development, 
homeostasis and repair, moving then to an examination of the pathology of IPF and the 
key characteristics of the disease. The roles of crosstalk and the characteristics of IPF will 
then converge on the phenomenon of cellular senescence, highlighting its possible role 
in the pathology of IPF.   
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 1.1  Epithelial-mesenchymal Crosstalk in Lung Physiology  
  
The key to any good relationship is communication; the relationship between cell types 
of the lung is no exception.   
  
A cell’s function and behaviour is dictated by its local micro-environment. This 
environment can be determined by the cell itself, producing proteins that function in an 
autocrine manner, and also by communication with its neighbours. This ‘crosstalk’ is a 
paracrine mechanism of cell communication that is important to numerous physiological 
processes. An important example of crosstalk is the relationship between the epithelium 
and the mesenchyme. This relationship facilitates the development of the lung during 
gestation, maintains homeostasis of the adult airways and contributes heavily to the 
processes of repair.   
  
By investigating crosstalk in these processes, it is possible to gain, not just an insight into 
intercellular communication, but also to the overall physiology of the lung, 
encompassing its structure, organisation and function. Likewise, what becomes 
apparent when looking at these aspects of physiology is that core communicatory 
pathways exist, with the same pathways functioning across a diverse range of roles. This 
section will set out to expatiate the processes of lung development, homeostasis and 
repair, exemplifying the role of crosstalk whilst giving a more general overview of the 
lungs.   
  
1.1.1. Development of the Lung  
  
Embryogenesis  
The lung begins to develop relatively late in the human embryo, starting 4-5 weeks into 
gestation. The process begins with mesenchymal mesodermal cells signalling to ventral, 
epithelial endodermal cells on the anterior foregut, producing factors such as bone 
morphogenic protein-4 (BMP4) and Wingless-type MMTV integration site family (WNT) 
2/2B, which specify commitment to a lung cell fate. Endodermal cells become 
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committed by expression of the transcription factor NK2 homeobox-1 (NKX2.1) and from 
this cohort of cells, over the next 35 weeks, the respiratory tree develops, going on to 
contain the complete repertoire of cells for the fully functioning, adult lung 1,2.   
  
The pseudoglandular phase  
Ventral mesodermal cells promote the budding of Nkx2.1+ endodermal cells giving rise 
to the nascent trachea and bronchi (Figure 1.1.1.) 3. Once separated from the developing 
oesophagus, the lung transitions from this early embryonic stage into the 
pseudoglandular stage. During this period the extensive respiratory tree is formed in a 
process of branching morphogenesis. This process is elicited by three geometrical modes 
of branching, which creates a highly stereotypic structure 4. Such patterning is again 
largely dictated by the surrounding mesoderm. Mesenchymal cells expressing the 
mitogen, fibroblast growth factor-10 (FGF10), promote the proliferation of epithelial 
cells whilst also dictating the direction of their growth 5,6. Regulation occurring 
downstream of FGF10, co-ordinates mitotic spindle orientation and promotes directed 
division in a distal direction, extending the respiratory network 7. Likewise, fibronectin 
laid down by the mesoderm interacts with epithelial β1 integrins, promoting planar 
growth and preventing epithelial multilayering 8. The strength of FGF10 signalling is 
greatest at the distal ends of the advancing airways and the pattern of its expression is 
crucial for morphogenesis. Endodermal crosstalk, involving sonic hedgehog (SHH) and 
BMP4, restricts mesodermal Fgf10 expression 5,6. This acts as an inhibitor of endodermal 
growth. In adjacent endoderm growth is not inhibited thereby allowing a process of 
branching.   
  
Commitment to cell fate  
Early in lung development cells of the endoderm are further committed to distinct 
lineages, occurring in a proximal-distal manner 9. As the strength of FGF10 signalling is 
lost in the more proximal regions of the airways, sex-determining region Y (SRY)-box 2 
(Sox2) expression is enabled in the epithelium. This creates and commits cells to a 
lineage that will give rise to the conducting portion of the developed airway. Reduced   
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WNT signalling facilitates this increase in SOX2 activity, which leads to inhibition of 
branching 10. This is, in part, due to a pre-emptive induction of differentiation pathways 
that make the cells refractory to branching signals 11.  Conversely, at the distal, budding 
regions of the airway, cells establish expression of SRY-box 9 (Sox9) and inhibitor of DNA 
binding-2 (Id2), leading to a population of cells that act as progenitor for the gas 
exchange (or respiratory) portion of the lung (Figure 1.1.2.) 12. SOX9 also further 
regulates distal branching and its loss leads to numerous defects in epithelial 
cytoskeletal arrangement and extracellular matrix (ECM) organisation, with perturbed 
transcriptional regulation of collagen type II, α-1 (COL2A1) 13.   
  
The canalicular phase  
As the process of branching morphogenesis nears completion the developing lung enters 
the canalicular stage. During this stage, mesodermal signalling promotes the further 
differentiation of Sox9+/Id2+ progenitors into the two alveolar cell types. This is 
discernible by the appearance of two, distinct epithelial transcriptional profiles. Type I 
alveolar epithelial cells (AEC1s) arise, expressing HOP homeobox (Hopx) and Podoplanin 
(Pdpn), developing alongside surfactant protein A-C (SftpA-C) expressing type II alveolar 
epithelial cells (AEC2s) 14. This stage also involves a greater association of the epithelium 
with the underlying vasculature and a narrowing of airway tubules. The mesodermal 
signals that drive this process have yet to be entirely elucidated. Temporal glucocorticoid 
signalling has been shown to be important in mouse, as has FGF signalling, with FGF-
induced branching morphogenesis antagonising alveolar differentiation via the GTPase 
Kras 15,16 .   
  
The saccular phase  
There is quick succession from the canalicular stage to the saccular stage, a stage in 
which the distal tubules bud into a series of sacs, each of which is intimately associated 
with the surrounding vasculature (Figure 1.1.3.). The extensive surface area of the 
epithelial-endothelial interface of the lung is achieved during this stage by the formation 
of primary septa, which give rise to the alveoli. Mesenchymal cells migrate into the walls 
of the distal airway, subdividing the alveoli into numerous compartments. These  
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mesenchymal cells arise from a common mesodermal progenitor termed 
cardiopulmonary progenitors (CPP). These ventrally located cells are identified by 
Wnt2/Gli1/Isl1 expression and are regulated via SHH signalling. They give rise to both 
vascular and airway smooth muscle cells, pericytes and proximal endothelia 17. Not  only 
this, but they contribute to the generation of cardiomyocyte and endocardial cells. CPPs 
appear to lose their multipotency as gestation draws to a close and the continued role 
of this cell lineage in the adult lung remains to be elucidated. Their role in the saccular 
stage however is important, for both the structural and the functional development of 
the epithelium.   
  
Alveologenesis  
Postnatally, the process of alveolar development continues, with alveologenesis 
occurring several months post-term in humans. It is facilitated by further mesenchymal 
infiltration, by cells that migrate and differentiate into fibroblasts, myofibroblasts and 
lipofibroblasts. Myofibroblasts further define alveolar septation by depositing elastin at 
the tips of the alveolar walls (Figure 1.1.4.) 18. The function of these myofibroblasts is 
under the control of SHH signalling. At the early stages of post-natal alveologenesis SHH 
promotes myofibroblast proliferation and differentiation, giving rise to Gli1+/Acta2+ 
cells. Inhibition of SHH signalling during this period results in enlarged alveoli, lacking 
secondary septa. Importantly though, with the completion of septal definition there is a 
decrease in SHH signalling and reduction in alveolar myofibroblast number 19.   
  
The resultant ECM scaffolding in the alveoli integrates with an extensive, interlinking 
network of connective tissue fibres. These fibres provide not only structure, but allow 
the appropriate distribution of tensile stress, allowing even conductance of air into the 
alveoli 20. Collagen is the predominating fibre in this network, which has a three-category 
hierarchy. Axial fibres sheath the respiratory tree from the large airways to the alveolar 
ducts, peripheral fibres, emanating from the visceral pleura, penetrate into the 
parenchyma where they are connected to axial fibres by septal fibres, which are 
continuous throughout the interalveolar space and form the alveolar walls 21.    
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Around two-four years after the birth, these developmental pathways will have enabled 
the generation of around 300 million alveolar units, creating a gas exchange surface of 
roughly 70 m2 22. The development of the lung is a masterclass in inter-cellular 
communication, most notably between the mesenchymal mesoderm and epithelial 
endoderm. The crosstalk required to orchestrate this development continues to find 
prominence throughout an adults’ life, contributing to both the maintenance of normal 
lung homeostasis, as well as co-ordinating the lungs response to injury.   
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1.1.2. Maintaining lung homeostasis  
  
The processes of development generate a complex tree of respiratory airways. Broadly, 
these airways can be categorised into two regions, the conducting airways, involved in 
the movement of air, and the respiratory airways, involved in facilitating gas exchange 
(Figure 1.1.5.) 23. The conducting airways begin at the trachea, which descends distally, 
undergoing around 23 generations of branching, giving rise to the bronchi, bronchioles 
and the terminal/transitional bronchioles. The respiratory airways consist of respiratory 
bronchioles, which combine conductance with gas exchange, alveolar ducts and alveolar 
sacs, where half of all alveolar units reside. Maintaining the function of these airways, 
even under a steady state, requires constant crosstalk. This section will set out to explore 
the mechanisms and cell-cell relationships that facilitate this.   
  
1.1.2.1. The tracheobronchial airways  
The dichotomy of roles in the airways is reflected in the differing cell types, and differing 
structure, of the conducting and respiratory regions of the lung. Regarding the 
epithelium, the proximal airways of the trachea and bronchi are populated by a thick, 
pseudostratified columnar layer composed of several cell types, all arising from 
developmental, Sox2 expressing endodermal cells (Figure 1.1.6.) 24,25.   
  
Mucosal cells  
A crucial role of this epithelial layer is host defence. Mucin 5ac (Muc5ac) expressing 
mucosal (goblet) cells, along with forkhead box protein J1 (Foxj1) and tubulin β-6   
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(Tubb6) expressing multiciliated cells are key to this. These two populations of cells make 
up the majority of the tracheobronchial epithelium. Mucosal cells are responsible for 
the elaboration of airway surface liquid (ASL), which coats the upper airways and 
protects the lungs from inhaled particles and micro-organisms. It also maintains immune 
homeostasis and can modulate macrophage function in response to infection 26. The 
large glycoproteins, MUC5AC and MUC5B, are important ASL components and their 
diverse and extensive range of carbohydrate sequences acts to sequester dangerous 
inhalants 27. Secretoglobin family 1A member 1 (Scgb1a1) expressing club cells, and 
secretory cells of the tracheal submucosal glands (SMG), are also important sources of 
mucin production 28,29.  
  
Multiciliated cells  
The removal of substances trapped in the ASL is achieved by its continuous transport out 
of the trachea and into the oesophagus. This can be elicited by cough but also the 
repetitive and co-ordinated beating of cilia, flagella-like projections situated on the 
apical surface of multiciliated cells. These cells have around 250 cilia each, which can 
beat at around 1,000 bpm. Cilia do not make contact with the viscous mucus and are 
instead bathed in a low viscosity, watery fluid called the periciliary liquid layer. This 
underlies the mucus layer and makes repetitive beating less energy demanding 30.   
  
Immune-modulating cells  
Other tracheobronchial cell types that are less numerous but also important in host 
defence include neuroendocrine cells and tuft cells. Pulmonary neuroendocrine cells are 
found in isolation or in groupings of cells called neuroepithelial bodies. These cells are 
part of the diffuse neuroendocrine system. Nervous innervation occurs at the base of 
these cells whilst, at the apical surface, they protrude microvilli into the luminal space. 
They can also secrete numerous amines and peptides that can co-ordinate the airway 
immune response 31. Tuft cells (also known as brush cells) function as solitary 
chemosensory cells, responding particularly to secreted bacterial compounds, activating 
innate response to potential infection 32.   
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Basal cells  
Underlying the pseudostratified epithelium, in a near continuous layer, is a population 
of basal cells (BCs). BCs are a multipotent stem cell characterised by the expression of 
transformation related protein-63 (Trp63), keratin-5 (Krt5) and, additionally in humans, 
nerve growth factor receptor (NGFR) and integrin subunit α6 (ITGA6). They make up 
roughly 20-30% of proximal airway cells, becoming less numerous and more disperse in 
a distal direction and they are also found at the base of SMGs in the upper trachea. BCs 
have the ability to maintain cell turnover in the steady state lung and also repopulate 
the airway in response to injury 33,34. Within the BC population different subsets can also 
be defined 35. For example, SMG-located BCs are able to give rise to duct and tubular 
cells, as well as airway epithelial cells 36. Another subset of keratin-14 (Krt14) expressing 
BC also exist, which make up around 20% of the epithelial BC population 37. These are a 
facultative progenitor that are unipotent in the normal epithelium, becoming activated 
and multipotent only in response to injury 38.   
  
The mesenchyme  
Below this epithelial surface is a population of fibroblasts and airway smooth muscle 
cells, believed to be primarily of a common CPP lineage, as well as nerve endings, 
vasculature and, in the trachea, cartilaginous rings. These cells provide structural as well 
as trophic support, an example of which is parabronchial smooth muscle cell secretion 
of FGF10 39. Roles such as this are an important facet of lung cell communication, and 
many more examples can be found in the proximal airways.   
  
1.1.2.2. Maintaining the proximal airways  
Maintenance of the steady state tracheobronchial airway requires careful co-ordination 
of inter-cellular communication, through both paracrine and autocrine signalling as well 
as cell-cell and cell-matrix interactions. Cell turnover in the lung is slow in comparison to 
other organs (although it does occur with consistency) and most cells can be found in a 
quiescent state 40.   
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Crosstalk is key to maintaining this quiescence and preventing unwanted differentiation 
(especially in progenitor cells) with several pathways regulating identified. 3dimensional 
(3D) tracheospheres, a model assay of the pseudostratified epithelium, demonstrate 
BMP4 signalling as key to regulating BC activity 41. Mesenchymal BMP4 signalling acts as 
a brake on proliferation and maintains quiescence through elevation of epithelial 
phospho-Smad1/5/8. Similarly, the Yes-associated protein-1 (YAP) also regulates mouse 
BC activity. YAP is a transcriptional co-activator in the Hippo kinase cascade and its 
conditional deletion in Trp63+ BCs leads to a loss of BC number through uncontrolled 
differentiation. YAP elicits this through functional interaction with TRP63 although the 
upstream mechanisms coordinating Yap expression are, however, yet to be elucidated 
42.   
  
Investigation of the BC transcriptome has revealed enrichment for genes involved in 
autocrine and paracrine signalling. Epidermal growth factor receptor (EGFR) family 
expression is enriched, indicating an importance of EGF signalling in BC function, and 
there is also enrichment for expression of the integrins Itga6 and Itgb6, both of which 
are required for the spatially-restricted activation of latent transforming growth factorβ 
(TGF-β) 43. TGF-β is an important factor throughout development, homeostasis, repair 
and disease. In a co-culture system of tracheal epithelial cells and mesenchymal 
fibroblasts, ITGB6 expressed on airway epithelial cells activates latent TGF-β. Active TGF-
β can then act in a paracrine manner on fibroblasts leading to the suppression of 
hepatocyte growth factor (HGF) secretion that, in turn, maintains epithelial quiescence 
44. More recent investigations into HGF have further underpinned its role in epithelial 
function. In a lung colony forming assay, epithelial cells fail to form colonies when 
monocultured, however, co-culture with mesenchymal cells helps to achieve this. 
Further addition of recombinant FGF10 and HGF enhances the potential of these 
epithelial cells with synergistic effects. Conversely, addition of TGF-β1 and BMP-4 
reduces colony growth, presumably through HGF suppression. Also, the mesenchymal 
cells in co-culture were found to wrap themselves around the epithelial cells, indicating 
that cell contact as well as paracrine communication is important in mediating this effect 
45.   
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Hedgehog signalling also plays an important role in maintaining airway quiescence. SHH 
signals via its downstream target GLI family zinc finger-1 (GLI1). In mouse, SHH is 
expressed in proximal airway epithelial cells with Gli1 expression found in corresponding 
mesenchymal cells, which express markers such as platelet derived growth factor 
receptor-α (Pdgfra), vimentin (Vim) and collagen type I, α-1 (Col1a1). Conditional 
knockout of Shh in epithelial cells leads to mesenchymal expansion. This signalling is 
bidirectional, with in vitro co-culture of epithelium and mesenchyme highlighting that 
SHH also promotes epithelial quiescence via a mesenchymal feedback-loop (Figure 
1.1.7.) 46.   
  
The small airways  
As the airways descend to towards the alveolar bed their composition changes from a 
pseudostratified, columnar epithelium to a more simple, cuboidal one. In mice, these 
airways, termed bronchioles, have been well characterised and well-studied. The 
progenitor cell responsible for maintaining these airways is understood to be the Scgb1+ 
Club cell. In humans, however this region of the respiratory tree is less well understood 
and observations in mouse may not directly relate to man.   
  
1.1.2.3. The alveoli  
The most distal regions of the lung airway, the alveoli, are however much better 
understood. They are comprised of just a few epithelial cell types, namely, AEC1 and 
AEC2, which arise from Sox9+/Id2+ expressing endoderm. Within the alveoli AEC1 
constitute roughly 8% of all cells yet make up around 90% of the lungs surface area. AEC2 
make up double the cell number yet cover only 7% of the alveolar surface. AEC1 are the 
largest by volume and surface area but they are extremely thin and share a fused 
basement membrane with the basolateral endothelia. These endothelial cells make up 
around 30% of all cells, second in number to the varying interstitial cells that comprise 
37% of all alveolar cells 47,48.   
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Squamous AEC1s can be identified by Pdpn+/Hopx+ expression and function to allow gas 
exchange between the air and the circulating blood, the primary function of the lungs.  
To maintain the delicate structure of the alveoli and prevent collapse during breathing,   
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surfactant covers the air-surface interface. Surfactant is a product of AEC2s, which can 
be identified by expression of Sftpc. These cuboidal cells lie in the corners of alveoli atop 
a discontinuous basement membrane, which allows communication with the 
interstitium and forms the AEC2 niche (Figure 1.1.8.). Lineage tracing studies in mouse 
have backed-up the long held understanding that AEC2 are a renewable source of AEC1, 
under both normal conditions and in response to injury 49,50. Alveolar cell turnover is 
very low in the normal lung and only around 1% of AEC2 in the adult lung display stem 
cell function at any one time. Their replication is intermittent, with a population doubling 
time of roughly 40-days, and these factors contribute to an alveolar renewal rate of only 
7% of alveoli per year 50. The perceived paradigm regarding AEC1 is that they are 
terminally differentiated with limited, if any, proliferative capacity. Recent investigations 
in mouse, however, have begun to suggest that AEC1 have the plasticity to facilitate 
generation of both AEC1 and AEC2 cells, and that a bi-directional lineage relationship 
exists between the two populations. Jain et al. identified AEC1s via Hopx and Pdpn 
expression in adult mouse alveoli and used a 3D culture model of FACS sorted, single 
cells to show that AEC1 can form alveolar organoids 51.   
  
Maintaining the alveoli   
Trophic intercellular communication is important in maintaining function and 
homeostasis of the alveoli. In the lung, mesenchymal cells sit beneath AEC2s, with 
fenestrations in the basement membrane facilitating communication between the two 
52. Treatment of mono-cultured, rat AEC2 with concentrated fibroblast conditioned 
medium (CM) in vitro promotes DNA synthesis and proliferation, facilitated by the 
mitogenic proteins HGF and keratinocyte growth factor (KGF) 53. KGF also maintains the 
AEC2 phenotype by increasing activation of c-Jun and abrogating expression of the AEC1 
marker, aquaporin-5 (Aqp5) 54. Similarly, isolated AEC2s, cultured in 3D mono-culture, 
fail to proliferate, yet, when co-cultured with Pdgfra expressing mesenchymal cells, 
AEC2s are able to form differentiated, sphere-like colonies termed alveolospheres 49.  
Likewise, epithelial-mesenchymal signalling is important for maintaining AEC1 function. 
In AEC1 and Pdgfra-expressing fibroblast co-culture, pharmacological inhibition of TGFβ 
signalling augments the ability of AEC1s to generate AEC1 and AEC2 organoids 51.   
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Signalling in the alveoli is bi-directional. Not only do fibroblasts maintain epithelial cells 
but epithelial cells can determine fibroblast activity. AEC2s produce prostaglandin E2 
(PGE2), which limits fibroblast proliferation and maintains quiescence in the uninjured 
lung. This acts as an important brake on fibroproliferation and conserves lung 
architecture 55.  The next section will describe how the lung responds when homeostasis 
is perturbed through injury.   
  
1.1.3. Responding to Injury  
  
The air we breathe contains a vast array of pathogens, pollutants and particulates, all of 
which can cause injury to the airways, disrupting established homeostatic niches. Due 
to the environmental abundance of such injurious stimuli, damage to the lung is 
common, and often accentuated by the consistent expansion and contraction of the 
airways with breathing. In order to appropriately respond to injury, 
epithelialmesenchymal crosstalk again plays an important role, facilitating both 
structural and functional repair. Epithelial and mesenchymal cells also communicate 
with the vasculature and the immune system, enabling angiogenesis and helping to limit 
infection, which forms another important aspect of secretory communication.   
  
Though injury is common, the type and the severity can be extremely different 
depending on the offending stimuli and where it acts. For example, chemical injury with 
naphthalene in mouse leads to specific loss of bronchiolar, Scgb1a1+ club cells, whereas 
bleomycin instillation exerts cytotoxic effects on AEC1s 55,56. Conversely, mechanical 
injury can cause loss of both of these cell types whilst also resulting in destruction of the 
basement membrane, this activates an extensive reparative response.    
  
1.1.3.1. Haemostasis and inflammation  
Loss of epithelial and basement membrane integrity elicits a dynamic repair response in 
the lung. When the basement membrane is breached extravasation of the blood occurs 
initiating the process of haemostasis. Platelets become activated and undergo 
degranulation leading to the formation of a fibrillar clot. This functions not only to limit 
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the loss of blood but also acts as a major signalling event, alerting the immune response 
to possible pathogenic intrusion. The first immune cells to emigrate to the wound-site 
are neutrophils, a cell whose primary function is bacterial clearance. This process is 
mediated via reactive oxygen species (ROS)-dependent killing and mechanisms such as 
NETosis 57. Neutrophils are found in the circulation and therefore initially enter the 
wound site passively, leaking out from damaged blood vessels. With platelet signalling 
they become actively recruited and infiltrate via diapedesis. Paradoxically, the 
recruitment and activity of these cells can act to exacerbate the damage in the airways 
58. Neutrophils are followed by resident macrophages, which phagocytose pathogens 
and other cellular debris whilst also having a huge impact on co-ordinating the repair 
process. Interestingly, intravital imaging of skin wounds has shown that macrophages 
may transiently enter the wound sites before neutrophils, departing and returning in 
two distinct waves 59. Macrophages are drawn from the circulation, as monocytes, and 
also attracted from their resident niche in the airways. The macrophage phenotype can 
be diverse and the extremities of these phenotypes have been well characterised. When 
macrophages first arrive, they exhibit a pro-inflammatory phenotype. They up-regulate 
cytokines such as interleukin-6 (IL-6) and further contribute to the generation of an 
inflammatory environment containing high levels of CXC chemokine ligand-8 (CXCL8) 60. 
This is coupled with a phenotype primed for bacterial clearance 61. Depletion of 
macrophages populations at certain phases of repair has demonstrated that these early, 
inflammatory macrophages play a substantial role initiating repair 62,63. They promote 
vascularisation by releasing vascular endothelial growth factor (VEGF) and also activate 
fibroblasts. This all leads to the formation of granulation tissue, a hallmark of the early 
phases of repair.   
  
1.1.3.2. Activation of fibroblasts  
Within the inflamed wound, the recruitment and activation of fibroblasts is an important 
process. The general understanding of their role is to repopulate damaged tissue and 
deposit a scaffold of ECM. This process allows mechanical and structural restitution of 
the damaged airway whilst also providing a platform for re-epithelialisation and 
regeneration. The migration of fibroblasts into the wound area is induced by numerous 
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stimuli from macrophages, epithelial cells and platelets. For example, in the skin, 
PDGFAA signalling is a key chemoattractant, inducing fibroblast migration towards the 
wound site 64. Lineage tracing in skin has revealed that this migration is complex, 
occurring in two different waves from two differing subsets of dermal fibroblasts. These 
differing waves play alternative roles in repair and are responsive to different signalling 
pathways. In the first wave, fibroblasts from the lower dermis are stimulated via TGFβ1, 
which causes differentiation and matrix deposition, allowing structural restitution and 
subsequent re-epithelialisation.  The second wave originates from the upper dermis and 
is mediated by SHH signalling. These cells facilitate regeneration of epithelial function 65.   
  
In the lung, the origin of infiltrating fibroblasts is difficult to determine and it is not 
known if such differential recruitment occurs. In uninjured epithelium, SHH normally 
acts as a control on fibroblast proliferation, maintaining their quiescence. With injury it 
is understood that a loss of this signalling through epithelial destruction then enables 
mesenchymal proliferation to facilitate repair 46. Regardless of the signalling mechanism, 
the recruitment of fibroblasts leads to their activation, part of which involves 
differentiation into a myofibroblast phenotype. In wound granulation tissue this can be 
observed by the transient expression of α-smooth muscle actin (αSMA), which endows 
the cells with contractile properties, enabling mechanical repair 66. TGFβ1 is a key 
signalling mediator in eliciting this activation, functioning via phosphorylation of SMAD 
proteins 2 and 3 67. When this signal is sustained however scar formation occurs through 
the overproduction of matrix. Application of exogenous TGF-β1 to wounded, Smad3- 
mouse, or treatment with TGF-β1 neutralising antibodies, reduces this scar formation 
68,69.   
  
Regulated ECM secretion is, however, a crucial part of the fibroblast response. The 
production of provisional matrix is important for re-epithelialisation and also regulating 
fibroblast behaviour. Monomeric collagen that is secreted during early phases of repair 
further promotes fibroblast proliferation. In the latter stages of repair this collagen 
becomes polymerised via cross-linking, which then acts as a break on fibroblast growth  
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70. The instructive cues for this behaviour arise, in part, from the macrophages present 
in the granulation tissue, which themselves respond to wound-site signalling, 
particularly type2 immune signalling. This causes them to promote upregulation of the 
collagen cross-linking enzyme, lysyl hydroxylase-2 (LOXL2) in fibroblasts, reducing their 
proliferation and also enhancing scaffold formation 71. As well as depositing matrix, 
fibroblast activation involves the up-regulation of secretory signalling factors that 
augment the initial inflammatory response and enhance the activity of neighbouring cell 
populations. For example, during viral influenza infection, crosstalk results in HGF and 
tumour necrosis factor-α (TNF-α) secretion that reciprocates on the epithelium, 
stimulating CXCL8 and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
production, further attracting neutrophils 72. Signalling via interleukin 1-β (IL1β) also 
induces further production of VEGF, PDGF and bFGF in fibroblasts as well as upregulation 
of KGF 73,74.    
  
1.1.3.3. Re-epithelialisation  
Such factors effect both the vasculature and the epithelium, which, when damaged and 
denuded, is required to undergo re-epithelialisation in order to facilitate the next phase 
of repair. The mitotic activity of the repairing epithelium only peaks after the completion 
of re-epithelialisation and the process is facilitated primarily by migration 75. With a 
denuding of the tracheal epithelium rapid migration occurs giving rise to a continuous 
yet ‘leaky’ and poorly differentiated layer 76.  This initial migration is carried out by 
several rows of epithelial cells closest to the wound edge 75. Whereas mesenchymal cells 
individually extend lamellipodia and filopodia to migrate, this only occurs in a few 
epithelial cells at the leading edge, and the entire epithelial sheet moves as one. The 
leading cells are connected along the wound edge by continuous actin stress fibres, 
which run parallel to the wound, creating mechanical tension (Figure 1.1.9A.) 77,78.  
Further back from the wound edge the cells also play a substantial role in migration.  
Movement at the front is facilitated by down regulation of tight and adherens junctions   
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at the back. This allows the epithelial sheet to stretch and cover the wound. This is 
enabled via an upregulation of ephrin-B1 (Figure 1.1.9B.) 79. Likewise, these cells also re-
arrange their cytoskeleton to lie perpendicular to the wound edge, enabling a release in 
tension at the rear, facilitating leading edge migration 80. Damage in the epithelium 
stimulates various signalling mechanisms that help create an environment amenable to 
repair. One of these is endongenous hydrogen peroxide (H2O2), which, in keratocytes, 
promotes migration, cytoprotection and resistance to apoptosis 81.  The activation of 
fibroblasts also assists in the re-epithelialisation process. HGF secretions enhance 
epithelial wound closure in both human bronchial epithelial cells (HBECs) and AEC2s  
82,83.   
  
  
48  
  
1.1.3.4. Epithelial regeneration  
With successful re-epithelialisation, epithelial regeneration is next required to restore 
function to the airway. In the trachea BCs take up the mantle of regeneration 34. BCs 
implanted onto xenografts in denuded mouse trachea demonstrate that, once migration 
has created a continuous (yet leaky) basal cell epithelium, proliferation occurs. The BCs 
become multi-layered and form tight junctions 84. This proliferation is mediated by 
diverse transcriptional changes in the epithelium, with upregulation of G2 and M phase 
genes 85, as well as signalling from the mesenchyme. BMP4 produced by fibroblasts 
normally maintains epithelial quiescence during homeostasis but, in response to injury 
the BMP4 antagonist Follistatin is upregulated, enabling proliferation 41. Proliferation 
occurs in cells that are poorly differentiated. The process of restoring a fully 
differentiated airway occurs first with the extrusion and apoptosis of a number of these 
cells (Figure 1.1.10.) 41. This precedes differentiation to the secretory and ciliated 
populations of the conducting airway, a process mediated by several signalling moieties. 
One such example is ROS. After injury BCs experience a flux change in ROS that activates 
Nrf2, altering Notch expression and shifting BCs to a reparative phenotype 86. 
Intracellular Notch activation leads to BC lineage segregation, with two mutually 
exclusive sub-populations arising. One population displays Notch2 activation and 
commitment to a secretory lineage; the other, inhibition of Notch and upregulation of 
FOXJ1, committing cells to a ciliated lineage 87. IL-6, produced by mesenchymal cells at   
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the site of injury, facilitate this commitment. IL-6 signals via the signal transducer and 
activator of transcription-3 (STAT-3), which ultimately inhibits Notch pathway activation 
88. The balance between these pathways is clearly important for regenerating the full 
complement of airway epithelial cell types and BC lineage segregation is also tempered 
by the need for stem-cell self-renewal, which is achieved primarily by concurrent, 
asymmetric division 35.    
  
In the alveoli, AEC2s are required for regeneration 49. Loss of AEC1s causes them to 
proliferate and migrate, recovering the denuded basement membrane. The cessation of 
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this growth and the induction of differentiation to an AEC1 phenotype is dependent on 
the fibroblasts. The promotion of fibroblast expansion via epithelial cell death allows 
ECM deposition. When AEC2 respond to injury and migrate they eventually come into 
contact with this new matrix which promotes their differentiation 47. Factors such as 
HGF and KGF are also important in this process although their roles are complex. For 
example, HGF stimulates repair at low concentrations in vitro but inhibits it when high  
53,89.   
  
1.1.3.5. Angiogenesis  
With restoration of both epithelial integrity and function, a greater part of the repair 
response is complete.  Throughout the process, it should be noted that angiogenesis also 
plays an important role, especially in the formation of granulation tissue, and it is key in 
resourcing the wound site with metabolites and immune cells. Endothelial cells also play 
a role in crosstalk between the differing cells of the wound site with regulation, in part, 
mediated by interactions with ECM deposited by active fibroblasts 90. Angiogenesis is 
also key in the final stages of regeneration, restoring complete function and returning 
the tissue to normal.   
  
Summary  
A multitude of cytokines, chemokines and growth factors are required for repair, arising 
from numerous interactions between differing cell types. Such pathways are extremely 
relevant to embryonic growth and the maintenance of homeostasis, with 
epithelialmesenchymal crosstalk constituting a key relationship in these processes. 
When these mechanisms become defective though, and the relationship between 
epithelial and mesenchymal cells breaks down, there can be serious, detrimental effects 
on all these aspects of lung physiology. One potential consequence is the development 
of chronic respiratory disorders. The next section of this introduction will particularly 
focus on one such disorder: pulmonary fibrosis.   
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 1.2  Pulmonary Fibrosis  
  
1.2.1 Clinical Presentation and Epidemiological Significance  
  
There are many forms of fibrotic lung disease (Figure 1.2.1.) 91. Broadly, they are termed 
diffuse parenchymal lung diseases (DPLDs) and, what they share in common, is a 
remodelling of the pulmonary interstitium, in a process that leads to loss of respiratory 
function. Affected patients present with shortness of breath, arising often in an insidious 
manner, which continually worsens over time. Cough is common, and patients typically 
display reduced lung volume and impaired gas transfer, as well as a restrictive defect on 
spirometry. The presentation of these symptoms and early testing mean that a whole 
range of diseases could be at play. Occupational exposures can indicate asbestosis or 
silicosis. Concurrent signs of other diseases, such as rheumatoid arthritis, can indicate 
fibrosis due to systemic connective tissue disease. Or, other DPLDs may be involved, 
including granulomatous DPLD or drug-induced DPLDs. When patients have no known 
occupational or environmental exposures and they present with fine end-inspiratory 
crackles and signs of digital clubbing, the most likely form of DPLD present is one of the 
idiopathic interstitial pneumonias (IIPs).   
  
1.2.1.1. Idiopathic interstitial pneumonias   
So called because of their unknown aetiology, IIPs are the most common form of DPLD. 
They can be further divided into idiopathic pulmonary fibrosis (IPF) and non-IPF IIP. Of 
the latter group, there are also several subtypes. Distinguishing between IIPs and 
concluding the right diagnosis is exceptionally important. High-resolution computed 
tomography (HRCT) is key to achieving this and it can provide robust information 
without being invasive. In cases where more information is required, biopsy and 
histology can be performed, providing a gold-standard for diagnosis, which can be 
backed-up with bronchoscopy and analysis of broncho-alveolar lavage (BAL). Getting the 
diagnosis right is critical because, although sharing similarities in symptomology, 
prognosis and therapeutic options can differ widely. For example, with the non-IPF IIP, 
cryptogenic organising pneumonia, fibrosis can be completely resolved within 6-12 
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months using corticosteroid treatment. For IPF however, the prognosis is a continual 
decline in respiratory function leading to death within 3-5 years, an outcome that, as of 
yet, cannot be prevented with treatment, only delayed.   
  
1.2.1.2. Idiopathic pulmonary fibrosis  
The clinical diagnosis of IPF requires HRCT and, in around 50% of cases in the US, surgical 
biopsy, as well as exclusion of environmental causes 92. Patients, typically presenting in 
their 60s and most commonly male, display a pattern of usual interstitial pneumonia 
(UIP). This patterning, whilst often heterogeneous, is typically found in the basal and 
peripheral regions of the lung. UIP is characterised by the presence of reticular opacities, 
a complex network of diffuse opacities where the ratio of gas to soft tissue has declined. 
Medium sized opacities, termed honeycombing, is common and a requirement for 
diagnosis. These honeycomb opacities are typically subpleural with well-defined walls. 
Smaller opacities, termed ground-glass opacities can also be observed, though they are 
not a requisite for diagnosis. Other key and prominent features are signs of traction 
bronchiectasis, a phenomenon in which contraction of fibrotic tissue around the small 
airways causes dilatation, and also a thickening of the interlobular septa (Figure 1.2.2.)  
92.   
  
If surgical biopsy is required, a UIP pattern can also be confirmed histologically (Figure 
1.2.3.) 93. In areas of honeycombing, there is a variable pattern of both fibrosis and 
seemingly non-affected lung. Where there is fibrosis, regions of the lung interstitium are 
distorted and thickened with an ablation of normal lung architecture. There are dense 
patches of fibroblast and myofibroblast expansion, coupled to thick depositions of ECM. 
When large in size and of a nodular appearance these patches are referred to as fibrotic 
foci. They are typically covered by a bronchiolar, cuboidal epithelium that is covered in 
mucus and inflammatory cells. More generally, infiltration of inflammatory lymphocytes 
is also observable but less consistently. AEC2 hyperplasia can also be seen 94. Together 
these alterations dramatically inhibit lung function and impair gas exchange.   
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1.2.1.3. Epidemiology  
This destruction of normal lung architecture and subsequent loss of function presents a 
serious problem for patients and clinical practice. The disease has a poor prognosis and 
patients suffer a reduced quality of life. In the UK, IPF affects roughly 32,500 people. 
Around 6,000 new cases are diagnosed each year and, overall, 5,300 people die from 
the disease per year 95. For patients, the outcome of the disease is made worse by the 
unpredictability of clinical progression. Markers for progression are starting to be 
validated and used but, from the point of diagnosis, a patient typically won’t know if 
they’ll experience a relatively slow decline in lung function, over 6-10 years, or a rapid 
decline, within periods of less than a year. Decline may also be intermittent, with 
patients experiencing relative periods of stability punctuated by short periods of acute 
exacerbation (Figure 1.2.4A.) 96. The certainty of impending respiratory failure coupled 
with the uncertainty of progression are serious factors determining patient well-being 
and make disease management highly challenging.  
  
From a clinical perspective, the problem of IPF is furthered by both the rising incidence 
of the disease and the increasing mortality arising from it (Figure 1.2.4B.) 97,98. There are 
currently over 9,000 hospital admissions a year due to IPF accounting for up to 86,000 
bed days. Respectively, this represents 1.3% of all admissions and 1.4% of all bed days 
due to lung disease. These figures are disproportional to the percentage of lung diseases 
that IPF actually accounts for, which is under 0.25% 95. Also, 80% of those diagnosed with 
IPF are over the age of 75, making it a disease of old age. With an ever-ageing population 
and projections of the number of over 60 year-olds to reach 1.4 billion by 2050 this could 
create an even greater issue for healthcare 99.   
  
1.2.2. Therapeutic Options  
  
The epidemiological statistics attached to IPF ultimately highlight the reality of a disease 
for which there is no cure. In the past few years, there have been significant advances in 
treatment options, with two clinically licensed drugs now available, but neither drug, 
Nintedanib nor Pirfenidone, reverse pathology of disease. Likewise, their efficacy as   
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determined by clinical trial endpoint, remains somewhat contentious, with arguments 
both for and against the utility of measures such as forced vital capacity (FVC) 100,101.   
  
1.2.2.1. Nintedanib  
Nintedanib is a tyrosine kinase inhibitor that targets multiple pathways, including VEGF, 
FGF and PDGF signalling, interfering with the processes of fibroblast proliferation, 
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migration, differentiation and ECM production in vitro 102. The rationale for its 
application in clinic is therefore strong and it is a recommended therapy in accordance 
with the ATS/ERS/JRS/ALAT guidelines for IPF treatment 103. In patients, Nintedanib’s 
validity has been established through three randomised control trials (RCT). The first was 
a phase 2 safety and efficacy trial, which found that a 150mg, twice-daily treatment, 
reduced the percentage of patients experiencing >10% decline in FVC, although 
mortality rates did not change 104. This RCT was followed up with two, phase 3, INPULSIS 
trials, using the same regimen across a total enrolment of 1,066 patients. The results 
(analysed collectively) found no significant benefit on mortality or acute exacerbation. 
There were however significantly less patients with a 10% decline in FVC. The report of 
non-serious adverse events was increased with treatment, as was report of diarrhoea 
and nausea 105.    
  
1.2.2.2. Pirfenidone  
Pirfenidone, like Nintedanib, has pleiotropic effects. In vitro, using a murine, 
macrophage-like cell line, it has inhibitory effects on inflammatory cytokine production, 
reducing TNFα production via a translational mechanism 106. In BLM-induced mouse 
fibrosis, the drug attenuates collagen deposition and supresses levels of IL-1β, IL-6 and 
CC chemokine ligand-2 (CCL2), though an explicit mechanism of action remains poorly 
defined 107. The CAPACITY and ASCEND RCTs have provided the best evidence for use of 
Pirfenidone 108,109. Part of the CAPACITY trial found a reduction in FVC decline over a 
72week treatment period versus placebo but there were, however, increased rates of 
vomiting, nausea, dyspepsia, anorexia, photosensitivity and rash. The ASCEND trial used 
the same high-dose regimen in a study of 555 patients. Like Nintedanib, Pirfenidone 
showed a significant reduction in the number of patients exhibiting more than a 10% 
decline in FVC, yet, like Nintedanib again, mortality was not impacted.   
  
1.2.2.3. Other therapeutic candidates  
Both Nintedanib and Pirfenidone, despite side-effects and seemingly no effect on 
mortality, represent major success stories in the field of IPF therapy. Many other 
promising treatment options have ended in disappointment at clinical trial. Most 
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recently, Simtuzumab, an antibody targeted against the collagen cross-linking enzyme 
LOXL2, disappointed at phase 2 trial 110. The drug failed to reduce mortality or decline in 
FVC despite a strong rationale for success, generated in vitro and in mouse. Prior 
investigation had revealed an upregulation of collagen cross-linking at sites of fibrosis 
with inhibition of LOXL2 reducing scar formation and aberrant signalling by factors such 
as VEGF 111. The reasons for trial failure were hypothesised to be either redundancy in 
fibroblast cross-linking capacity or failure of the drug to reach its target in the lungs. 
Candidate therapies such as Warfarin, Imatinib and N-acetylcysteine (as either 
monotherapy or in conjunction with Pirfenidone) have also failed to show a meaningful 
impact on disease progression 112–115. However, by stratifying IPF patients into cohorts 
according to levels of circulating antibodies for type V collagen, Wilkes et al. have 
demonstrated efficacy of an immunotherapeutic (IW001) modulating the body’s 
response to this auto-antigen. This therapy was used in a phase 1 trial over 24 weeks 
and, in the high-dose cohort, there was a trend towards stabilisation of FVC 116. The 
preliminary success of this trial reflects the necessity for patient stratification. It also 
suggests that the classification of IPF may be too broad, representing a number of 
clinically distinct disease entities.   
  
1.2.3. Biological Alterations in IPF  
  
The changes in lung architecture seen clinically represent a plethora of biological 
alterations occurring at a cellular level within the lung, whilst the limited efficacy of 
treatment options reflects the unknown cause of the disease. Understanding the 
biological alterations that occur is typically approached using two models: the isolation 
of primary cells from IPF patients and their investigation in vitro, and the in vivo model 
of lung fibrosis, the bleomycin (BLM) mouse model. BLM is a chemotherapeutic agent 
often used in the treatment of testicular cancer. Treatment in mice, typically via 
intratracheal administration, leads to an inflammatory response followed by chronic 
tissue re-modelling that recapitulates many of the aspects of IPF. Both approaches have 
been key in identifying pertinent biological alterations in the IPF lung. One of the key 
effector cell types identified in this disease is the lung fibroblasts.   
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1.2.3.1. Lung fibroblasts in IPF  
The macro and microscopic loss of pulmonary architecture in IPF is the result of 
interstitial, mesenchymal cell expansion and matrix deposition. Fibroblasts form a 
heterogenous population of varying cell subtypes that act in conjunction to destroy the 
normal lung. Within this population numerous pathological characteristics have been 
observed and these cells are understood to be the key effector cell of disease pathology.     
  
Activation  
Firstly, in IPF, fibroblasts appear to be aberrantly activated. In normal wound healing 
fibroblasts are activated in response to a loss of tissue homeostasis. Part of this 
reparative activation involves differentiation to a contractile, αSMA myofibroblast 
phenotype 117. TGF-β1 is a key molecule in mediating the activation and, as well as being 
elevated in the IPF lung, it can robustly induce myofibroblast differentiation in vitro 67. 
TGF-β1 induces production of H2O2 via members of the NADPH oxidase (NOX) family of 
enzymes in human lung fibroblasts (HLFs) 118 and one of these enzymes, NOX4, is critical 
in the fibroblast response to injury 119. Coincidently, NOX4 is highly expressed in the 
fibrotic foci of IPF patients and, if NOX4 is knocked down by siRNA, isolated IPF HLFs 
(FHLFs) are less able to differentiate and secrete collagen when treated with TGF-β1. 
When knockdown is elicited in concurrence with BLM instillation in the mouse, fibrosis 
is prevented 119. Taken together, this indicates that a key alteration in FHLFs is an 
aberrant activation in response to injury-associated stimuli.   
  
Proliferation  
As well as being activated, FHLFs become excessively proliferative. Collagen that is 
crosslinked by active fibroblasts acts as a negative regulator of sustained proliferation 
70. The PI3K-AKT-S6K1 pathway facilitates this regulation and is responsive to PTEN 
activity.  
PTEN activity is deficient in IPF derived cells cultured on polymerised collagen 120. 
Similarly, AKT can further promote proliferation via phosphorylation and inactivation of 
forkhead box O3a (FOXO3A). Both FHLFs and IPF human tissue sections show the 
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presence yet the inactivity of FOXO3A 121. These cells are therefore unable to respond 
to environmental cues and internally co-ordinate growth, subsequently leading to 
inappropriate proliferation.   
  
Resistance to apoptosis  
The continued accumulation of fibroblasts in IPF is thought to be related to their inability 
to respond to apoptotic signalling. Isolated FHLFs have an altered response to Fas 
signalling as well as an inability to respond to starvation signals 122,123. When starved, 
FHLF display persistent activation of the mammalian target of Rapamycin (mTOR), a key 
kinase in nutrient sensing pathways and inducer of autophagy, the process of cellular 
self-eating. In prolonged response to nutrient depravation, normal HLFs (NHLFs) from 
aged patients transition through autophagy to apoptosis via the ultimate deactivation 
of mTOR. Conversely, FHLF elude this regulation and resist apoptosis 123.     
  
Invasiveness  
FHLFs also exhibit invasive properties that further contribute to the destruction of lung 
architecture. Hyaluronan (HA) is a non-sulphated glycosaminoglycan synthesised by 
mesenchymal cells via HA synthase enzymes (HAS). In the mouse model of lung fibrosis 
HA interacts with the mesenchymal marker CD44 and accumulates. Overexpression of 
Has2 in Acta2+ fibroblasts results in increased collagen deposition and worsened 
BLMinduced mouse fibrosis. This is, in part, attributed to an increased invasiveness; 
demonstrated by the isolation of HAS2 overexpressing cells that display an increase in 
spontaneous invasion into Matrigel 124. As well as HA-CD44 interactions, α6-integrin B, a 
mechanosensing integrin subunit, promotes pericellular proteolysis of basement 
membrane collagen and subsequent myofibroblast invasiveness. The expression of this 
subunit is also higher in both FHLFs in vivo and when isolated in vitro (Figure 1.2.5.) 125. 
Such invasive properties are attributed to a ‘transcriptome-wide invasion signature’. 
This signature, identified through 3D invasion assays using murine lung fibroblasts, has 
highlighted the mechanisms of invasion, including PTEN downregulation and matrix 
metalloproteinase (MMP) upregulation, whilst also predicting and validating the 
upstream regulators of such action, elucidated as TGF-β1, FGF2, EFG and PDGF-BB 126. 
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The result of this phenotype is a loss of respiratory airway architecture, with fibroblasts 
disrupting the basement membrane and impairing epithelial function.   
   
1.2.3.2. Lung epithelium in IPF  
The IPF fibroblast gains pathological characteristics during the course of the disease and 
these characteristics come at the expense of the overlying epithelium, which also 
undergoes substantial biological alterations leading to a loss of normal function.    
  
Alveolar cells  
In IPF, necrosis and cell death occur in distal AEC1s 55,127. Loss of these cells is observed 
alongside hyperplasia of both AEC2 and BCs. AEC2 normally constitute a small number 
of alveolar epithelial cells, acting as a quiescent progenitor population. Throughout the 
IPF lung, regions of AEC2 hyperplasia have been identified in which SFTPC+ cells have 
proliferated to form a simple, cuboidal epithelium around regions of fibrosis 128. In 
response to injury AEC2 differentiate to restore AEC1 loss, in IPF however they retain 
surfactant protein expression and fail to differentiate to AEC1s, furthering the loss of 
respiratory lung function. The phenotype of these AEC2 in patients also includes the 
accumulation of dysmorphic and dysfunctional mitochondria. This is understood to be 
the result of impaired mitophagy and elevated stress in the endoplasmic reticulum (ER). 
PTEN-induced putative kinase-1 (PINK1) is a regulator of mitochondrial function and, in 
IPF, its expression is low. Knockout of Pink1 in mouse recapitulates a similar 
mitochondrial morphology with affected cells upregulating Tgfb and Il6, and mice 
suffering a more severe fibrotic response when challenged with BLM 129.  
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Distal airway cells  
A similar story of dysfunction is seen with BCs. Like AEC2s, BCs are a quiescent 
progenitor. Throughout the proximal, tracheobronchial airways they form a 
nearcontinuous layer at the base of a pseudostratified epithelium, becoming more 
dispersed in the distal airways. In the IPF lung however, the distal airways are populated 
by a continuous layer of densely packed BCs. This has been identified by TRP63 staining 
in a study that also found BC colonisation of the alveoli 130. This bronchiolisation was 
coupled with honeycomb cyst formation in which regions of mucin filled airway become 
lined with ectopically differentiated mucosal and ciliated cells, typically infiltrated by 
inflammatory cells (Figure 1.2.6.) 128,131.   
  
This description of an IPF epithelium in which there is hyperplasia, dysregulated 
differentiation and loss of proximal-distal patterning has recently been given more 
clarity via the method of single-cell RNA sequencing. Using distal lung from IPF patients 
and healthy controls, Xu et al. have shown with greater resolution the scale of epithelial 
change in IPF. Three distinct populations of epithelial cell were identified, all with gene 
expression patterns in keeping with conducting airway cells. These included TP63/KRT5 
expressing BCs as well as MUC5AC/MUC5B expressing goblet cells. Interestingly though 
the third type lacked an expression profile consistent with any classical epithelial cell 
type. These ‘intermediate’ cells expressed both the hallmarks of AEC2s, AEC1s and also 
the proximal airway. These cells also showed increased expression for VIM and, through 
gene enrichment analysis, showed significant alterations in TGF-β, PI3K/AKT and 
HIPPO/YAP signalling pathways. Upregulation of VIM confers a more mesenchymal 
phenotype on these cells, impairing their epithelial function and perturbations to these 
pathways disrupts epithelial mesenchymal crosstalk, disrupting homeostasis 132.   
  
Other alterations  
Though alterations in fibroblast and epithelial biology are critical in IPF many others have 
also been identified. Proteomic analysis of peripheral blood cells in IPF patients has 
revealed a profile in which regulation of repair responses are inhibited, there is a 
downregulation of pathways required for host defence and an increase in kinase   
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signalling proteins, most significantly VEGF 133. The lung microbiota also appears altered, 
with an increased bacterial burden in BAL that can change composition during acute 
exacerbation 134,135.   
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1.2.4. Driving Forces in IPF  
  
Though the end-state alterations that occur in IPF are well defined, the driving forces 
that lead to them and a possible cause of the disease remain to be fully understood. 
Epidemiological studies have thus far been unable to identify an environmental cause 
and, although disease progression can be predicted through additional co-morbidities, 
the initiating event in IPF remains elusive 136,137. One issue that may contribute to this is 
the insidious onset of the disease. Patients presenting with symptoms may potentially 
have been victim to the disease for many years, with observations at clinic only 
representing the closing stages of pathology.   
  
1.2.4.1. Genetic predisposition   
Much research has gone into identifying genetic factors that may initiate and drive the 
disease. Initial findings were reported primarily in patients with the familial form of IPF 
(F-IPF), during small scale investigations, yet more recent studies have been able to 
utilise genome wide sequencing across much wider cohorts of patients with the sporadic 
form of the disease.   
  
SFTPC  
An early study in one family with F-IPF identified a common mutation in SFTPC. This 
mutation resulted in exon skipping and production of an altered SFTPC pro-protein. The 
result was identified as an inability of SFTPC+ epithelial cells to transport the pro-protein 
within the cell, leading to defective processing, secretion and ER stress, as evidenced by 
a lack of mature protein in patient BAL 138. A further study, in which SFTPC was 
sequenced in 89 patients with UIP, found only 10 single nucleotide polymorphisms, of 
which only one caused a change in amino acid sequence and protein alteration 139. This 
study, coupled with another, conducted in 35 IPF patients, found SFPTC mutations to be 
a rare cause of the sporadic disease 140.   
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MUC5B  
MUC5B is a mucin that plays an important role in host defence of the conducting airway. 
Genome wide sequencing, in a study that included 492 patients with IPF, identified a 
common variant in the promoter region of MUC5B , a finding corroborated in two 
further, independent cohorts 128,141. The suggestion from these studies was that 
enhanced activity in the MUC5B promoter creates too much of the protein. This alters 
the balance of mucins in the airway and impairs host defence by impeding mucus 
clearance. Seibold et al. identified this clearly relevant polymorphism in 38% of their 
study cohort. A more recent study in 115 Dutch patients also found MUC5B mutation to 
associate with IPF, however, though this mutation predisposes patients to IPF, it does 
not influence or predict survival 142.   
  
TERT  
Telomerase reverse transcriptase (TERT) is an enzyme that maintains telomere length. 
Telomeres cap the end of chromosomes and are degraded with each replication of the 
cell, activating a process of cell cycle arrest. Telomere maintenance is important for 
maintaining proliferative activity and TERT functions alongside TERC, the RNA 
component of the enzyme. Unlike SFTPC and MUC5B, TERT and TERC function 
throughout all cell types of the body and are not restricted to the lungs. Investigations 
into both F-IPF and the sporadic form identified mutations in TERT and TERC 143,144. A 
further study also found mutations but these were rare, detected in only 1 in 100 
patients 145.   
  
AKAP13  
A recent study by Allen et al. has identified a novel genome-wide association between 
the SNP rs62025270 and susceptibility to IPF. This polymorphism is understood to 
regulate expression of A-Kinase Anchoring Protein 13 (AKAP13), a scaffold protein that 
functions as a Rho guanine nucleotide exchange factor, activating RHOA in response to 
G-protein signalling. The protein is understood to contribute to thrombin mediated 
activation of TGF-β in the epithelium and is therefore thought to modulate the 
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epithelium’s response to injury. Targeting this pathway may be an attractive approach 
for future therapeutics 146.  
  
Current thinking suggests that these mutations, found across familial and sporadic cases 
of IPF, indicate a blurring of the distinction between the two diseases, suggesting that 
they reflect two ends of a spectrum of genetic predisposition 147. However, a large 
proportion of patients do not appear to have significant mutations and, in those that do 
but who experience late onset of the disease, the mutations are not the sole drivers of 
the disease. Therefore, it is more likely that defects in genes such as SFTPC, MUC5B and 
TERT coalesce with environmental factors to create a lung environment permissive for 
the development of IPF.   
  
1.2.4.2. Dysfunctional epithelial-mesenchymal crosstalk  
As discussed previously, communication between the epithelium and the mesenchyme 
is crucial for numerous processes, including embryonic development, maintenance of 
homeostasis and repair. Evidence suggests that, on top of a permissive genetic 
background, a breakdown in epithelial mesenchymal-crosstalk could play a critical role 
in driving the pathology of IPF.  
  
Matrix interactions  
As well as secretory communication, the relationship between a cell and its’ surrounding 
matrix are also key in regulating behaviour. Dysregulated interactions with the ECM have 
been consistently observed in FHLFs and have been thought to contribute to their 
pathological phenotype. As well as promoting proliferation, matrix stiffness can cause 
differentiation to an ACTA2 expressing, myofibroblast phenotype and promote 
migration 148,149. Transcriptional proteins of the Hippo pathway, YAP and the 
transcriptional coactivator with PDZ-binding Motif (TAZ), are highly expressed in fibrotic 
regions of IPF lung. They are key in responding to the ECM environment and regulate 
cell activation and matrix production, in part through targeting plasminogen activator 
inhibitor-1 (PAI-1). In vitro, knockdown of YAP/TAZ reduces pro-fibrotic fibroblast 
activity 150. Likewise, the matrix produced by FHLFs creates a positive feedback loop that 
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sustains fibrotic activity. FHLFs cultured on non-IPF derived ECM show little translational 
differences when compared to NHLFs in the same conditions. When cultured on 
IPFderived ECM however, there is an upregulation of ECM production, which also 
recapitulates the composition of that found in IPF tissue 151.  
  
Developmental signalling  
It has become well established that a potentially critical driver in the pathology of IPF is 
an aberrant reactivation of the signalling pathways found in development. The growth 
and patterning of the embryonic lung, as previously eluded to, requires complex 
interactions between numerous cell types, with many of the signalling molecules 
continuing to play roles in maintaining adult homeostasis. In IPF it appears that there is 
an inappropriate activation of these pathways, with developmental and homeostatic 
factors driving pathological activity. Strong evidence for this has been derived from the 
gene expression profiles of mesenchymal stromal cells in the terminal airways and 
alveoli. The profile of these cells has revealed an IPF-specific enrichment for genes 
required in branching morphogenesis and tissue patterning. Most notably an 
upregulation of SHH and TGF-β pathways has been identified, coupled with a 
downregulation of FGF-10 152. As well as this, much evidence has been gathered to 
implicate WNT signalling as playing an aberrant role in IPF.   
  
Hedgehogs   
SHH facilitates myofibroblast differentiation and matrix deposition in the developing 
lung. This is also true for isolated, adult HLFs. SHH can function through GLI transcription 
factors and, in the BLM-injured mouse, there is an observed induction of SHH and GLI 
activity 153. Likewise, in an injury-induced model of interstitial renal fibrosis, SHH is 
induced causing a fibrotic response in Gli1+ cells 154. The activation of these pathways 
has also been identified in IPF lung tissue, where SHH is expressed in the epithelium with 
its responsive element, GLI1, in the mesenchyme. As well as differentiation and ECM 
production, recombinant SHH also promotes fibroblast migration and resistance to 
apoptosis 155. Inhibition of GLI transcription factors, via blocking their DNA binding 
domains, reduces BLM-induced fibrosis decreasing lung collagen content, RNA levels of 
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myofibroblast markers and creates a less inflammatory environment by reducing 
expression of factors such as Vegfa, Pai1 and Il1b 156.   
  
WNTs  
There are numerous members of the WNT family of signalling proteins and many of them 
are both elevated and functionally relevant in IPF. In human tissue, the signalling 
molecules, as well as their receptors and intracellular signal transducers, are increased 
in IPF, localised primarily to the alveolar and bronchiolar epithelium. In vitro, treatment 
with recombinant WNT ligands induces epithelial proliferation and also myofibroblast 
activation 157. A member of the WNT signalling pathway, the WNT1-inducible signalling 
protein-1 (WISP1) is elevated in patient and mouse AEC2s. Treatment of normal AEC2 
with the recombinant protein increases proliferation, as well as markers of 
epithelialmesenchymal transition (EMT). Subsequent targeting of this protein in the BLM 
mouse model with neutralising antibodies improves lung function and survival 158. 
Similarly, molecular inhibition of β-catenin, the nuclear effector of WNT-targeted gene 
expression, attenuates fibrosis, when given in concurrence with BLM in the mouse 159. 
One of the WNT family members, WNT3A, up-regulates transcription and production of 
IL-1β and IL-6 in human AEC2s, an outcome that also occurs with WNT3A treatment in 
mouse. This protein is also elevated in human, fibrotic alveolar epithelium as well as in 
human BAL 160.   
  
Growth factor signalling  
Such developmental signalling pathways form an integrated network and subsequently 
other growth factors can interact and influence their activity. For example, TGF-β 
activates WNT signalling via decreasing expression of the antagonist to the canonical 
signalling pathway, Dickkopf-1 (DKK1). This occurs in a p38 mitogen-activated protein 
kinase (MAPK)-dependent manner and, in human IPF tissue, a paucity of DKK1 
expression is observed in comparison to normal lung. Overexpression of DKK1 
ameliorates dermal fibrosis, highlighting the capacity of TGF-β to mediate fibrosis via 
WNT 161. Likewise, the upregulation of TGF-β and SHH signalling in IPF patients, stratified 
according to disease progression, has an effect on other developmental pathways, 
  
69  
  
including those of FGF-10 and BMP-4, which are downregulated. This is most noticeable 
in fibrotic foci where there is a downregulation of FGF-10 signalling 152. Isolated 
mesenchymal stromal cells also lose their epithelial-supportive capacity, a function 
related to FGF-10 activity, which can be reinstated with TGF-β inhibition 162. Deletion of 
the TGF-β receptor (type 2) in mouse epithelium is protective against BLM induced 
fibrosis, although emphysema also develops spontaneously in these mice after birth 163.    
  
1.2.4.3. Dysfunctional repair  
As well as reactivation of developmental signalling, one of the most enduring paradigms 
concerning IPF initiation and progression revolves around the hypothesis that recurrent 
injury in the lung leads to a progressive inability of the epithelium to repair. This 
epithelial deficiency is coupled with an over-activation of mesenchymal repair 
responses, compounding the issue and leading to fibrosis 164. The specific source of 
injury in IPF remains elusive. The lungs, however, are exposed to a diverse range of 
potentially damaging stimuli and, after many decades of exposure, a tipping point may 
be reached in which the airways can no longer adequately respond. The lungs of IPF 
patients also exhibit all the relevant hallmarks of injury and excessive repair.   
  
Hallmarks of injury and repair  
With injury, blood loss is limited by haemostasis, a process involving activation of the 
coagulation cascade. This process is under exceptionally tight regulation to prevent 
inappropriate blood clotting. The expression of a key member of this cascade, Factor Xa, 
is increased in IPF alveolar and bronchiolar epithelium, signifying airway injury. This 
factor also has potent effects on initiating mesenchymal repair processes and eliciting 
fibroblast differentiation 165. With injury also comes immune cell infiltration and a 
temporal increase in inflammatory signalling. CXCL8 and CCL2 are key members of this 
inflammatory repertoire and both are elevated in the BAL fluid of IPF patients 60,166. 
Likewise, both IL-6 and CXCL8 are also elevated in the blood of patients experiencing an 
acute exacerbation, an elevation predictive of increased mortality 167. The presence of 
increased numbers of myofibroblasts also points towards an attempted repair response. 
These cells are only transiently increased in the facilitation of repair and their 
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persistence reflects a protracted upregulation of damage signals expressed in the IPF 
lung 66,155,156. A loss of AEC1s, concurrent with AEC2 and BC migration and hyperplasia, 
also signify a failed repair response. AEC2s and BCs are typically maintained in a state of 
quiescence, becoming active upon loss of airway cells 33,49. Their hyperactive nature in 
IPF suggests continuous airway damage.   
  
Consequences of recurrent injury  
Though a causative agent remains unidentified, the increase of these hallmarks of injury 
and repair in the IPF lung creates a strong impression that recurrent injury is the key 
initiator of the disease. More direct evidence to substantiate this hypothesis can be 
found in murine models of lung injury.   
  
During investigation of the progenitor functions of AEC2s, Barkauskas et al. employed a 
protocol of targeted AEC2 ablation. They found that the specific deletion of AEC2s, 
occurring in around 50% of the cellular population, once every two weeks simply led to 
efficient re-epithelialisation with no fibrosis. Daily ablation however led to parenchymal 
fibrosis, hypothesised to be the result of persistent denudation of the basal lamina and 
disruption of epithelial mesenchymal crosstalk 49. As well as this, Cao et al. observed the 
effects of recurrent BLM on fibrosis establishment. With their model of mouse fibrosis, 
in which they injected BLM at 12 day intervals, they found that with each treatment 
there was a loss of gas exchange function, as assessed via measuring blood oxygen 
levels. With the first three treatments, however, function recovered to normal within 
the recovery interval. Aqpn5+/Pdpn+ AEC1s were destroyed with each BLM injection but 
alveolar function was restored by Sftpc+ AEC2 re-epithelialisation. The mesenchyme also 
appeared to appropriately respond in transient fashion. Single BLM treatment led to an 
increase in Acta2 and Col1a1 expression that abated 35-days post-injury. With the 
continuation of treatment though there was a continual decline in lung function. After 
the sixth treatment, the AEC2 response failed and there was a loss of alveolar structure.   
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This was paralleled by a sustained elevation of markers of mesenchymal fibrosis and 
histologically persistent scarring (Figure 1.2.7.) 168.   
  
1.2.4.4. Age  
The list of driving forces in IPF also includes age, a process associated with a progressive 
decline in homeostasis throughout the body. The rate of incidence of IPF increases with 
age and the majority of patients are over the age of 75 (Figure 1.2.8A.) 95,169. Therefore, 
the changes associated with age are thought to be key in the pathology of the disease.    
  
The congenital disorder Dyskeratosis congenita (DKC) is a condition characterised by a 
premature shortening of telomeres, manifesting in symptoms similar to progeria. 
Interestingly, despite no environmental exposure, an investigation found that two DKC 
patients developed sporadic UIP and went on to die from respiratory failure 170. Similarly, 
short telomeres are a risk factor for IPF and mutations in telomere regulators have been 
detected in IPF patients 143,171. Mice that have been naturally aged suffer a more severe 
response to BLM, with worsened fibrosis and elevated BAL levels of TGF-β, IL-17A and 
CXCL1 when compared to young counterparts (Figure 1.2.8B.) 172. Part of the changes 
that occur with age revolve around inflammation. The nuclear factor (NF)- B is a critical, 
systemic regulator in the inflammatory process, regulating transcription of numerous 
proteins such as TNF-α, IL-1β, IL-6 and CXCL1. Numerous pathways can induce its 
activity, including the ERK and p38 MAPK pathways 173. The activity of NF- B is thought 
to be important in driving the process of ageing. There are numerous subunits of NF- B, 
which can dimerise in differential configurations to either promote or suppress 
inflammation. In a transgenic mouse, with the suppressive components knocked out, 
there is chronic and progressive, low-grade inflammation. This inflammation drives 
premature ageing and impairs the regenerative processes in liver and gut 174. Likewise, 
inhibition of NF- B attenuates skeletal muscle loss in aged mice and prevents bone loss 
in models of osteoporosis 175. Another feature of ageing, that is likely to be important in 
IPF, is stem cell exhaustion. With age the ability of stem cells to repair and maintain their 
resident tissue declines. For example, in geriatric mouse muscle, the resident stem cells, 
the satellite cells, lose their ability to activate upon injury and proliferate to promote 
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muscle repair 176. Inflammation is again implicated in driving this decline in function. Hair 
follicle stem cells in the skin lose their functionality with age. This is associated with an 
age-related increase in local environmental cytokine signalling, which hyperactivates 
STAT-3, a transcription factor functioning downstream of Janus kinases (JAKs). JAKs 
respond to external cytokine signalling and JAK knockout decreases STAT3 
phosphorylation, promoting stem cell function 177.   
  
The biological changes that occur in ageing, which may cause or allow IPF development, 
have, however, yet to be fully elucidated. Understanding the biological landscape of the 
aged lung may better reveal the context within which IPF occurs and better direct 
therapeutic intervention.    
  
Summary  
Taken together, the evidence regarding persistent injury and aberrant repair are 
compelling. With the addition of genetic alterations, aberrant developmental signalling 
and a background of age, these features constitute the predominating characteristics of 
IPF. Importantly, these characteristics are not disparate, and epithelial-mesenchymal 
crosstalk is one feature involved throughout. Another phenomenon, one that perhaps 
unifies all these characteristics in IPF, is that of cellular senescence. The final section of 
this introduction will explore the cellular phenotype of senescence and discuss its role 
in the pathology of IPF.  
  
  
    
 1.3  Cellular Senescence  
  
Senescence has a pleiotropic role in human biology. It can be both beneficial, limiting 
cancer development, and detrimental, driving the ageing process. This antagonistic 
pleiotropy makes understanding its role in disease complex. Not only this, but there are 
numerous pathways leading to senescence, the selection of which can dramatically alter 
the role of the senescent cell.   
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1.3.1. What is Senescence?  
  
Senescence is a complex program of cell-cycle arrest, coupled with extensive phenotypic 
changes, including changes to morphology, metabolism and secretome. The term 
senescence derives from the Latin senex, meaning older man, and was first described by 
Leonard Hayflick in 1965 after the observation that primary fibroblasts in culture have a 
finite proliferative lifespan with serial passage 178. Following on from this, much research 
into senescence has focused on its role in cancer biology.   
  
In young organisms, senescence plays a crucial role in tumour suppression. 
Tumourigenesis occurs with the activation of oncogenes and the inactivation of tumour 
suppressor genes. A key suppressor is p53, a nuclear protein that responds to DNA 
damage and cell, stress signals; inhibiting proliferation to allow time for repair, or 
inducing apoptosis when damage is too great. Loss of p53 function is common in many 
types of cancer and its restoration can lead to tumour regression 179. This occurs due to 
induction of cellular senescence, which halts tumour growth and stimulates the immune 
system 180,181. Tumour suppression, however, represents just one facet of the numerous 
roles of senescence.   
  
1.3.1.1. Inducing stimuli  
Numerous stimuli can induce senescence. Broadly, senescence can be categorised into 
two forms, replicative and cellular (Figure 1.3.1) 182. The senescence observed by 
Hayflick was replicative senescence, the result of a loss of stability in chromosomal   
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telomeres, a form of senescence results from intrinsic cell events 183. With each 
replicative cycle of a cell telomere degradation occurs, ultimately disrupting 
chromosomal integrity and activating a DNA-damage response (DDR). This causes p53 
phosphorylation and activation of cyclin dependent kinase (CDK) inhibitors, preventing 
progression through the cell cycle and inhibiting growth. This is important in limiting 
tumourigenesis as, with continued mitotic divisions, the possibility of DNA mutations 
increases. By preventing proliferation, the risk of oncogenic mutation is decreased.    
  
Cellular senescence results from extrinsic stimuli and it can occur at any point of a cells 
replicative lifespan, irrespective of telomere integrity. Substantial DNA damage 
occurring in any chromosomal region activates the same pathways as replicative 
senescence. A DDR response is activated with downstream activation of the CDK 
inhibitor p21 184. Oncogenic signalling can induce cellular senescence, as can several 
other stimuli. ROS can cause senescence in a p38 dependent manner as can 
environmental cytokine signalling 185–188. Both neighbouring senescent cells and 
developmental pathways, functioning via TGF-β and SMAD, are also able to induce 
senescence as well as mitochondrial dysfunction 189–194.   
  
1.3.1.2. Senescence pathways  
All senescence pathways converge on the inhibition of Retinoblastoma protein (RB) 
phosphorylation, which prevents cell cycle progression by restricting transcription of E2F 
genes. RB inhibition is the result of upstream inhibition of numerous other cyclins and 
CDKs, facilitated by two main pathways, the p53-p21 and p16-pRB pathways. The 
p53p21 pathway, activated in response to DDR, ROS and oncogenic stimulation, is 
regulated by alternative-reading-frame (ARF) proteins, which inhibit the activity of E3 
ubiquitinprotein ligase (MDM2), an enzyme that degrades p53 195. This induces p21 
activity, which inhibits cyclinE-CDK2 activity. The p16-pRB pathway can be directly 
activated by oncogenic RAS signalling, or p38-mediated ROS signalling, and appears to 
function secondary to the p53-p21 pathway 196. Active p16 inhibits proliferation via 
inactivation of cyclinD-CDK4/CDK6 (Figure 1.3.2.) 197.   
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These pathways can be transiently induced in response to minor damage and 
deactivated upon repair, allowing a cell can revert to a proliferative state. It is only with 
sustained activation of these pathways that senescence is induced. For example, after 
irradiation induced DNA damage, cells recover via transient p53 expression. 
Pharmacologically sustained p53 expression however leads to differential gene 
expression and senescence 198. Likewise, the long-term activation of CDKN1A (which 
encodes for p21) by DDR leads to p38 and TGF-β signalling that causes mitochondrial 
dysfunction. Such dysfunction reduces oxidative phosphorylation, increasing the 
production of ROS (such as H2O2). This ROS consequently reinforces the senescence 
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pathways by creating further DNA damage, further activating the p16-pRB pathway. This 
process can be averted via the complete depletion of cellular mitochondrial content, 
achieved by PINK1 mediated targeting of the ubiquitin ligase, Parkin, to the 
mitochondria, promoting mitophagy 199. That elimination of mitochondria prevents 
senescence induction heavily implicates this heterogenous population of organelles in 
both establishing and maintaining this phenotype 200,201.   
  
1.3.1.3. Cellular changes  
The entrance of a cell into a permanent state of senescence is coupled with a diverse 
range of phenotypic changes. These arise from extensive chromatin remodelling events. 
Early remodelling occurs in satellite heterochromatin, located in the peri-/centromeric 
regions of the chromosomes. These regions undergo striking decondensation (in 
response to both senescence inducing pathways) in a process termed 
senescenceassociated distension of satellites (SADS) 202. These changes are followed by 
chromatin condensation in numerous other regions of the chromosome. The 
accumulation of these distinctly patterned, senescence-associated heterochromatic foci 
(SAHFs) act to sequester transcription of numerous genes, most notably those required 
for cell cycle control, including E2F genes 203,204. The regulation of these changes is 
controlled by lamin B1, which is downregulated to facilitate these changes 205,206.   
  
These alterations subsequently introduce a plethora of changes to a senescent cells 
transcriptome. Interestingly, the pattern of transcriptional differentiation varies 
substantially between cell types, despite induction via common pathways 207. 
Microarray analysis of fibroblasts in a state of replicative senescence reveals 
upregulation of mRNA for PAI- 1 and 2, CCL2, CXCL1 and MMP- 1 and 2. Concomitantly, 
there is down-regulation of cyclooxygenase-1 (COX1) and MMP3. Conversely, in retinal 
epithelial cells, Follistatin (FST) and prostaglandin D synthase (PTGDS) are upregulated 
without significant changes to inflammatory genes208.   
  
There are also alterations in cell morphology and metabolism, as well as alteration to 
the mitochondrial phenotype 209,210. With senescence there is an enlargement of 
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mitochondrial mass, and increases in mitochondrial volume fraction, organelle number 
and the copy number of mitochondrial DNA (mtDNA) 201. Similarly, then is an increase in 
the ratio of mtDNA/total cell protein 211.  However, these changes represent just some 
of the alterations that have been identified in senescent cells.   
  
The most significant changes to cell behaviour arise from an upregulation of genes 
encoding an array of secretory cytokines, chemokines, protease and growth factors, 
collectively termed the senescence-associated secretory phenotype (SASP). This 
phenotype does not arise in cases of transient DNA damage and p53 is not required to 
maintain it, instead persistent DDR signalling elicits both its activation and its 
maintenance 212. Analysis of the secretome of irradiated fibroblasts shows that SASP is 
composed of a broad range of proteins. These include factors such as: IL-6, CXCL1, 
CXCL8, GM-CSF, IL-7, Osteoprotegerin and HGF, though many others are also typically 
produced 213. Overall, the SASP is dominated by inflammatory cytokines, immune 
modulators and growth factors (Figure 1.3.3.).   
  
Activation of the NF- B pathway is an important upstream regulator of SASP induction, 
with activation leading to an up-regulation of IL1A and IL1B gene expression 214. They 
are produced as pro-proteins and their function is facilitated by the inflammasome, a 
multiprotein complex required for driving inflammation. Through stimulation of 
caspase-1 it can promote the processing of the precursor proteins of IL-1β and IL-1α, as 
well as IL-18 and IL-33, via a non-canonical protein processing pathway 215,216. The   
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inflammasome is heavily implicated in oncogene-induced senescence (OIS), with an 
increase in production of the mature forms of IL-1β and IL-1α. These cytokines are 
critical in inducing SASP, with inhibition of processing or inhibition of activity blunting 
SASP secretion, decreasing levels of IL-6 and CXCL8 191,217.   
   
1.3.1.4. Impact on the local environment  
Senescent cells exert their effect on the local environment via this secretory phenotype 
and such effects can be dramatic. SASP can facilitate and maintain senescence, with 
secretory factors such as IL-6, CXCL8 and WNT16B acting in an autocrine manner to 
establish persistent growth arrest 218,219. Not only this, but the components of SASP can 
induce senescence in neighbouring cells. Co-culturing normal epithelial cells with 
senescent fibroblasts can induce epithelial senescence, an event attributed to the 
properties of secretory proteins that can be recapitulated with senescent cell CM. 
Quantitative proteomics has revealed that VEGF signalling and the TGF-β pathway are 
be key in mediating this paracrine effect 191.   
  
Therefore, cellular senescence can be induced in response to numerous stimuli that, if 
sustained, create a stable form of cell-cycle arrest and the acquisition of an inflammatory 
secretory phenotype. But, aside from limiting tumourigenesis, what role does 
senescence play?  
  
1.3.2. The Homeostatic Roles of Senescence  
  
The context in which a cell becomes senescent is crucial in determining the role that 
SASP plays. In the young organism senescence plays numerous homeostatic functions 
that are carefully controlled to benefit organism fitness. As previously discussed, cellular 
senescence can occur at any stage of a cells proliferative lifespan, in response to not only 
DNA damage and oncogenic signalling, but also developmental pathways and cytokine 
signalling.   
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1.3.2.1 Embryonic development  
Senescence plays an important role from the earliest stages of an organism’s lifespan. In 
the embryonic mouse, senescence has been observed at numerous sites, including: the 
closing neural tube, apical ectodermal ridge (AER), interdigital webs, mesonephric 
tubules and endolymphatic sac (Figure 1.3.4.) 190,192.   
  
The AER is found at the distal tip of the nascent limb bud, marking the dorso-ventral 
boundary, and forming a signalling centre that facilitates both tissue growth and 
patterning. This is achieved by reciprocal signalling with a region of underlying, distal 
mesenchyme that forms the progress zone (PZ). In mice, at embryonic day 11, staining 
reveals AER-specific positivity for p21 and the classical senescence marker, 
senescenceassociated β-galactosidase (SA-βgal), as well as evidence of growth arrest. 
Interestingly, p53 signalling is absent, indicating senescence induction through a unique 
pathway. PZ mesenchymal signalling maintains this AER senescence by pERK signalling 
and in turn senescence promotes mesenchymal growth (Figure 1.3.5.) 190. In the kidney, 
organ development requires the involution of early forming mesonephric tubules, 
facilitating transition to a stage of metanephric development and establishment of the 
adult kidney. During early growth of the mesonephric tubules, the luminal epithelial cells 
express proliferation markers. As development continues this transitions to markers of 
senescence. This again occurs in a p53-independent manner, controlled by p21, and 
activated by TGF-β, Hedgehog and WNT pathways 192. Importantly, in both instances of 
senescence induction, immune infiltration occurs at the end stage of development and 
senescence markers decline. These investigations revealed a transient role of 
senescence in development, highlighting another example of epithelial-mesenchymal 
crosstalk in development and eluding to the role of developmental signals in regulating 
senescence.   
  
1.3.2.2. Wound repair  
Wound repair is characterised by the phases of haemostasis, inflammation, granulation 
tissue formation, re-epithelialisation and regeneration. In young mice, senescence has 
been identified as an important component of this process.   
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Using a mouse model that reports the presence of senescent cells via luminescence, and 
that can be pharmacologically treated to cause selective removal of these cells, the role 
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of senescence in repair has been better elucidated. Upon full-thickness, dermal 
punchbiopsy, a transient induction of senescent cells is observed, arising around day-3 
postinjury and peaking at day-6, prior to returning to baseline. Depletion of senescent 
cells during this time-course leads to an impairment of re-epithelialisation, as well as a 
loss of angiogenesis and collagen deposition. Senescence is induced in local fibroblasts 
and endothelial cells, which upregulate production of PDGF-AA and VEGF at the early 
stages of induction. These senescent cells further recruit fibroblasts and promote their 
differentiation to myofibroblasts, enabling efficient wound repair (Figure 1.3.6.) 220. A 
key inducer of fibroblast wound-site senescence has been identified as the matricellular 
protein, CCN1. CCN1 binds to integrin α6β1 and heparin sulphate proteoglycans, 
activating a DDR and ROS generation, leading to p16-pRB induced senescence. In the 
skin wounds of mice, and over a time-course of several days, the presence of 
CCN1mediated senescent cells causes an increase in gene expression of matrix 
degrading MMPs and limits the fibrogenic response in granulation tissue formation 221.  
  
1.3.2.3. Tissue regeneration  
Senescence also promotes tissue regeneration. New-born, primary mouse keratinocytes 
(PMKs) are able to regenerate skin when transplanted into tissue biopsy wounds, 
expressing numerous stem-cell markers. A short-term (2-day) incubation of PMKs with 
the CM of OIS cells enhances the expression of these markers, increasing colony-forming 
capacity in vitro and augmenting regeneration in skin grafts 222. These results indicated 
that a transient exposure to SASP can enhance the plasticity and regenerative potential 
of cells in the local environment, further implicating senescence as a beneficial, 
homeostatic process.   
  
Similarly, a key roadblock to the full regeneration of tissue is the development of fibrosis. 
In the liver, senescence has been found to limit fibrosis, enabling regeneration. Using a 
mouse model of cirrhosis, in which young mice are treated with CCl4 causing tissue   
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damage, fibrosis occurs, mediated by activated hepatic stellate cells (HSCs). 
Concomitant with the onset of fibrosis regression and tissue regeneration is the 
accumulation of senescent HSCs in regions of fibrosis. In this disease model, but in mice 
with a double knock-out of Tp53 and Cdkn2a, senescence is impeded and subsequently 
there is an increase HSC proliferation, an increase in ECM deposition and persistent, non-
resolving fibrosis 223. Similarly, in a mouse model of kidney fibrosis, p16 is significantly 
elevated post-injury injury. However, in a Cdkn2a- mouse, injury results in increased 
interstitial proliferation and subsequent fibrosis 224. Likewise, using an aortic constriction 
model of cardiac fibrosis in a Tp53-/Cdkn2a- mouse, senescence is decreased 
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corresponding to an increase in fibrosis. Inducing senescence can increase fibroblast 
senescence and reduce fibrosis 225. Importantly, however, studies in the cirrhotic mouse 
liver revealed that this homeostatic function of senescence is under strict, temporal 
regulation, with natural killer (NK) cell recruitment in the wild-type mouse leading to the 
selective clearance of senescent cells 223.  
  
1.3.3. The Detrimental Roles of Senescence with Age  
  
The benefits of senescence come when its induction is transient and tightly controlled. 
This so called ‘acute’ senescence is what facilitates embryonic development, wound 
repair and tissue regeneration in young organisms. When senescent cells persist, 
however, through either a lack of clearance or an accumulation, they become 
detrimental to tissue function. These ‘chronic’ senescent cells naturally accumulate in 
aged organisms and are now thought to be the central contributors to age-related tissue 
dysfunction and disease.   
  
1.3.3.1. The driving force in ageing  
In mammals senescent cells accumulate with age 226,227. The significance of this and the 
causal link between senescence and ageing has been described in two key investigations, 
both utilising the BubR1 mouse. This mouse has a hypomorphic mutation in the BubR1 
protein, a key mitotic checkpoint protein, which creates a progeroid phenotype, with 
shortened life-span, sarcopenia and impaired wound healing. By crossing this mouse 
with a Cdkn2a knockout, it was found that, with the subsequent absence of senescence, 
BubR1 lifespan was increased and muscle loss decreased 228. Further evidence was found 
after establishment of the INK-ATTAC mouse. This mouse, with a BubR1hypo background, 
has a reporter for p16, allowing for identification, but also a selective clearance of 
Cdkn2a expressing cells. Expression of CDKN2A coincides with expression of an 
apoptosis inducing element that can be activated upon pharmacological intervention. 
Investigation revealed that age-related phenotypes arise due to senescence cell 
accumulation and that clearance in older mice is able to delay the progression of several 
age-related changes, although reversal is not possible 229. In conjunction with the 
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concept of senescence driving ageing, mice strains that demonstrate sustained 
regulation of gene splicing display reduced markers of senescence and are longer-lived 
230.   
  
1.3.3.2. Promoting tumourigenesis  
The studies by Baker et al. demonstrated that senescence drives the ageing process. 
Encompassed within this though are numerous other detrimental effects of senescence. 
Almost paradoxically, the tumour suppression mechanism of senescence creates an 
environment, via SASP, that promotes tumourigenesis in neighbouring cells. Co-culture 
of senescent fibroblasts and pre-malignant mammary epithelial cells causes them to 
become invasive and undergo full malignant transformation 231. Senescent CM also 
induces upregulation of EMT markers in mammary, alveolar epithelial cells, evidenced 
by reduction in tight junction and adherens proteins and an increase in VIM expression. 
Key mediators of this are IL-6 and CXCL8 and neutralising antibodies towards these can 
reduce epithelial membrane invasion 213. As well as this, reduction of IL1A translation, 
by treatment with Rapamycin, reduces SASP and suppresses the ability of senescent 
fibroblasts to promote prostate tumour growth in mice 232.   
  
1.3.3.3. Impairing regeneration  
The transient exposure of SASP CM to progenitor cells enhances their stem-cell 
properties and regenerative capacity 222. However, in this same study, prolonged and 
repeated exposure to SASP lead to the impairment of regeneration, due, in part, to the 
effect of paracrine senescence. Chronic senescence in the liver also leads to failed 
regeneration and fibrosis. In mouse models of liver cirrhosis, senescence is transiently 
induced to limit fibrosis, with cells subsequently cleared by the immune system 223. This 
immune-mediated clearance is achieved by granule exocytosis, another form of 
secretory communication. Blocking this process leads to the persistent accumulation of 
senescent liver cells that leads to fibrosis 233. This implicates an important role of the 
immune system in facilitating acute senescence. Implantation of senescent cells into 
mice leads to the recruitment of innate immune cells, particularly macrophages. 
Insertion embedded within alginate beads allows secretory communication but prevents 
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immune-mediated senescent cell destruction. By studying the cells that accumulate 
around these beads it has been found that exposure to the senescent microenvironment 
leads to macrophages transiently entering a state of senescence themselves. The 
hypothesis was put forward that, with age, innate immune cell dysfunction causes 
chronic immune senescence, impairing clearance of other senescent cells and further 
impairing regeneration 234.    
  
Senescence therefore represents a cellular protocol that, though initiated under the 
pretences of limiting cancer, facilitating development and assisting repair, becomes a 
hazard to human health when unnecessarily sustained. This persistence occurs with age, 
the fault, in part, of a declining immune system, and within this setting, senescence 
ultimately impedes the processes of repair, a result that is followed by a decline in tissue 
function.   
  
1.3.3.4. Targeting senescence   
The deleterious effects of senescence in age have led to the development of numerous 
strategies aimed at targeting senescent cells and alleviating their effects. These 
strategies range from senescence reprogramming, to dampening SASP, or to the 
targeted apoptosis of senescent cells.   
  
Reprogramming of aged cells is complex. A recent study by Ocampo et al. used shortterm 
induction of the classical, pluripotency inducing transcription factors: Oct4, Sox2, Klf4 
and cMyc (OSKM) to ameliorate the hallmarks of ageing in mice. The genetic background 
of these mice meant that they prematurely aged and were able to express OSKM upon 
doxycycline treatment. Treatment extended mouse lifespan and reduced the hallmarks 
of ageing, an effect that was, in part, achieved by a systemic reduction in DNA damage, 
p53 activity and a downregulation of Cdkn1a and Cdkn2a, as well as expression of IL6 
235. Viable therapies for humans, however, cannot as easily rely on genetic modulation, 
therefore pharmacological therapies are attractive. Selfmaintenance of senescence 
involves autocrine IL-6 signalling 218. IL-6 binds to cytokine receptors on the cell surface 
leading to trans-phosphorylation of JAK 1 and 2. JAKs phosphorylate STAT3, which 
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translocates to the nucleus and regulates transcription of numerous genes, including 
those required for SASP. Molecular inhibition of JAK signalling inhibits this process and 
reduces production of numerous SASP proteins. Treatment in aged mice decreases 
systemic inflammation and is able to alleviate frailty 236. The selective clearance of 
senescent cells from chronologically aged and progeroid mice also delays the onset of 
age-related pathology and extends healthspan 237. This has been achieved with the Bcr-
Abl and Src family tyrosine kinase inhibitor Dasatinib (D) and the flavonoid Quercetin 
(Q), which, when used in combination, create what is termed a ‘senolytic’ therapy. 
Similar senolytic strategies have been achieved using an inhibitor of anti-apoptotic 
proteins (BCL-2 and BCL-xL), ABT263, with  which treatment in both prematurely and 
naturally aged mice rejuvenated muscle and haematopoietic stem cell populations 238. 
Most recently, targeted apoptosis of senescent cells has been achieved with a small 
peptide that blocks the interaction of p53 and FOXO4. This prevents p53 nuclear 
localisation and subsequently causes nuclear exclusion, leading to cell intrinsic apoptosis 
via caspase-3/7 235. Interestingly, the authors of this paper were unable to reproduce 
the selectivity of D+Q in vitro and ABT263 was found to influence control cells at low 
concentrations. Regardless, senescence is becoming well established as a viable 
therapeutic target, with clearance facilitating numerous beneficial effects across several 
animal models.  
  
  
1.3.4. Evidence for Senescence in IPF  
  
What, however, is the relevance of senescence to IPF? Does it play an important role in 
the disease and could it also be targeted? Thus far, there is compelling evidence to 
suggest that the answer is yes.   
  
Firstly, one of the driving forces in IPF is an aberrant reactivation of developmental 
signalling pathways, including signalling via WNTs, Hedgehogs and TGF-β (Intro 2.4.2.) 
Acute senescence plays a role in development and these pathways are important in 
establishing the phenotype 190–192. In particular, TGF-β can induce embryonic senescence 
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and WNT signalling can maintain senescence in an autocrine fashion. Therefore, if these 
pathways are persistently reactivated in IPF it could lead to the induction of senescence. 
Secondly, IPF is characterised by recurrent injury and an impaired wound healing 
response (Intro 1.2.4.3.). Though acute senescence in young animals is known to 
promote wound healing 220, its role in the context of age is hazardous, with chronic 
senescence understood to impair regeneration 222. Repeated injury could therefore 
cause persistent senescence that ultimately leads to the impairment of airway 
regeneration observed in IPF. Thirdly, IPF is a disease of ageing (Intro 1.2.4.4.). Age is 
the greatest risk factor for IPF and 80% of patients with the disease are over 75 169. With 
age there is an increase in the burden of senescent cells, cells that are causal in driving 
both the process itself and numerous other age-related pathologies 228,229. These cells 
go unchecked by a faltering immune system and accumulate to become chronically 
senescent and damaging to the local environment 234. This aged background 
subsequently provides fertile ground for the induction of senescence and its chronic 
activation. Taken together, this provides the rationale for the conception of a paradigm 
in which the acute signalling of developmental and repair pathways become chronically 
activated in the IPF lung, leading to the accumulation of senescent cells that further 
contribute to impaired regeneration and fibrosis. Direct evidence for such a paradigm 
does exist and recent publications have made the pathological role of senescence in IPF 
considerably more salient.   
  
1.3.4.1. Senescence in IPF  
Up until recently there has been little in vivo evidence of fibroblast senescence in IPF. 
Isolated FHLFs display the characteristics of senescence in vitro but the understanding 
was that there was a detrimental absence of senescence in this disease 239,240.  
Subsequently, strategies were employed to induce senescence with the aim of using it 
as a brake on excessive fibroplasia. HAS2, known to be a potent inducer of fibroblast 
differentiation and invasiveness, is more significantly expressed in the IPF lung and its 
overexpression in mouse leads to a more severe response to BLM 124. By depleting HAS2, 
senescence can be induced in mouse fibroblasts and it was subsequently suggested that 
the pathological phenotype conferred by HAS2 prevents senescence and therefore 
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prevents wound resolution. HAS2 was subsequently proposed as a target to promote 
resolution of fibrosis 240. Furthering this, a study investigating the micro RNA, miR-34a, 
found that it was upregulated in FHLFs. However, mice deficient in this miRNA 
developed a worsening of BLM-induced fibrosis. miR-34a induces HLF senescence, 
suggesting that it acts in a negative feedback loop, inducing senescence in response to 
fibroplasia, limiting fibrosis. Restoring this feedback was therefore suggested to help 
resolve fibrosis 241.   
  
Other studies have, however, focused on the detriment of an excessive senescence 
burden in IPF. In young mice BLM-induced fibrosis can resolve over time (although this 
is not a universal finding). However, in aged mice fibrosis does not resolve. This is 
associated with an increase in the burden of senescent fibroblasts. Both young and aged 
mice accumulate senescent fibroblasts in response to injury. In the young though, their 
existence is transient whereas in the aged these cells persist. This chronic accumulation 
was found to impair resolution and promote fibrosis 242. Likewise, shortening of 
telomeres is associated with a poorer prognosis in IPF. Telomere specific dysfunction in 
AEC2s causes them to become senescent and lose their regenerative capacity. This 
causes subsequent lethality upon BLM instillation 145. A consequence of telomere 
dysfunction in AEC2s is an increase in production of pro-inflammatory cytokines, 
creating an environment of low-grade, sterile inflammation, analogous to ageing. The 
occurrence of this in the lung is able to contribute to myofibroblast differentiation 243.  
Cellular senescence has also been identified in the epithelial cells of IPF lung tissue. In 
vitro, TGF-β1 induces senescence in primary HBECs, causing them to produce elevated 
levels of IL-1β, which subsequently causes fibroblast differentiation 244. Protecting AECs 
from senescence by knocking out expression of the protein caveolin-1, reduces 
senescence and also attenuates fibrosis 245. Senescence markers have been found in 
AEC2s within IPF tissue. This is understood to be the result of an elevation of the 
senescence-associated micro-RNAs, miR-34a-c 246.   
  
Finally, senescence has most recently been identified in both the epithelium and the 
mesenchyme of IPF patient tissue, in a study investigating the targeted clearance of 
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senescent cells (Figure 1.3.7.). Expression of p16 was found to be increased with 
increasing disease severity and the senescence secretome is complicit in fibrogenesis. 
Transgenic ablation and treatment with the senolytic combination of D+Q was found to 
selectively clear senescent cells. The effect of this was an improvement in pulmonary 
function and overall health after BLM instillation 247. This study provides the best 
evidence so far that senescence plays a critical role in IPF and that senescent cells are a 
viable target for therapeutic intervention.   
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 1.4  Summary and Thesis Aims  
  
This introduction has attempted to cover a diverse range of biological concepts and 
research, encompassing the current understanding of epithelial-mesenchymal crosstalk, 
IPF and cellular senescence. The aim of this introduction has been to impress the 
importance of communication between cell types, highlighting the importance of these 
processes in both health and disease. More specifically it has aimed to identify examples 
of crosstalk within normal lung physiology, discuss how this goes wrong in the pathology 
of IPF and observe how it participates in the phenomenon of senescence. Subsequently, 
the importance of the fibroblast phenotype in mediating crosstalk (through 
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inflammatory signalling) has been highlighted. Ultimately this introduction has aimed to 
demonstrate that the driving forces of IPF are interconnected with the processes of 
cellular senescence, a connection enabled by secretory crosstalk between the 
epithelium and the mesenchyme.   
  
Consequently, the overarching experimental aim of this thesis was to understand more 
about the biology of IPF-derived fibroblasts, uncovering new insight into their 
pathological properties, with a particular focus on their roles in inflammation and 
senescence. The hypothesis of this work was that a breakdown in 
epithelialmesenchymal crosstalk is a key driver of IPF, with the senescent fibroblast 
acting as a critical orchestrator of this process and a viable therapeutic target.    
  
Specifically, the aims of this project were broken down into:  
1. The isolation of primary HLFs and their phenotypic characterisation in vitro.  
2. The establishment of an in vitro model of secretory crosstalk, allowing 
investigation of epithelial-mesenchymal crosstalk.  
3. Determining the effect of FHLF co-culture on the ability of the epithelium to 
respond to injury.  
4. The induction of senescence in NHLF to create a benchmark cell phenotype with 
which to compare FHLFs.  
5. Pharmacological modulation of secretory crosstalk in vitro.     
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2. Methods and Materials  
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 2.1  Cell Culture  
  
2.1.1. General plastic ware and chemical reagents  
  
Cells were propagated in sterile tissue culture flasks, (Thermo Scientific, USA) or (Greiner 
Bio-one, Austria). Experiments were performed on Nunc cell-culture treated multidishes 
(Thermo Scientific, USA). Cell suspensions and other tissue culture reagents were 
handled in 15 ml (Thermo Scientific, USA) and 50 ml (Greiner Bio-one, Austria) centrifuge 
tubes and transferred with serological pipettes: 5 ml, 10 ml, 25 ml (Fisherbrand, USA). 
Sterile micro-centrifuge tubes (0.6 ml and 1.5 ml) were purchased from (Thermo 
Scientific, USA). Cell culture grade, endotoxin free ddH2O and phosphate-buffered saline 
(PBS) were also purchased from (Thermo Scientific, USA). Tris-buffered saline (TBS) was 
made using tris-base (Fisher Bioreagents, USA), sodium chloride (Fisher Bioreagents, 
USA), ddH2O (purified by a PURELAB-Ultra system) (Elga, USA), and hydrochloric acid 
(Fisher Bioreagents, USA).   
  
2.1.2. Cell culture conditions and general practice   
  
Cell Culture  
All cells were cultured at 37 oC, 5% CO2, under atmospheric levels of O2. Cells were 
routinely passaged before reaching confluency. Passage consisted of: removal of the 
culture media, a brief wash with serum-free media, trypsinisation (Gibco, UK), 
neutralisation with media containing 10% foetal bovine serum (FBS) (Gibco, UK) and 
transfer into a fresh flask. For the seeding of cells into experimental plates, cells were 
counted after neutralisation using a haemocytometer. The suspension of cells was then 
pelleted via centrifugation at 200g for 4 mins, the supernatant aspirated, and the pellet 
re-suspended in 1ml of media. The proportion of cells was then aliquoted and seeded as 
required.   
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Long-term storage  
For long-term storage, cells were trypsinised and pelleted as previously described. Cells 
would then be re-suspended in cryo-media, a mixture of 50% media, 40% FBS and 10% 
dimethyl sulfoxide (DMSO) (Sigma Aldrich, UK). Cells in cryo-media suspension would 
then be aliquoted into cryogenic storage vials (1 ml/vial) (Thermo Scientific, USA) and 
stored at -80 oC in a Mr. Frosty (Thermo Scientific, USA). The Mr. Frosty, containing 
isopropanol (Fisher BioReagents, USA), facilitated a cooling rate of ≈1 oC/min. Cells were 
stored for a minimum of 24 hrs at -80 oC prior to long-term storage in liquid nitrogen 
(LN2).   
  
Defrosting cells  
Cells were defrosted from LN2 storage by the addition of pre-warmed media. 1 ml of 
media would be added to each vial and gently mixed by repetitive pipetting. The 
defrosted cells would then be transferred to a T75 flask with 20 ml media, to dilute the 
DMSO. After overnight adherence, the media was replaced.   
  
2.1.3. Cell lines  
  
To model the lung airway epithelium, the 16HBE14o- (HBECs) transformed cell line was 
used. This line has been immortalised via transfection with SV40 T-antigen encoding 
DNA. The cells form tight junctions, become polarised and display vectorial ion 
transport, making them appropriate for airway modelling 248. Though other lines were 
available (such as BEAS-2B or A549), this line was chosen as distal bronchiolisation is 
evident in IPF and represent an interesting aspect of IPF pathology (Intro. 2.3.2.). HBECs 
were a kind gift from Dr Jo Porter (University College London) and were cultured in 
alpha-minimum essential medium (αMEM) (w/ L-glutamine and penicillin-streptomycin) 
(Lonza, Switzerland), with 10% FBS.   
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2.1.4. Primary fibroblast isolation  
  
Primary human lung fibroblasts (HLFs) were isolated from patient tissue via a standard 
method of explantation. This process started with the surgical removal of lung tissue by 
the Cardiothoracic surgery team at the Royal Devon & Exeter Hospital (RD&E). Tissue 
that was surplus to requirements for diagnostic purposes was stored on ice and 
transport to the lab. Tissue sections were further dissected into 1 mm3 pieces. These 
explants were recessed into 10 cm2 tissue culture dishes and covered in a minimal 
volume of Dulbecco’s modified eagle medium (DMEM) (Gibco, UK), 20% FBS with 
Amphotericin-B (2.5 μg/ml) (VWR, UK). Plates were incubated for 24 hrs prior to the 
addition of more media, submerging the explants. These plates were cultured for a 
further 3–5 weeks to allow cell outgrowth, without media change but with 
Amphotericin-B addition every 3-4 days. When good outgrowth had occurred, plates 
were washed in serum-free media, trypsinised and passaged into T175 flasks.  
Confirmation of the successful isolation of a fibroblastic population of cells was achieved 
by positive immunofluorescent staining for the mesenchymal marker vimentin and the 
absence of staining for the epithelial marker cadherin (CDH1). Cells were then available 
for use in experiments or for population expansion.   
  
2.1.5. Primary HLFs and continuous culture  
  
Of the cells derived by this process during this project, seven were normal HLF lines 
(NHLFs). These cells were derived from the marginal tissue surrounding a tumour 
resection, tissue was free of any obvious pathology. Of the seven, five were from males, 
two from females and the average age of donor was 72 years-old.   
  
Fibrotic HLFs (FHLFs) were derived in-house from one patient during this project; three 
other primary FHLF lines (BR001-3) were provided as a gift from Professor Ann Millar 
(University of Bristol). All IPF tissue was obtained by video-assisted, thoracic surgical 
biopsy and was used to assist with the diagnosis of IPF via histological identification of a  
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UIP pattern. All donors were subsequently confirmed to have IPF. Donor information for 
explanted HLFs is provided in (Table.2.1.1.) with cells ascribed a donor ID as stipulated 
by the RD&E. All HLFs were cultured in DMEM (w/ high glucose, L-glutamine, phenol red, 
penicillin-streptomycin; and w/o sodium pyruvate and HEPES) 10% FBS, the 
amphotericin used in the early stages of explantation was not used during continuous 
culture.   
  
All primary cells were used in experiments between passage 3 and 11. Population 
doublings were not consistently accounted for, but the passage range was used under 
the assumption from previous work in this lab that significant phenotypic changes do 
not occur within this range, and that the observable behaviour of a primary cell line at 
p11 should reflect, with equivalence, the behaviour at p3.   
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2.1.6. Co-culture systems  
  
Experimentation in co-culture required the use of transwell, hanging inserts (Greiner 
Bio-One, Austria). A 24-well size was used with a culture area of 33.6 mm2. Inserts had a 
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transparent PET membrane with 0.4μm diameter pores, at a density of 2x106  cm-2. The 
membrane was suitable for HBEC culture, allowing secretory component exchange. The 
inserts do not come into contact with cells co-cultured basolaterally and do not cause 
cell damage or prevent growth. For co-culture experiments, at -24 hrs, HLFs were seeded 
at a density of 12,000 cells/well (unless stated otherwise) in an experimental, 24-well 
plate. HLFs were cultured in DMEM 10% FBS and not seeded into the outer wells of 
experimental plates, these were filled with media, maintaining humidity in co-culture 
experiments. HBECs were concurrently seeded at a density of 22,000 cells/well in 
transwell inserts in a separate plate, with αMEM-/10% FBS. 24 hrs later, at 0 hr, the 
inserts were transferred into co-culture with HLFs. This coincided with media change to 
a 1:1 mix of DMEM /-αMEM 10% FBS. Media was not changed again for the duration of 
the experiment (Figure 2.1.1). Though serum was used throughout all experiments it is 
appreciated that the array of different factors within potentially add an unnecessary 
level complexity to the co-culture system. The conditions for co-culture experiments, 
including cell number, time-course and the media used was previously optimised, with 
the most robust set up used throughout this investigation.   
  
2.1.7. Stress-induced premature senescence (SIPS)  
  
For the investigation of senescence in NHLFs, SIPS was induced in NHLFs using H2O2 
(H2O2; 30% w/w [= 9.79 M] in H2O, Sigma Aldrich). Reproducing a consistent and equal 
burden of senescence across experiments was extremely difficult to achieve; different 
NHLF lines responded differently to H2O2 treatment with large variations in toxicity that 
were unexpected. Consequently, the protocol was individually tailored to each cell 
isolate to achieve reproducible senescence across donors. Quantification of the 
percentage of senescent cells was performed and this displayed along with the 
experimental data. What follows is a generalised form of the SIPS protocol.   
  
NHLFs were seeded at 1.0x106 cells / T75 flask and allowed to adhere overnight under 
normal conditions. For the following 5 days flasks were treated with 200 (±100) μM H2O2 
daily (am). On day 6 flasks were passaged 1 in 3 (±1) and allowed to adhere overnight.  
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On day 7 the media was changed, and cells allowed to recover for up to a further 6 days.  
On day 13 cells were passaged, counted and seeded for experiments.   
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 2.2  Cell-based Assays  
  
2.2.1. Trans-epithelial electrical resistance measurements  
  
Trans-epithelial electrical resistance (RTE) provides a measure of ionic permeability, 
indicative of cell monolayer development. The EVOM2, Epithelial Volt/Ohm Meter 
(World Precision Instruments, USA) was used to measure RTE. This instrument uses an 
STX2 chopstick electrode to apply an AC current across the epithelial layer via two silver 
coated electrodes. The voltage is measured and resistance in Ohms calculated. RTE data 
are expressed in KΩ cm2. The average Ω reading across a blank insert membrane was 
450 Ω (n = 5, SEM = 13 Ω). The culture surface of each insert was 3.36 mm2. RTE was 
calculated by: ((reading –  blank reading) / surface area) / 1,000.  
  
2.2.2. Wound healing assays  
  
Wound healing assays were performed throughout this investigation to identify the 
capacity of HBECs to re-epithelialise after injury. For all wound healing assays, HBECs 
were cultured on transwell inserts for 72 hrs without media change. Inserts were then 
removed and placed in a 12-well plate. Using a p200 pipette tip, a scratch was drawn 
down the centre of the insert, wounding the cells. Without media change, inserts were 
then returned to their respective culture conditions. Immediately after wounding (0 hrs) 
cells were imaged using an EVOS XL Core cell imaging system (Invitrogen, UK). Images 
were taken again at various timepoints up to 9 hrs. Quantification of the percentage 
wound closure was performed using ImageJ. For each wounded HBEC culture, the 
wound void was demarcated on ImageJ, allowing calculation of the percentage area of 
the wound. The macro used on ImageJ was:  
  
run("Fill", "slice"); 
run("Clear Outside"); 
run("Make Binary"); 
run("Measure");  
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The percentage wound closure was calculated by finding the percentage by which each 
wound void had decreased in area at each timepoint.   
  
2.2.3. SA-βgal activity staining  
  
SA-βgal staining works on the principal that, due to an excess accumulation of damaged 
organelles and macro-molecules during senescence, there is a significant increase in 
lysosomal β-D-galactosidase activity, enough to be detectable at a sub-optimal pH of 6.0 
249. This activity has been robustly identified as a characteristic unique to senescent cells, 
although some cells maintained at confluence can also display this activity. The protocol 
used to detect SA-βgal activity was taken directly from ref. 249, following the 
chromogenic assay method.   
  
Staining   
The composition of 1 ml of X-gal staining solution was achieved according to 
(Table.2.2.1). The reagents used were made up in dH2O and included: 100mM citric acid 
solution, C6H8O7.H2O; 200 mM sodium phosphate (dibasic) solution, NaH2PO4.H2O; 100 
mM potassium hexacyano-ferrate (II) trihydrate solution, K4[Fe(CN)6] 3H2O; 100 mM 
Potassium hexacyano-ferrate (III) solution, K3[Fe(CN)6]; 5 M sodium chloride, NaCl; 1 M 
magnesium chloride hexahydrate solution, MgCl2.6H2O; 20 mg/ml 5-Bromo-4-chloro-
3indolyl β-D-galactosidase (X-gal), made up in N,N-dimethylformamide. All reagents 
were purchased from Sigma Aldrich, UK. Each component of the solution was made in 
advance and stored at 4 oC. The final solution was made on the day of staining.   
  
Cells, cultured for at least 24 hrs post seeding, were washed with PBS 3x for 10 sec then 
fixed for 20 min at RT in 4% paraformaldehyde (PFA) (Fisher Bioreagents, USA). This was 
followed by a 3x 5 min PBS wash at RT. Staining solution was then added, and PBS added 
to any remaining empty wells (to maintain humidity). The plate was then sealed in 
parafilm and incubated at 37 oC overnight. After incubation, cells were washed 1x 1 min 
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in PBS at RT prior to imaging using an EVOS XL Core cell imaging system (Invitrogen, UK) 
SA-βgal activity was highlighted in cells via a blue chromogenic stain.   
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SA-βgal quantification  
SA-βgal activity was quantified using ImageJ. Images of cells were taken (at 10x 
magnification: 400 μm scale bar) and the total number of cells, and the number of blue 
staining cells, were counted using the ImageJ cell counter. This allowed percentage 
positivity to be calculated.   
  
2.2.4. Mitochondrial membrane potential measurements  
  
2,000 cells/well were seeded into clear 96-well plates and allowed to adhere overnight 
under normal culture conditions. Tetramethylrhodamine, ethyl ester (TMRE) (Sigma 
Aldrich, UK) and carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (Sigma 
Aldrich, UK) were diluted from stock in normal media. FCCP was added to the media of 
each relevant well and incubated for 10 min. The media was removed and replaced with 
a dilution of TMRE. The plate was then incubated for 15 min followed by 2x 30sec wash 
with PBS. PBS was then replaced with normal media. The plate was then read using a 
SpectraMax M2e microplate reader (VWR, UK). A bottom read at excitation/emission 
548/575 nm was performed. Data are presented as fluorescence intensity.   
  
2.2.5. Cell viability and cell counting assays  
  
Cell viability was assessed using the ReadyProbes Cell Viability Imaging Kit (Invitrogen, 
UK). This kit comprises of a NucBlue Live reagent and NucGreen Dead reagent. NucBlue 
stains the nuclei of all cells, with an excitation/emission maxima of 360/460 nm. This 
staining was visible with the EVOS FL cell imaging system DAPI filter. NucGreen stains 
dead cells that have compromised cell membranes. Excitation/emission maxima of 
504/523 nm allow visualisation with the GFP filter. For live cell staining, 2 drops/ml of 
each reagent was added to the cell media. Cells were then incubated under normal 
conditions for 30 min and then viewed by fluorescence microscopy. To count all cells, 
images were taken and analysed using the ImageJ 3D objects counter plugin. This 
identified all cells with NucBlue staining. Cells also staining for NucGreen were counted 
manually.   
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Alamar blue (Sigma Aldrich, UK) was also used to quantify cell number. The reducing 
environment of live cells allows the conversion of resazurin, the active component of 
Alamar blue, from a non-fluorescent, blue compound to resorufin, a highly fluorescent, 
red compound. Resazurin is non-toxic and cell permeable.  For each cell line assessed, a 
serial dilution of seeding densities was plated and allowed to adhere overnight. Alamar 
blue was then diluted 1:10 into the cell media and incubated under normal conditions 
for 2 hr 30 min. The resulting fluorescence was measured using a SpectraMax M2e 
microplate reader. Fluorescence intensity was plotted against cell seeding density, and 
linear regression analysis performed, giving a standard curve. This protocol was 
repeated for proliferation experiments. The number of cells in experimental conditions 
was calculated using the standard curve.   
  
Cell number was further quantified in several experiments using a haemocytometer. 
HLFs, seeded in a co- or mono-culture format at 12,000 cells / well (in a 24-well plate), 
were washed and trypsinised with 100 µl of trypsin. After 2 mins, this was neutralised 
by addition of 100 µl of media (w/ 10% FBS) and mixed via pipetting. 8 µl of cell 
suspension was then transferred to a window of a haemocytometer and the cells were 
counted across 5 grids. This was repeated with a second aliquot of suspension and the 
total number of cells divided by the number of grids used, giving an average. This was 
used to calculate the number of cells per well.   
  
    
 2.3  Molecular Assays  
  
2.3.1. Reverse transcription – quantitative polymerase chain reaction (RT-qPCR)  
  
RNA isolation  
Working areas (fume-hood, work bench) and pipettes were cleaned with RNAse Away 
spray (Thermo Scientific, USA). Cell culture media was removed from tissue culture 
plates and TRI reagent (Sigma Aldrich, UK) added in a fume-hood. Using a pipette tip, 
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the surface of each plate was scraped and the reagent repetitively mixed. Samples were 
then transferred into 1.5 ml micro-centrifuge tubes and stored at -20 oC until subsequent 
use.   
  
From -20 oC, samples were returned to a clean fume-hood and allowed to defrost and 
stand at RT for 5 min. 200 μl molecular biology grade chloroform (Thermo Scientific,  
USA) was then added (per 1 ml TRI reagent) and samples were vortexed for 8 sec. 
Samples were incubated at RT for 10 min prior to centrifugation at 4 oC, 14,000 g for 15 
min. This created three phases: a lower phase = organic protein (pink), intermediate 
phase = DNA (white) and an upper phase = aqueous, RNA (clear). The aqueous phase 
was carefully removed from each tube, taking care not to contaminate with protein or 
DNA, and transferred to a fresh micro-centrifuge tube on ice. 500 μl molecular biology 
grade isopropanol (Thermo Scientific, USA) was then added (per 1 ml TRI reagent) and 1 
μl Glycoblue RNA co-precipitant (15mg/ml; Ambion, UK). Isopropanol facilitates RNA 
precipitation and Glycoblue gives the RNA a blue colouration. Samples were inverted to 
mix and allowed to stand at RT for 10 min prior to centrifugation at 4 oC, 13,000 g for 12 
min. This centrifugation created a blue RNA pellet. On ice, the supernatant was removed 
by vacuum pump and the pellet was washed via addition of 500 μl ice-cold 75% ethanol 
– made up in 0.1% diethyl pyrocarbonate (DEPC) ddH2O (Sigma Aldrich, UK). The samples 
were inverted to detach the pellet and aid the ethanol washing. Samples were then 
centrifuged again at 4 oC, 10,000 g for 8 min, returned to ice and the supernatant 
aspirated. After aspiration, with the micro-centrifuge lids left open, the samples were 
left at RT to dry. The pellets were then re-suspended in 11 μl ice-cold, nuclease-free H2O 
(Ambion, UK) via repetitive, but gentle, pipetting. Samples could then be stored at -20 
oC until required.   
  
To quantify sample RNA content, 1 μl of sample was analysed using a NanoDrop 8000 
spectrophotometer (Thermo Scientific, USA). Prior to this the machine was calibrated 
and blanked (with nuclease-free H2O). RNA concentration was measured in ng/µl. 
Protein contamination was also measured via the A260/A280 ratio. A ratio of 2.00 was 
considered optimal, samples with a ratio below 1.70 were discounted for further use.   
  
109  
  
  
DNAse treatment  
To eliminate any genomic DNA contamination, samples were treated with a DNAse kit.  
1.2 μl 10X Precision DNAse reaction buffer (Primerdesign, UK) was added to samples on 
ice, along with 0.5 μl Precision DNAse enzyme (Primerdesign, UK), per 10 μl sample. 
Samples were briefly vortexed and pulse-spun. Using a thermocycling heat-block, 
samples were then incubated at 30 oC for 10 min (to activate the enzyme), followed by 
incubation at 55 oC for 5 min (to deactivate the enzyme). Samples were then returned 
to 4 oC.   
  
cDNA synthesis  
RNA samples were diluted to equivalent concentrations with nuclease-free H2O. 
Samples were then briefly vortexed and pulse-spun. qScript reagents were defrosted on 
ice, vortexed and pulse-spun. A cDNA synthesis reaction mix was created according to 
Table.2.3.1a using qScript 5X Reaction Mix (Quanta Biosciences, UK) and qScript Reverse 
Transcriptase (Quanta Biosciences, UK). cDNA synthesis reaction mixes were briefly 
vortexed and pulse-spun prior to an incubation protocol of: 22 oC for 5 min, 42 oC for 30 
min, 85 oC for 5min and a final hold at 4 oC. cDNA samples were then diluted 1:2 with 
nuclease-free H2O. Samples could then be stored at -20 oC, until required.    
  
Reference genes  
The reference genes GAPDH and B2M were used for all RT-qPCR experiments. The 
validity of these reference genes was confirmed using a GeNorm Reference gene kit 
(Primerdesign, UK). This kit comprises of 11 housekeeping genes (CYC1, ACTB, SDHA, 
TOP1, ATP5B, GAPDH, RPL13A, EIF4A2, UBC, B2M and YWHAZ) which were tested on 
HLF samples from NHLF or FHLF mono-cultures, either 24 or 144 hrs post-seeding, or 
cocultures, 144 hrs post-seeding. The resulting Ct values were analysed using qBASE+ 
software. The average expression stability of reference targets was analysed to give a  
GeNorm M value, of which values <0.50 were considered stable for reference gene use. 
For the experimental conditions described, GAPDH had an M value <0.40 and B2M a 
value <0.34.   
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RT-qPCR reaction   
For the RT-qPCR reaction, 20X TaqMan Gene Expression Assay (Thermo Scientific, USA), 
including genes of interest and reference genes, PrecisionPLUS Master Mix 
(Primerdesign, UK) and cDNA samples were defrosted on ice, vortexed and pulse-spun. 
RT-qPCR reaction mixes were made according to Table.2.3.1b. 8 μl of each mix was 
dispensed into the relevant well of an RT-qPCR 96-well plate (Primerdesign, UK). This 
was followed by 2 μl of cDNA. Technical duplications of each reaction were not 
performed. An optical adhesive seal (Primerdesign, UK) was then firmly applied and the 
reaction plate spun for 1 min in a plate centrifuge. The plate was then run on a Roche 
LightCyler96 RT-qPCR machine (Roche, UK). The PCR reaction was setup as follows: 1x 
pre-incubation (95 oC for 120 sec), followed by, 40x 2-step amplification (95 oC for 10 
sec, 60 oC for 30 sec), ending with 1x cooling (37 oC for 30 sec). For the TaqMan primers 
used, the reaction was measured on the FAM channel. The TaqMan primers used were 
predesigned, with an amplification efficiency of 100% (±10%), according to the 
manufacturer. A list of primers used can be found in Table.2.3.2.   
  
Relative quantification analysis  
Ct values were obtained for each reaction using the LightCycler96 software. A Ct value 
is described as the cycle at which the fluorescence of a sample rises above the 
background fluorescence and is pre-determined by the software. The geometric mean 
of reference gene Ct values was calculated for each experimental sample. This value was   
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then subtracted from the Ct value of each corresponding gene of interest, giving a ΔCt 
value. The average ΔCt value for experimental controls was calculated, giving a calibrator 
value. This was subsequently subtracted from all ΔCt values to give a ΔΔCt value. All 
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statistical analyses were performed using ΔΔCt values. RT-qPCR data is shown using 
average fold change values. Fold change was calculated by finding the antilogarithmic 
value of each logarithmic ΔΔCt value.   
  
Limitations of analysis  
Though a standard approach for analysing and presenting qPCR data, this approach is 
caveated by that fact that individual genes are calibrated and normalised to themselves. 
This approach means that the relative quantity of other genes assessed is not reflected 
in the fold change value. Therefore, a gene of interest may display a 4-fold increase 
under experimental conditions, appearing to be an extremely significant result when 
compared to a 2-fold increase for an alternate gene, however the quantity of RNA 
measured may extremely small and the differences of no real biological impact. This 
issue can be overcome by calibrating results to the controls of all genes analysed. This 
can better display the relationship between RNA levels for the different genes analysed. 
Though useful, however, this approach is also flawed due the experiments in this 
investigation utilising various panels of transcripts. Having different genes means that 
the relative change between experiments is not comparable, as a the addition of a 
certain gene could vastly skew the observable relative quantity. If the same gene set was 
used each time, with genes known to affect each other’s expression and regulation, 
whole gene-set calibration would be useful. Therefore, with these considerations in 
mind, the ΔΔCt method with graphs plotting fold change was used throughout.   
  
2.3.2. Relative mtDNA Copy Number Analysis  
  
The 16-kilobase mitochondrial genome (mtDNA) encodes 13 mitochondrial proteins 
required for the electron transport chain. There are many copies of this genome 
throughout a cell, with their replication occurring independently of the cell cycle. The 
copy number of mtDNA can be indicative of cell health and mitochondrial function. The 
human mtDNA monitoring primer set quantifies the relative mtDNA copy number by 
amplifying two regions of mtDNA (SCLO2B1 and SERPINA1) and two regions of nuclear 
  
114  
  
DNA (nDNA) (ND1 and ND5). nDNA content is used as a reference for mtDNA and the 
difference in Ct values is used to calculate mtDNA copy number.   
  
DNA preparation  
DNA was isolated using the PureLink genomic DNA mini kit, which comprised of: 
proteinase-K, RNase-A, genomic lysis/binding buffer, spin columns, collection tubes, 
wash buffer-1, wash buffer-2, and genomic elution buffer (Invitrogen, UK). Adherent 
cells were trypsinised and centrifuged (4 min, 200 g). The supernatant was then 
removed and the cellular pellet re-suspended in 200 μl PBS. 20 μl of proteinase-K and 
20 μl of RNase-A were added and the sample briefly vortexed. Sample was then 
incubated at RT for 2 min. 200 μl genomic lysis/binding buffer was added, the sample 
briefly vortexed and then incubated in a waterbath for 10 min at 55 oC. 200 μl of 100% 
ethanol (Sigma Aldrich, UK) was added and the sample briefly vortexed. The 640 μl lysate 
was then transferred to a spin column (with collection tube) and centrifuged at 10,000 
g for 1 min. The collection tube was changed, 500 μl wash buffer-1 added and the sample 
centrifuged again at 10,000 g for 1 min. This step was repeated using wash buffer-2, with 
centrifugation at 22,000 g for 3 min. 50 μl of genomic elution buffer was then added to 
the spin column and it was incubated for 1 min at RT. The spin column, with fresh 
collection tube, was then spun at 10,000 g for 1 min. The elution buffer was taken from 
the collection tube and re-added to the spin column. It was then centrifuged at 22,000 
g for 2 mins. The eluted genomic DNA was then transferred to a fresh micro-centrifuge 
tube and stored at -20 oC.   
  
RT-qPCR  
DNA samples and RT-qPCR reagents were defrosted on ice. DNA content was measured 
using a NanoDrop 8000 spectrophotometer (Thermo Scientific, USA) and samples 
diluted to equivalent concentrations with nuclease-free H2O (Ambion, UK). The reaction 
mix was formulated according to Table.2.3.1c using Human mitochondrial DNA 
monitoring primer set (Clontech, USA) and PrecisionPLUS Master Mix w/ SYBR green 
(Primerdesign, UK). A mix of nuclease-free H2O and PrecisionPLUS master mix was first 
added to a RT-qPCR 96-well plate (Primerdesign, UK), followed by DNA samples, then 
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the relevant primers. The plate was sealed with an optical adhesive seal (Primerdesign, 
UK) and spun for 1min. The reaction was then performed on a Roche LightCyler96 
RTqPCR machine (Roche, UK). The PCR reaction was setup as follows: 1x pre-incubation 
(95 oC for 120 sec), followed by, 40x 2-step amplification (95 oC for 10 sec, 60 oC for 45 
sec), ending with 1x melting (65 oC for 60 sec, 95 oC for 10 sec and 97 oC for 1 sec). For 
the primers used, the reaction was measured on the SYBR green channel.  
  
Analysis  
To calculate mtDNA relative copy number, two ΔCt values were calculated, from the 
difference in Ct values of ND1 and SCLO2B1, and ND5 and SERPINA1. These values were 
converted to 2ΔCt and averaged, giving a mean copy number of mtDNA for each sample.   
  
2.3.3. Western blotting  
  
Protein preparation  
The media of cells in culture was removed and the cells washed twice in PBS. Tissue 
culture plates were kept on ice for 5min prior to PBS aspiration and addition of ice-cold 
RIPA buffer, (10ml): 100 μl IGEPAL CA-630 (Sigma Aldrich, UK), 0.05 g sodium 
deoxycholate (Fisher BioReagents, USA), 100 μl 10% sodium dodecyl sulphate (SDS) 
(Fisher BioReagents, USA), 1x tablet Complete Mini Protease Inhibitor Cocktail (Roche, 
UK); 9.8 ml PBS. For investigation into phosphorylated protein expression, PhosphoSafe  
Extraction reagent (Millipore, UK) was used, which better preserves protein 
phosphorylation status. Using a pipette tip, cells in buffer were scraped and then 
transferred to micro-centrifuge tubes. These were then stored at -80 oC for later use. 
Samples were defrosted on ice and centrifuged at 4 oC, 20,000 g for 5 min. The 
supernatant was then transferred to fresh micro-centrifuge tubes on ice.   
  
For protein quantification, the Pierce BCA protein assay kit (Pierce, USA) was used. A 
serial dilution of known protein standards (starting from a solution of 2 mg/ml bovine 
serum albumin (BSA - Millipore, UK)) was made in a 96-well plate as a standard curve. 
10 μl of each protein sample was added to a well, followed by 100 μl BCA solution. Plates 
  
116  
  
were covered and then incubated for 15-30 min at 37 oC. Plates were analysed using a 
FLUOstar microplate reader (BMG Labtech, Germany). Using MARS software, a standard 
curve was generated from the BSA standards and sample protein concentration was 
calculated. Samples were diluted in ddH2O to give equivalent protein concentrations.   
  
Gel loading and transfer  
On ice, protein samples were prepared for gel loading according to Table.2.3.3 using 4x 
Bolt LDS sample buffer (Invitrogen, UK) and 10x Bolt sample reducing agent (Invitrogen, 
UK). Samples were then incubated at 70 oC for 10 min. A Bolt Mini Gel Tank (Invitrogen, 
UK) was then assembled and half filled with running buffer, (500 ml): 20 ml 20x Bolt 
MOPS SDS running buffer (Invitrogen, UK) and 480 ml ddH2O. Bolt 4-12% Bis-Tris Plus 
gels (Invitrogen, UK) were used and 1 μl of SeeBlue Plus2 pre-stained protein standard 
(Invitrogen, UK) was added to the left-hand well of each gel. 35 μl of each protein sample 
was then added to the adjacent wells. The remaining running buffer was added to the 
tank and the gel run at 200 V for 22 min (or for 35 min when investigating zonula 
occludens-1 (ZO-1) protein expression).   
  
After running, gels were removed from their cassette and incubated in transfer buffer, 
(1L): 3.03 g tris base (Fisher BioReagents, USA); 14.4 g glycine (Fisher BioReagents, USA); 
200 ml methanol (Fisher BioReagents, USA) and 800 ml ddH2O, for 15 min at RT. 3MM 
chromatography filter papers (Whatman, USA) were also soaked in transfer buffer. An 
Immobilon-FL PVDF membrane (Millipore, UK) was first wet in methanol then soaked in 
transfer buffer. Transfer sandwiches were then made according to the following order: 
electrode, sponge, 4x filter paper, gel, membrane, 4x filter paper, sponge, electrode. 
Sandwiches were placed in a wet transfer tank with an ice pack and magnetic stirrer, this 
was then filled with transfer buffer. Proteins were transferred for 1 hr at 100 V, changing 
the ice pack every 30 min (ZO-1 transfer was performed over 1 hr 30 min).   
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Antibody staining  
After transfer, membranes were removed and washed, 3x for 5 min in TBS. They were 
then incubated in blocking buffer (3% BSA – TBS) for 1 hr at RT. This was followed by a 
3x 5 min wash in TBST, made using TBS and Tween20 (Sigma Aldrich, UK). The primary 
antibody of interest and β-actin mouse mAb loading control (Sigma Aldrich, UK) were 
diluted in antibody dilution buffer (3% BSA – TBST). The antibodies used can be found in 
Table2.3.4. Membranes were incubated for 1hr at RT. A 3x 5min wash in TBST followed 
and membranes were then incubated with the secondary antibodies, goat anti-mouse 
IgG-HRP (Santa Cruz, USA) and goat anti-rabbit IgG-HRP (Santa Cruz, USA), made up in 
antibody dilution buffer. A final 3x 5min TBST wash was performed.   
  
Imaging and densitometric analysis  
Blots were imaged via chemiluminescence. A 500 μl chemiluminescence reaction mix 
was made per blot. This consisted of 200 μl each of parts A and B SuperSignal West Pico 
chemiluminescent substrate (Thermo Scientific, USA), and 50 μl each of parts A and B   
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SuperSignal West Femto chemiluminescent substrate (Thermo Scientific, USA). This mix 
was added to each blot prior to imaging via an Azure c600 blot imaging system 
(Cambridge Biosciences, UK). Densitometric analysis was performed using the ImageJ 
Gel Analyser plugin. The optical density of each band was normalised to its loading 
control (β-actin) and calibrated to the experimental control, giving a relative density.    
  
2.3.4. Immunofluorescence (IMF) staining  
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Protocol and imaging   
For IMF, cells were seeded onto Lab-Tek Chamber Slide system (Thermo Scientific, USA) 
and cultured for at least 24 hrs prior to washing and fixation with 4% PFA, clarified with 
NaOH. For HBECs cultured on transwell inserts, inserts were transferred to a fresh plate 
for the IMF staining process. IMF was performed in accordance with the protocol in 
Table.2.3.5 using: Triton X-100 (Sigma Aldrich, UK); BSA (Millipore, UK); Goat serum 
(Sigma Aldrich); DAPI (Sigma Aldrich); and ProLong Gold Antifade mountant (Invitrogen, 
UK). The antibodies used can be found in Table.2.3.4. For insert-cultured HBECS, 
mounting was achieved by dissecting the basal membrane from the inserts with a 
scalpel. This was then transferred to a glass microscopy slide, with mountant and cover 
slide then added. After slides were cured in mountant, imaging was performed using an 
EVOS FL cell imaging system (Invitrogen, UK).  
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2.3.5. Analysis of mitochondrial morphology  
  
IMF images were taken of HLFs stained with anti-ATP5B antibody, which binds to a 
subunit of mitochondrial specific adenosine triphosphate (ATP) synthase. IMF imaging 
provided a structural outline of the mitochondria and their morphology could be 
analysed via ImageJ. The following macro was used:  
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run("Subtract Background...", 
"rolling=75"); 
setOption("BlackBackground", false); 
run("Make Binary"); run("Erode"); 
run("Skeletonize");  
  
The macro converts Alexa Fluor 488 (bound to ATP5B) signal into skeletonised image. 
This image represents signal as particles. Thickness is not factored into this process, only 
the presence of continuous signal, thereby creating a pixilated network of 
representative mitochondria. This allows quantification of various structural 
parameters. The particle networks generated could be counted and measured, giving an 
indication of the number of distinct mitochondria within a cell and the area they occupy. 
Furthermore, the individual mitochondria themselves could be assessed, providing 
information on parameters such as the average size of mitochondria within a cell and 
how the morphologies differ. An example of this analysis is shown in Figure 2.3.1.   
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2.3.6. IL-33 enzyme-linked immunosorbent assays (ELISA)  
  
Assay protocol  
Samples of basolateral CM, collected from 72 hr mono- or co-cultures, were defrosted 
on ice after storage at -80 oC. ELISA was performed using the Human IL-33 DuoSet ELISA 
(R&D Systems, USA), which contained: human IL-33 capture antibody; human IL-33 
detection antibody; human IL-33 standard and streptavidin-HRP. These reagents were 
used in addition to the DuoSet Ancillary Reagent Kit 2 (R&D Systems, USA), containing: 
ELISA plate-coating buffer; reagent diluent, stop solution (2N sulfuric acid); colour 
reagent A (hydrogen peroxide); colour reagent B (tetramethylbenzidine); wash buffer; 
clear microplates and an ELISA plate sealer. Firstly, capture antibody was diluted to a 
working concentration in PBS and 100 μl added to a 96-well plate. This plate was 
incubated overnight at RT. The plate was then washed with 400 μl wash buffer 3x and 
blocked, via addition of 300 μl reagent diluent to each well. The plate was incubated for 
1 hr at RT. A further 3x washes were performed. 100 μl of standards (in reagent diluent) 
and 100 μl of sample CM was then added to the relevant wells, the plate covered and 
incubated for 2 hr at RT. 3x washes were performed. 100 μl of detection antibody was 
then added with another 2hr RT incubation. After a further 3x washes, 100 μl of 
streptavidin-HRP was added to each well and the plate incubated at RT for 20 min, in 
the dark. The plate was washed 3x and 100 μl of substrate solution added to each well. 
Another 20 min incubation at RT in the dark was performed followed by the final 
addition of 50 μl stop solution to each well. The plate was gently tapped to mix and the 
optical density (OD) read using a SpectraMax M2e microplate reader (VWR, UK), set to 
450 nm and 540 nm.   
  
Analysis  
The 540 nm OD readings were subtracted from the 450 nm reading for each well, 
correcting for optical imperfections in the plate. A standard curve was constructed by 
plotting the log of human IL-33 standard concentrations against the log of OD values.  
Regression analysis provided an equation for the subsequent calculation of CM sample 
IL-33 concentrations.   
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2.3.7. Multiplex ELISA (Luminex)  
  
Multiplex ELISA assays were performed using a MAGPIX analyser (Millipore, UK). The 
MAGPIX analyser uses Luminex xMAP technology to perform ELISA-based assays for 
numerous analytes at one time. Luminex technology utilises sets of 6.45 μm magnetic 
microspheres, coated with a capture antibody, to detect a range of proteins in a given 
sample. Each set of beads has a specific proportion of red and infrared fluorophores, 
creating a unique detection signature. Target proteins bind to the beads, a biotinylated 
detection antibody is then introduced and the sample is incubated with reporter 
molecule (streptavidin-phycoerythrin (strep-PE) conjugate). Red and greed LEDs 
interrogate each bead, which is identified with CCD camera. The 532 nm green ‘assay’ 
laser excites the strep-PE conjugate, determining analyte concentration, whilst the 635 
nm red ‘classify’ laser excites the internal fluorophores, identifying the analyte and 
enabling doublet discrimination by light scatter.   
  
Preparation of reagents  
Having been stored at -80 oC, 500 μl CM samples, obtained from the basolateral 
compartment of 72 hr mono- or co-cultures, were defrosted on ice. MILLIPLEX Map Kit 
(Millipore, UK) reagents were reconstituted (if required) and allowed to warm to RT. 
These reagents included: human cytokine/chemokine standard; human cytokine quality 
controls 1 and 2; 96-well plat with sealers; assay buffer; 10x wash buffer; human 
cytokine detection antibodies – premixed 38-plex beads; strep-PE conjugate and bead 
diluent. Antibody beads were sonicated for 30 sec and vortexed for 1 min prior to use. 
Quality controls 1 and 2 were reconstituted in dH2O, inverted to mix and briefly 
vortexed. The human cytokine/chemokine standard was reconstituted in dH2O, giving a 
10,000 pg/ml concentration standard for all 38 analytes. Standards were created via a 
1:5 dilution down to a concentration of 3.2pg/ml. CM samples were also allowed to 
warm to room temperature.   
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Immunoassay procedure  
Prior to assay running, the Luminex MAGPIX analyser (Millipore, UK) analyser was 
calibrated. Then, 200 μl of wash buffer was added to each well of the Map Kit, 96-well 
plate. The plate was shaken for 10min at RT and the buffer removed. 25 μl standard / 
control was added to the relevant wells, 25 μl of assay buffer was added to sample wells 
and then 25 μl of matrix solution (non-CM) to all wells. 25 μl of CM samples was added 
to sample wells and 25 μl of antibody beads to each well. The plate was incubated 
overnight at 4 oC. The beads were captured using a handheld magnetic separator block 
(Millipore, UK) and the plate washed 2x with 200 μl wash buffer. 25 μl of detection 
antibodies was added to each well, the plate was sealed and then incubated for 1 hr at 
RT on a plate shaker. 25 μl of strep-PE was added to each well, the plate incubated for 
30 min at RT and then washed, as previous. 150 μl Drive fluid 4PK (Millipore, UK) was 
added to each well and the beads re-suspended for 5 min on a plate shaker. The plate 
was then run on the MAGPIX analyser.   
  
Analysis  
Data was analysed using xPONENT software. Median fluorescent intensity (MFI) data 
was analysed using a 5-parameter logistic method, allowing calculation of 
cytokine/chemokine concentrations in each sample. Standard curves for each analyte 
are displayed in Appendix 1. (Figure 6.1.1.) along with minimum detection ranges 
(Figure 6.1.2.).   
  
    
 2.4  Statistical Analyses  
  
Biological replication  
Throughout this work n numbers were generated using a combination of repeated, 
independent experiments using cells from a single patient donor and experiments using 
the cells from different patient donors. Independently repeated experiments were 
deemed to constitute a biologically distinct repetition due to: differing passage, culture 
and experimentation at differing times, and cells populations being expanded from 
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differing subsets of originally expanded tissue explant material. Such combinations of n 
number are highlighted in figure legends whereby the n number is denoted along with 
the patient donor identification and the number of times such donor was used.   
  
Statistical testing  
Regarding all statistical analysis, despite small sample sizes used throughout 
experimentation, parametric tests were utilised under the assumption that data had a 
normal distribution, and this was preferred to the use of non-parametric tests. All data 
are presented as mean values. All error bars are representative of standard error of 
mean (SEM). All statistical analysis was performed using GraphPad Prism 5. Analysis 
between two groups was performed using a student’s t-test. Analysis between multiple 
groups was performed using either 1-way ANOVA, with Tukey’s multiple comparisons, 
or 2-way ANOVA, with Bonferroni multiple comparisons. For analysis between multiple 
groups with repeated measures over time, 2-way RM ANOVA, with Bonferroni multiple 
comparisons was used. A difference between groups was deemed statistically significant 
when the p value for each relevant test was <0.05.   
  
    
  
  
  
  
  
  
  
  
  
  
  
3. Results  
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3.1  Phenotypic characterisation of normal and fibrotic human lung fibroblasts in  
mono-culture  
  
3.1.1. Introduction  
  
FHLFs: drivers of IPF pathology  
The FHLF is understood to be the primary mediator of fibrotic remodelling in IPF. This 
heterogeneous population of cells proliferate in the interstitium, differentiate into 
myofibroblasts and deposit excessive amounts of ECM, destroying normal lung 
architecture. Numerous pathogenic characteristics of FHLFs have been identified 
(Intro.2.3.1.). They are aberrantly over-activated in response to injury-associated and 
pro-fibrotic stimuli 119,250, circumvent proliferation-suppressing signalling 251, display a 
spontaneous, invasive phenotype 252, and an intransigence to pro-apoptotic stimuli 123. 
Therefore, investigating this population of cells is important to further understanding 
the cellular mechanisms involved in IPF.   
  
Inflammatory wound signals   
FHLFs drive fibrosis in a lung environment subjected to recurrent injury and the lungs 
response to injury involves a diverse range of inflammatory signalling. IL-6 and CXCL8 
are secreted proinflammatory signalling molecules that play an important role in the 
early response to injury. They are elevated in the early wound site and enhance the 
infiltration of leukocytes, as well as promoting endothelial migration and angiogenesis, 
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contributing to the formation of granulation tissue 60,253. Increased expression of these 
factors is indicative of injury and associated with IPF 167.   
  
Regulation of IL-6 and CXCL8 production can be mediated by members of the IL-1 
cytokine family. IL-1α and IL-1β are the archetypal family members but another nine 
members also exist, including IL-33. IL-1α is constitutively expressed at low levels in all 
cells and can function in both its pro-protein, immature form and its cleaved, mature 
form. IL-1α, as well as IL-33, are dual function cytokines, with the ability to function as 
classical, secretory cytokines as well as an ability to function as direct transcription 
factors. Both cytokines function as ‘alarmins’, damage associated markers that can 
activate the immune response. This occurs when they are released into the local 
environment by injury-induced cell necrosis 254. IL-1α release from damaged epithelial 
cells induces upregulation of IL-6 and CXCL8 255. IL-1β is an inducible cytokine that is not 
constitutively expressed in normal cells. Along with IL-33, it is activated by the 
inflammasome 256. Production and activation can be stimulated by numerous stimuli, 
but predominantly by bacterial signalling. Along with TGF-β, IL-1α and IL-1β are also 
important in stimulating fibroblast collagen deposition at the wound site.   
  
CXCL1 and G-CSF are two additional proteins that are elevated in response to injury. The 
CXCL1 chemokine is a long-acting, long-range attractant for neutrophils, the first type of 
leukocyte to infiltrate the wound-site 257. G-CSF plays a similar role. It is a pleiotropic 
cytokine that functions as an attractant and growth factor for neutrophils in the wound 
site 258. Collectively these cytokines and chemokines form part of a wider inflammatory 
signalling network that is important in early wound inflammation. Although numerous 
cell types can produce these factors, in the lung fibroblasts also play an important role 
as immune mediators 259,260. As IPF is a disease of recurrent injury it was hypothesised 
that levels of these proteins would be elevated in the HLFs derived from patients with 
IPF, indicative of sustained wounding.  
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Inflammation and senescence  
Though the factors discussed are important in wound inflammation, they also find 
prominence in ageing and senescence. With age there is development of a systemic 
background of the low-grade, sterile inflammation, regulated by the NF- B pathway 174. 
This pathway can promote cellular senescence and upregulate expression of IL1A and 
IL1B 214. This again increases cytokine and chemokine production, both of which can 
reinforce the state of senescence and cause other non-cell autonomous effects 213,218,261. 
Likewise, chronic senescence results in increased secretion of IL-6, CXCL8, CXCL1 and 
CCL2 201. Therefore, elevation of these proteins in FHLFs could also be indicative of a 
background of age and senescence, both of which are implicated in IPF.   
  
Regulators of senescence  
To understand if senescence is a characteristic of FHLFs, investigating the pathways that 
regulate this process is also important. Senescence is established via induction of two 
main pathways, the p53-p21 and p16-pRB pathways (Intro.3.1.2.). Both p21 (encoded 
by CDKN1A) and p16 (encoded by CDKN2A) are established markers of senescence. 
CDKN2A however, also encodes several different transcript variants, which produce at 
least two different proteins. Both ultimately regulate progression through the cell-cycle 
but by different means: p16, inhibits CDK4 and 6, preventing RB phosphorylation, and is 
referred to as p16Ink4a, p14Arf, which is specified by an alternate reading frame (ARF), 
sequesters MDM2, preventing degradation of p53 and promoting cell cycle arrest. It was 
hypothesised that if FHLFs have a senescent phenotype, RNA levels of CDKN1A and 
CDKN2A would be elevated.   
  
Mitochondrial phenotype in senescence and IPF  
Mitochondrial phenotype is another facet of fibroblast biology that is linked to 
senescence and IPF. Hyperplasic AEC2s derived from IPF honeycomb lesions and 
senescent fibroblasts display a high mitochondrial content and these mitochondrial are 
enlarged, dysmorphic and with an increased surface area. mtDNA copy number is also 
increased and there is impaired activity in complex I and IV of the electron transport 
chain 129,200. Senescent fibroblasts produce more superoxide and peroxides, due to a 
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decrease in mitochondrial membrane potential and an increase in proton leak, whilst 
mitochondrial changes in IPF AEC2s coincide with ER stress. In these epithelial cells this 
phenotype is due to a lack of mitophagy, the upregulation of which can alleviate 
senescence 201. Altered fission/fusion dynamics also play a role. Mitochondria form a 
heterogenous population of organelles within a cell (referred to as heteroplasmy) that 
can form extensive networks by fusion or become more punctate by fission. The 
epithelium of aged mice and senescent fibroblasts display a preference for fusion, with 
downregulation of the fission protein DNM1L and upregulation of the fusion proteins 
OPA1 and MFN1 262. PINK1 is an important regulator of both mitochondrial dynamics 
and mitophagy. It is downregulated in IPF and PINK1 knockout in an epithelial cell line 
leads to upregulation of TGFB and IL6. Likewise, PINK1 knockout mice are more 
vulnerable to pulmonary fibrosis 129. Though the significance in IPF fibroblasts has yet to 
be fully investigated, an altered mitochondrial phenotype, and altered mitochondrial 
regulation, in isolated FHLFs could provide evidence for a senescent-like phenotype in 
these cells, which may contribute to the fibrotic process.  
  
In summary, the hallmarks of wound-associated inflammation, senescence and ageing, 
as well as mitochondrial phenotype, are inter-linked. Investigating these aspects in 
FHLFs has not yet been explored in detail, therefore, initial experiments set out to 
understand these characteristics in isolated FHLFs and question whether they are 
different when compared to NHLFs.   
  
Hypotheses  
1. FHLFs will display an inflammatory phenotype in comparison with NHLFs, with 
elevated expression of senescence-associated cytokines and chemokines.  
2. FHLFs will exhibit dysfunctional mitochondrial content resulting from altered 
expression of key genes involved with mitochondrial homeostasis.  
     
    
3.1.2. Results  
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3.1.2.1. FHLFs in mono-culture display limited hallmarks of inflammation and 
senescence.  
  
To investigate whether FHLFs are more inflammatory when compared to NHLFs, cells 
were first isolated from patient samples, obtained from the RD&E. FHLFs were derived 
from patients undergoing surgical biopsy for IPF diagnosis and NHLFs were derived from 
the marginal tissue of lung tumour resections, via a method of explantation. HLF 
populations were expanded under normal culture conditions on plastic. Cells were 
seeded at a density of 30,000 cells/well of a 12-well plate and maintained under normal 
conditions for a period of 24 hrs prior to the extraction of RNA. Via RT-qPCR, RNA levels 
were measured, assessing levels of:   
  
Wound inflammatory genes: IL6, CXCL8, IL1A, IL1B, CXCL1, CSF3, TNFA  
Senescence regulatory genes: CDKN1A, CDKN2A   
  
The results are displayed as an average fold change, relative to the expression of the 
reference genes GAPDH and B2M and calibrated to the levels found in NHLFs (Figure 
3.1.1). CDKN2A RNA levels were significantly elevated in FHLFs but levels of CDKN1A did 
not significantly differ. The results also showed a tendency towards an increase in IL6, 
CXCL8, IL1A and IL1B, and a decrease in IL-33 but these results did not reach statistical 
significance. Both CXCL1 and CSF3 were reliably expressed in some, but not all, donor 
lines. In FHLFs, the average expression of IL1A was 8.26-fold greater than NHLFs, but the 
standard deviation (SD) was 10.91, indicative of a high variability between the donors 
used. Indeed, with the exception of CDKN2A levels, the average SD for FHLF fold change 
was 2.52, compared to 0.48 in NHLFs.   
  
Despite the limited variations at an RNA level, the importance of the FHLF phenotype 
and the potential role of a much broader range of immune-modulating factors in IPF led 
to further investigation of the FHLF phenotype at the secretory protein level. Protein   
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concentrations in the CM, collected after a 72 hr incubation period in mono-culture, was 
assessed via Multiplex ELISA (or, in the case of IL-33, by standard ELISA) and a range of 
39 immune-modulating cytokines, chemokines and growth factors were analysed 
(Figure 3.1.2.). The panel of analytes assessed were not specific to wound inflammation 
or senescence but did include a multitude of factors associated with both. All analytes 
were detectable but, for 29 of them, protein concentration was below 20 pg/ml. 
Concentrations of IL-1α, IL-1β and IL-33 were exceptionally low in the CM (>10 pg/ml), 
as too was the concentration of the pro-inflammatory cytokine TNF-α. The 
antiinflammatory cytokines, IL-4, IL-10 and IL-13 were also detected at exceptionally low 
concentrations. Nine of the measured factors were detected at concentrations greater 
than 50 pg/ml, of which CCL2 and CXCL10 were found at high concentrations >750 
pg/ml. Of these nine analytes, there were only significant differences between NHLF and 
FHLF for two of them. GM-CSF and CXCL10 were both significantly elevated in FHLFs. 
Taken together, this suggests that, in mono-culture, FHLFs are not substantially more 
pro-inflammatory than NHLFs.   
  
3.1.2.2. Regulation of FHLF mitochondrial phenotype is not altered at an RNA level and 
FHLFs do not have an altered copy number of mtDNA.  
  
PINK1 is a major homeostatic regulator of mitochondrial homeostasis, playing a key role 
in the clearance of defective mitochondria by mitophagy. Mitochondrial fission and 
fusion events are regulated by proteins such as DNM1L and MFN1, respectively. The RNA 
levels of these genes were assessed via RT-qPCR in NHLFs and FHLFs, monocultured for 
24 hrs (Figure 3.1.3A.). There were no significant differences in RNA levels between any 
of these transcripts, implying that regulation of mitochondrial phenotype is equivalent 
in NHLFs and FHLFs. mtDNA copy number was also assessed via RT-qPCR. Only two FHLF 
lines were assessed but their mean copy number fell within the range of NHLF mtDNA 
copy number (Figure 3.1.3B.). This non-significant difference in copy number indicated 
equivalent mitochondrial heteroplasmy between cell types.   
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3.1.2.3. FHLFs in mono-culture do not have an altered mitochondrial membrane 
potential but do display an altered mitochondrial morphology.  
  
Mitochondrial dysfunction, which encompasses mitochondrial membrane 
depolarisation, drives cellular senescence and is associated with IPF. Mitochondrial 
membrane potential (Δψm) represents a component of the proton motive force (Δp), the 
force that drives protons into the mitochondrial matrix after exclusion by the electron 
transport chain. A high proton motive force is indicative of high mitochondrial energy 
output via adenosine ATP synthase, which uses protons to generate ATP.  Δψm can be 
measured with various lipophilic, cationic dyes, including JC-1 and TMRE. These dyes 
accumulate in the mitochondrial membrane matrix in an inverse proportion to Δψm, with 
more dye accruing in a more negatively polarised membrane. Δψm can be reduced by 
treatment with uncoupling proteins, such as FCCP, which causes protons to pass freely 
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across the inner mitochondrial membrane. FCCP is typically used as a positive control 
when investigating Δψm.  
  
TMRE was used to assess the membrane potential of NHLFs and FHLFs under normal 
conditions in mono-culture. Firstly, an appropriate experimental concentration of TMRE 
was established using NHLFs (Figure 3.1.4A). Cells were seeded at a density of 2,000 
cells/well in 96-well plates and cultured for 24 hrs prior to treatment with TMRE across 
a range of concentrations, either with or without 20 μm FCCP. Fluorescence was then 
measured via a plate reader. The background intensity was high at 0 nM TMRE/TMRE + 
FCCP but there was a linear, concentration-dependent increase in fluorescence intensity 
with increasing TMRE concentration. Uncoupling was not significantly observable at 200 
nM TMRE but was at higher concentrations, with the greatest difference at 800 nM. This 
concentration was used in subsequent experiments. To try and further accentuate the 
uncoupling effect, 30 μM FCCP was trialled with NHLFs (Figure 3.1.4B). A significant 
difference in Δψm was found with this concentration and it was chosen for further 
experiments. When comparing Δψm in NHFL and FHLF there was no significant difference 
in coupled potential (Figure 3.1.4C).   
  
To investigate mitochondrial morphology, NHLFs and FHLFs were cultured in chamber 
slides (10,000 cells/chamber) under normal conditions for 24 hrs prior to fixation and 
IMF staining for ATP5B, a subunit protein of ATP synthase. To better understand the 
mitochondrial morphology, IMF images were analysed by converting the fluorescent 
signal to a skeletonised image using ImageJ (Figure 3.1.5.). Imaging demonstrated that 
the mitochondria of NHLFs form a complex and interconnected network of large 
organelles. Conversely, though the cells themselves were also bigger, FHLF mitochondria 
were substantially smaller, more punctate and less interconnected. In this form, it was 
possible to quantify numerous parameters of mitochondrial morphology via ImageJ, 
assigning an arbitrary unit of particle size to the mitochondrial signal (Figure 3.1.6.). 
Compared to NHLFs, the average number of mitochondria per FHLF was significantly 
higher. The average mitochondrial areas were the same, although the average size of 
each mitochondrion was significantly less in FHLFs. Likewise, the average number of 
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branches each mitochondrion had was decreased in FHLFs. There was no difference in 
the average length of mitochondrion branches, but the average, maximum branch 
length per cell was less. The average number of junctions made by each mitochondrion 
was also less in FHLFs. These results highlight significant changes in mitochondrial 
morphology, with an apparent fragmentation of the mitochondrial network in FHLFs.   
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3.1.3. Discussion   
  
This section set out to investigate the intrinsic, pathological characteristics of FHLFs, 
assessing expression of inflammatory and senescence-associated markers, as well as the 
mitochondrial phenotype. This was achieved by isolating FHLFs from patients with 
confirmed IPF and comparing them to NHLFs from patients without fibrosis. Importantly, 
all HLFs were derived from aged patients, therefore, any differences between cell types 
were less likely due to age-related changes and more reflective of pathology. Not only 
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this but the detrimental cellular changes that occur with age, including increases in 
inflammation, changes to mitochondrial homeostasis and an increased predisposition to 
become senescent are likely to affect both FHLFs and the control cells. Via RT-qPCR and 
multiplex ELISA, it was found that mono-cultured FHLFs do not express significantly 
higher levels of inflammatory proteins, with the exception of GM-CSF and CXCL10. There 
were however significant differences in mitochondrial morphology, but this was not 
coupled to altered mtDNA copy number or mitochondrial membrane potential.   
  
Inflammation and senescence markers  
Genes relating to wound-associated inflammation and senescence were investigated at 
the RNA level, with the hypothesis that, due to recurrent injury in IPF these markers 
would be elevated. IL6, CXCL8, IL1A, 1IL1B, IL33, CDKN1A and CDKN2A were expressed 
in both cell types. There was inconsistent expression however of CSF3 and CXCL1, 
despite detection of these proteins at concentrations >50 pg/ml in CM. Typically, these 
proteins are not normally expressed and expression is induced in response to signalling 
from stimuli such as IL-17, lipopolysaccharide (LPS) and/or TNF-α 263,264. IL-17 and TNFα 
secretory protein concentrations were very low (<10 pg/ml), suggesting an absence of 
the paracrine signalling required to drive their expression. RNA was also collected after 
24 hrs of culture, whereas CM was collected after 72 hrs. It is therefore possible that any 
differences were down to a temporal variation in expression, a variation that could be 
checked by assessing RNA levels after 72hrs of culture. IL1A and IL33 are also not 
normally expressed in HLFs and are induced in response to inflammasome activation.  
The trend towards IL1A RNA increase may point towards inflammasomal activation in 
FHLFs, suggesting a more inflammatory phenotype. Conversely, IL6, CXCL8 and IL1B are 
typically expressed in fibroblasts. Though FHLFs displayed a greater average fold change 
for these transcripts, there was no significant difference compared with NHLFs. Taken 
together, this suggests that at an RNA level FHLFs do not have a more inflammatory 
phenotype. An important feature of the RNA data however was the variability in FHLF 
fold change, with data showing a broad range and large standard deviation. For all genes 
analysed, at least one FHLF cell line displayed a decrease in fold change when compared 
to NHLFs. This potentially reflects the heterogeneity of lung fibroblasts within IPF, 
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highlighting that, even within regions of fibrosis, some cells may not display the 
pathological characteristics associated with this disease and explaining the lack of RNA 
differences. However, these results may also have been indicative of pathological 
differences between cell types at a protein level.   
  
Consequently, a broad range of immune-modulating proteins were analysed in HLF CM. 
For 28 of these proteins, concentrations were below 50 pg/ml. Such a small 
concentration was considered to be non-physiologically relevant and few conclusions 
can be drawn from those results. Despite strong expression at an RNA level (relative to 
reference genes), neither IL-1α, IL-1β or IL-33 were highly expressed in HLF CM. This 
might be expected however as these proteins typically function intracellularly, being 
released only in instances of necrosis or on appropriate activation of the inflammasome. 
To understand their relevance in HLF mono-culture, protein expression would need to 
be assessed by ELISA of cell-lysate or by western blotting, an experiment that could be 
performed in future studies. Though not assessed at an RNA level, there was a significant 
difference in protein concentrations of CXCL10, a chemokine associated with the early 
wound response. CXCL10 expression is typically induced by IFN-γ signalling, which in the 
HLF CM was produced at extremely low concentrations (<10 pg/ml). Interestingly, 
CXCL10 is also considered to be an antifibrotic chemokine. Exogenous CXCL10 treatment 
is protective against BLM-induced lung injury in mice and CXCL10-/- mice suffer more 
severe fibrosis 265–267. CXCL10 is postulated to inhibit fibroblast migration, thereby 
reducing accumulation and matrix deposition in the airway, yet fibroblasts lack the 
receptor for this chemokine, CXCR3, and consequently the mechanism by which this 
occurs is unclear. Likewise, these effects have been evidenced using mice treated with 
BLM in the context of an acute, non-infectious injury and the role of CXCL10 in 
established fibrosis remains uncertain. It is difficult to interpret why this potentially 
antifibrotic protein is elevated in mono-cultured FHLFs, yet CXCL10 is also a key 
woundassociated chemokine, important in post-wound immune cell recruitment 253. It 
may therefore be that its upregulation reflects a propensity of FHLFs to generate an 
injuryassociated environment in culture. However, aside from this chemokine, the 
overall picture created by HLF RNA and protein assessment is that there is little intrinsic 
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difference between the two and that FHLFs are simply more variable than NHLFs. This 
could indicate that, in the absence of relevant stimuli, FHLFs are not inherently 
pathogenic, although there are other possibilities. Many of the proteins assessed in this 
work are expressed in different isoforms, with variations in splicing playing an important 
role. For example, the ratio of VEGF splice isoforms can alter the lung microenvironment 
to be either anti- or pro-fibrotic 268. Whether differing isoforms of such proteins were 
expressed by normal and fibrotic HLFs was not assessed but could be performed in 
future.   
  
Mitochondrial phenotype  
The results from investigating mitochondrial phenotype were also of interest. There was 
no difference at an RNA level of the regulatory genes PINK1, DNM1L and MFN1, 
suggesting that mitochondrial homeostasis and the balance between fusion and fission 
is not differentially regulated between NHLF and FHLF. This fails to corroborate previous 
literature suggesting a loss of homeostatic regulation in IPF, ageing and senescence, and 
a cellular preference towards mitochondrial fusion. Likewise, in senescent cells and aged 
AEC2s there is an increase in mtDNA copy number 129,201. This was also not observed in 
FHLFs. However, there was limited access to IPF tissue in this study and it would be 
interesting to repeat these experiments with more donor lines and better expand on 
these results in the future. It was also expected that FHLFs would have more depolarised 
mitochondrial membranes, as depolarisation leads to increased ROS production, 
important in both myofibroblast differentiation and induction of senescence 119,200. This 
was not evident. There was no significant difference between FHLF and NHLF Δψm, 
indicating that the mitochondria do not have an altered polarisation status. This could 
begin to suggest an equivalence in mitochondrial function between NHLFs and FHLFs, 
with no difference in mitochondrial ROS production. However, TMRE is just one measure 
of mitochondrial function and mitochondrial ROS production was not directly measured. 
JC-1 fluorescence could also have been assessed, further elucidating Δψm, and ROS 
production could have been measured by dyes such as MitoSox. These dyes could be 
used following the same experimental design as TMRE experiments but, as well as 
measuring fluorescence via plate reader, could be assessed by microscopy. For example, 
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when using JC-1, an increase in membrane potential leads to increased dye 
accumulation. This causes a shift in fluorescence emission from green (529nm) to red 
(590nm), which can be observed via microscopy. If the results of TMRE were truly 
reflective of membrane potential in NHLFs and FHLFs it would be expected that both cell 
types would display an equivalent ratio of red/green fluorescence signal, further 
suggesting equivalent mitochondrial health and activity.  
  
The analysis of mitochondrial morphology was achieved by establishing a new, 
quantitative methodology, which has thus far been unreported. This method was useful 
for allowing statistical analysis from IMF images. Analysis revealed that FHLFs, although 
having equivalent mitochondrial content, had significantly smaller and more punctate 
mitochondria, which were also more numerous. These changes would suggest the 
occurrence of more fission events, leading to fragmentation of the mitochondria. It was 
therefore surprising that DNM1L was not upregulated in FHLFs, although this was not 
assessed at the protein level (something that could be assessed via western blot). 
Though there were significant differences in morphology via this methodology there 
were limitations to this approach. The images captured and analysed were in 2D, 
overlooking the complex, 3D mitochondrial network within a cell and only one antibody 
type was used (more confidence could be gained through use of a different 
mitochondrial antibody such as TOM20). Similarly, it remains unknown how these 
potential differences relate to function and ultimately few conclusions can be drawn. 
This is also true for the experiments with TMRE and mtDNA copy number. Ideally, 
mitochondrial function would be assessed via an extracellular flux analyser, which 
provides data on cell metabolism by analysing glycolytic function and mitochondrial 
respiration. This would provide a more complete picture of the mitochondrial 
phenotype and will be a focus of future investigations.    
  
Importance of micro-environment   
In summary, these results suggest that, in terms of inflammation, senescence and 
mitochondrial phenotype, there is little difference between HLFs isolated from IPF 
patients and normal controls. Though evidenced by investigation using a small 
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repertoire of genes, it may be that these aspects are not important to IPF pathology. 
However, as previously discussed, there is strong evidence to suggest that they are. It 
may then be that the conditions in which these cells were investigated was 
inappropriate. Mono-culture on plastic differs vastly from the 3-dimensional, multi-cell 
type environment of the lung. Indeed, a study by Parker et al., in which NHLFs and FHLFs 
were also isolated, found that the environment the cells were cultured on was more 
important to the establishment of pathological characteristics than the intrinsic 
differences of the cells themselves 151. HLFs in this investigation were not stimulated and 
they were cultured under standard culture conditions. They were therefore not exposed 
to stimuli found in either the normal or the IPF lung. Furthermore, recent global gene 
expression analysis into the profile of HLFs has suggested that the differential profile of 
NHLFs and FHLFs is lost once the cells have adapted to an in vitro environment. The 
authors proposed that the IPF environment is key to differential activity, not the intrinsic 
propensity of the FHLF itself 269. Together, it is therefore likely that HLFs in 2D 
monoculture are simply not subjected to an environment relevant enough and require 
more physiological stimuli to expose any pathological differences. The subsequent 
sections of this thesis will present work aimed at better recapitulating the lung micro-
environment, in an attempt to further understand the role of FHLFs in IPF pathology.   
  
  
  
 3.2  Modelling Secretory Communication in vitro  
  
3.2.1. Introduction  
  
To better recapitulate the lung micro-environment, it was decided to establish a model 
of co-culture, in which HLFs were cultured with epithelial cells. By culturing these two 
cell types together, it was thought that secretory communication between them would 
create more physiologically relevant stimuli for the HLFs, enabling a better investigation 
of their role in health and disease.   
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The importance of epithelial-mesenchymal crosstalk  
As well as evoking a more physiological response in fibroblasts, establishing a model of 
crosstalk in vitro could also allow a recapitulation of the secretory communication found 
in the airways. Epithelial-mesenchymal crosstalk is fundamental to the development of 
the embryonic lung, crucial in maintaining homeostasis of the adult airways, and 
important in facilitating wound repair. Importantly, aberration of these processes is key 
to the pathology of IPF. Therefore, by modelling secretory communication in vitro, these 
facets could also be investigated, at first in the context of normal physiology and then in 
the context of disease.   
  
Co-culture  
Methods involving the co-culture of epithelial and mesenchymal cells have been utilised 
before in the investigation of numerous aspects of lung biology, focused primarily within 
the context of normal lung function. The effect of mesenchymal cells on the epithelium 
has been investigated, using cells isolated from young mice, showing that co-culture 
allows epithelial progenitors to form mixed-lineage, tracheobronchial colonies 162 and 
AEC2s to proliferate and form alveolospheres 49. Similarly, co-culture allows a bronchial 
epithelial cell line to differentiate, establish ionic impermeability and better respond to 
injury 83. Co-culture also has reciprocating effects on the mesenchyme. Using 
immortalised cells, IL-1α release from damaged epithelial cells induces the release of IL6 
and CXCL8 from fibroblasts 270 and isolated rat epithelial cells can control fibroblast 
proliferation, with co-culture reducing their growth 55. However, the effects of coculture 
using primary human cells within the context of IPF continues to offer opportunity for 
further investigation.   
  
In methods of co-culture, both secretory communication and cell-cell contact are 
important in mediating beneficial, physiological effects and previous co-culture methods 
have included: culturing epithelial and mesenchymal cells together, culturing epithelial 
and mesenchymal cells on opposing sides of a permeable membrane, or culturing 
mesenchymal cells in a basolateral compartment, with epithelial cells cultured apically 
on a semi-permeable membrane. Though all feasible, the latter of these methods was 
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chosen in this investigation. To understand changes in inflammatory wound signalling 
and senescence-associated secretion from HLFs, it was chosen as it allows easy 
interrogation of signalling proteins in the media. When cells are cultured either side of 
a membrane secretory factors can be trapped between cell types and therefore go 
undetected. Similarly, when co-cultured cells are seeded together and intermixed, it 
becomes difficult to isolate RNA from the respective cell types. In this study a method 
was therefore optimised in which HLFs were cultured with epithelial cells in a system 
allowing secretory communication, whilst preventing direct cell contact between these 
two compartments.  
  
16HBE14o-  
HLFs were co-cultured with the human bronchial epithelial cell line 16HBE14o- (HBEC), 
a transformed cell line that retains many of the characteristics of differentiated 
bronchial epithelium in vitro. In submerged culture, HBECs have many of the 
characteristics of BCs, the progenitor cells of the tracheobronchial airway that are key 
to facilitating both airway development and responding to injury. HBECs have a classical, 
cobblestone morphology, form tight junctions and, after formation of a confluent 
monolayer, become polarised with a reduction in ionic permeability 248,271. Though 
primary HBECs would more faithfully recapitulate the lung airway, this cell line was 
chosen to provide better consistency and greater experimental control, allowing 
interrogation of the impact of crosstalk with primary HLFs.   
  
Methodology  
HLFs were routinely cultured in DMEM and HBECs in αMEM. All co-culture experiments 
were subsequently optimised with cells cultured in a 1:1 mix of these two media types, 
thereby including all necessary growth factors for each cell type. HBECs were cultured in 
transwell inserts with a semi-permeable membrane (0.4 μm pore size). After seeding, 
inserts were placed into a standard culture plate, in which NHLFs had previously been 
seeded. Co-cultures were maintained for 72 hrs without media change (Figure 2.1.1.). 
Initial experiments were performed using NHLFs, with the aim of developing an 
understanding of the model for subsequent use with FHLFs.   
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Hypotheses   
1. Co-culture with NHLFs would promote HBEC development and repair in response 
to injury.   
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3.2.2. Results   
  
3.2.2.1. Co-culturing NHLFs with HBECs decreases NHLF proliferation, changes RNA 
levels and alters secretory phenotype.  
  
Initial investigations focused on the effect of co-culture on NHLF behaviour. Firstly, NHLF 
proliferation was measured over a 72 hr culture period (Figure 3.2.1). NHLFs were 
seeded in equal densities at -24 hrs and transferred to experimental conditions at 0 hrs. 
NHLFs were transferred to either co-culture with HBECs or kept in mono-culture (Figure 
2.1.1.). At 24 hr intervals, cell numbers were counted using a haemocytometer and a 
relative cell number (RCN) calculated from the initial seeding density. By 72 hrs, RCN was 
significantly lower in co-cultured NHLFs when compared to mono-culture NHLFs. To 
investigate this further, and uncover whether the reduced RCN in co-culture was due to 
a lack of cell viability, NHLFs were incubated with ReadyProbes Cell Viability reagents 
and imaged via fluorescent microscopy, after 72 hrs of mono- or co-culture (Figure 
3.2.2A). Under fluorescent excitation, these reagents highlight viable cell nuclei in blue 
and non-viable nuclei in green. Images were taken and quantified via ImageJ. In both 
mono- and co-cultured cells there was an exceptionally low number of non-viable cells 
(Figure 3.2.2B). The number of viable cell nuclei in mono-cultured NHLFs was 
significantly higher than in co-culture. These results suggest that HBECs influence NHLF 
cell number. This could be the result of a change in proliferation, with an increase in 
competition for resources in the media or signalling from the epithelium. The normal 
lungs have a low rate of proliferation and epithelial cells are known to maintain 
fibroblast quiescence as part of normal homeostasis. A similar phenomenon may be 
occurring in co-culture.   
  
Wound inflammatory and senescence associated RNA levels were also assessed via 
RTqPCR (Figure 3.2.3.). RNA was isolated from NHLFs in either mono- or co-culture, after 
72 hrs of culture. There was a significant increase in RNA levels of IL6, CXCL8, IL1A, IL1B 
and CXCL1 following co-culture. Levels of CDKN1A, CDKN2A and PINK1 were significantly 
decreased and there was no change in levels of IL33 and CSF3. Interestingly, whereas at   
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24 hrs CXCL1 and CSF3 were not reliably expressed at 72 hrs they were, suggesting that 
they may be under temporal regulation.  The developmental signalling protein WNT3A 
and the inflammatory protein TNF-α were not reliably expressed. However, the 
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interesting implication was that, in co-culture, NHLFs are more pro-inflammatory whilst 
also less likely to be entering a state of senescence.   
  
Protein concentrations in the CM after 72 hrs of culture also significantly differed 
between mono- and co-culture. Using Multiplex and standard ELISA, immunemodulating 
proteins were measured in the basolateral CM of NHLF mono-cultures, NHLF co-cultures 
and HBEC mono-cultures (Figure 3.2.4.). As previously, all 39 analytes were detectable 
but again the majority were at low concentrations, <100 pg/ml, including concentrations 
of IL-1α, IL-1β and IL-33. Of those detected at concentrations >100 pg/ml, all were 
significantly elevated in co-cultured NHLFs. For VEGF, G-CSF, GM-CSF, CX3CL1, CXCL10, 
IL-6 and CXCL8, co-culture concentrations were significantly higher than either NHLF or 
HBEC mono-cultures; no differences were observed between monocultured NHLF and 
HBECs. In the case of CCL7 and CCL2, there was an increase with coculture, but 
production by mono-cultured HBECs was extremely low, highlighting that these two 
factors are likely to be exclusively produced by the NHLFs, an interesting result 
considering that in LPS-challenged mice CCL2 is localised exclusively to epithelial cells 
272. Conversely, NHLF mono-culture CM contained extremely low concentrations of TNFα 
and CXCL1, with significantly higher concentrations in HBEC mono-culture. In the case of 
CXCL1 co-culture did not change protein concentration but, for TNF-α, co-culture 
significantly reduced levels in the CM, suggesting that TNF-α is predominantly derived 
from the epithelium and that co-culture can reduce its expression. One important 
consideration to make is that only the basolateral CM of co-cultures was analysed. As 
HBECs form a functioning epithelial layer they become polarised, this polarity means 
that secretion can be directed exclusively in either a basolateral or an apical direction. 
Therefore, the effect of co-culture may cause significant changes in apical HBEC 
secretion that will not have been observed with these experiments. However, these 
results do reaffirm those found at an RNA level, indicating a more inflammatory 
environment in co-culture, influenced by secretory signalling.   
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3.2.2.2. NHLF co-culture enhances epithelial development via bi-directional secretory 
communication.   
  
The effect that NHLF co-culture had on the epithelial cells phenotypes was next 
considered, using the same experimental conditions and in the context of epithelial 
development - a process reliant on crosstalk and implicated in IPF. Firstly, ionic 
permeability, considered as a function of development, was quantified by measuring 
trans-epithelial electrical resistance (RTE). This was achieved using a chopstick electrode 
voltohmeter. As ionic permeability decreases, electrical resistance is increased and this 
quantitative increase is taken as qualitative increase in epithelial barrier integrity and 
function, a process that occurs in the developing lung. RTE was measured at 24 hr 
intervals, up to 72 hrs, in mono- or co-cultures. With each day, RTE increased in both 
culture types (Figure 3.2.5A.), however from 24 hrs onwards, there was a significant 
increase in RTE when HBECs were co-cultured with NHLFs. At 72 hrs this difference 
remained significant (Figure 3.2.5B.).   
  
This augmentation of RTE in co-culture was achieved with an initial NHLF seeding density 
of 12,000 cells/well. To see if this effect was a function of basolateral cell number, the 
experiments were repeated across a range of NHLF seeding densities (Figure 3.2.6A.). 
After 72 hrs of co-culture it was found that, with either half or double the seeding 
density, RTE was still increased compared to mono-culture and that there was no 
significant difference in RTE between differing seeding densities (Figure 3.2.6B.). There 
is therefore a large tolerance in this system for cell number and it would be interesting 
to further investigate just how few HLFs are required to mediate an increase in RTE.  
  
The setup of the transwell co-culture is designed to prevent epithelial-mesenchymal 
contact. To test whether the increase in RTE was the result of exclusively secretory 
communication, RTE was measured over 72 hrs in mono-cultured HBECs treated with the 
CM from either an NHLF-HBEC co-culture, or the CM from an NHLF mono-culture (Figure 
3.2.7A.). The CM was derived from a previous 72 hr culture and transferred directly to 
mono-cultured HBECs at 0 hrs. By 72 hrs, co-culture and both CM treatments had   
  
156  
  
   
  
157  
  
  
  
158  
  
significantly increased RTE compared to HBEC mono-culture. Co-culture and treatment 
with co-culture-derived CM equally elevated RTE and there was no significant difference 
between them. The elevation from NHLF mono-culture-derived CM was, however, 
significantly less potent than that of the two co-culture treatments, indicating that a 
bidirectional relationship exists between the cell types and that signalling from the 
epithelium may be required to promote the secretion of trophic factors by NHLFs (Figure  
3.2.7B.).   
  
The effect of co-culture on HBEC cell number was also considered. Cell number was 
counted using a haemocytometer and RCN calculated at 24 hr intervals (Figure 3.2.8A.). 
At 72 hrs, RCN was significantly lower in co-culture than in mono-culture (Figure 
3.2.8B.), indicating that co-culture reduces both NHLF and HBEC cell number. To 
understand the relationship between RCN and RTE, RTE was measured at 72 hrs just prior 
to cell counting. By plotting the values of RCN against corresponding RTE, an inverse 
relationship between cell number and RTE was found, where the greater the RCN, the 
lower the RTE (Figure 3.2.9.). Since increased cell number was therefore not required for 
increased RTE, this further raised the question of how does co-culture promote epithelial 
barrier development?  
  
Tight junction formation is a requisite of HBEC function and enables establishment of an 
epithelial barrier that is both impermeable to macromolecules and ions. It was 
hypothesised that the increase in RTE elicited by co-culture could be the result of 
increased tight junction formation. ZO-1 is an archetypal tight junction protein 
expressed in numerous epithelial cell types. The presence of ZO-1 was examined in 
HBECs cultured over 72 hrs by IMF (Figure 3.2.10A.). The protein was expressed 
predominantly at the periphery of each cell where it formed junctions. This was evident 
in both culture conditions. Epithelial layer thickness and an undulating contour meant 
that any one plane of focus under microscopy could not show all cellular junctions and, 
prima facie, there was no observable difference in protein expression. Therefore, 
western blotting was performed on protein lysates (Figure 3.2.10B.). By analysing the 
relative density of chemiluminescent banding, no significant difference in ZO-1 protein   
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expression was quantifiable between mono- and co-culture, indicating the RTE 
improvements are not related to expression level or localisation of this tight junction 
protein (Figure 3.2.10C.). It may be that a distinction could be found by assessing 
expression of other types of tight junction protein, such as E-cadherin - an experiment 
that could be performed in the future.   
  
HBEC RNA levels were also measured, 72 hrs after culture. As well as the repertoire of 
inflammatory signals previously analysed, the epithelial marker CDH1 and the 
mesenchymal marker VIM were also assessed, as well as the BC marker KRT5 and the 
epithelial inflammatory cytokine TNFA (Figure 3.2.11.). CDH1 and KRT5 were both 
reliably expressed but levels did not change under differing culture conditions. VIM was 
also expressed and levels decreased in co-culture, suggesting a shift towards a more 
epithelial phenotype. Regarding inflammatory markers, IL1A, CSF3 and TNFA levels were 
all decreased in co-culture, whereas other transcript levels remained the same. The 
decrease in TNFA levels were consistent with the reduced CM protein levels previously 
observed. The decrease in inflammatory markers was contrary to results found in 
cocultured NHLFs, suggesting that the co-cultured epithelium is less inflamed despite 
functioning in a seemingly more pro-inflammatory micro-environment.   
  
3.2.2.3. NHLF co-culture enhances HBEC re-epithelialisation after injury.   
  
Crosstalk facilitates epithelial repair and epithelial injury is implicated as a driving force 
in IPF; therefore, to begin to understand the dynamics of wound repair in the model of 
crosstalk, HBECs in mono- or co-culture, were wounded, allowing investigation of the 
role of secretory communication in re-epithelialisation. HBECs were cultured for 72 hrs 
then mechanically wounded by drawing a scratch down the centre of the monolayer 
with a 200 μl pipette tip. The inserts were then returned to their respective culture 
environment and incubated for a further 9 hrs, with phase contrast images taken at 3 hr 
intervals. With these images the percentage of wound closure was calculated. Briefly, 
using ImageJ, for each phase contrast image the wound void was demarcated, allowing 
conversion to a binary image. The area of the image covered by wound void could then 
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be calculated at each subsequent time interval. By calculating subsequent wound areas 
as a percentage of the starting area, the percentage by which the wound had closed over 
time could be gauged. For example, in the HBEC mono-culture wound shown in (Figure 
3.2.12.), at 0 hr wound closure was 0%, at 3 hrs the void had decreased in size by 5.33% 
and by 9 hrs it had decreased by 51.07%. Analysis was performed as a percentage of 
starting wound due to the variability of starting wound size. The images in Figure 3.2.12. 
represent the images and analyses generated when comparing reepithelialisation 
between mono- and NHLF co-cultured HBECs over 9 hrs (Figure 3.2.13A.). After 9 hrs, 
the percentage wound closure in co-culture was significantly higher than mono-culture, 
with a mean of 66.16% closure versus 40.33% (Figure  
3.2.13B.). Therefore, co-culture promotes re-epithelialisation.   
  
When looking at phase-contrast images it was difficult to understand how 
reepithelialisation was taking place. To gain a better understanding, 9 hrs post-wounding 
HBECs were fixed and stained for actin, using Texas Red-conjugated phalloidin and IMF 
images taken. At a lower magnification, representative mono-culture images show a 
region of open wound and a region of closing wound (Figure 3.2.14A-B.). In both, there 
was actin present around the periphery of cells, and also in fibres, which ran across 
multiple cells. At a higher magnification (Figure 3.2.14C-D.), these stress fibres were 
found to orientate parallel to the leading edge. Further back from this front, orientation 
was re-configured, with fibres running perpendicular to the leading edge. The 
fluorescent signal arising from these fibres at the leading edge was very strong, however, 
at certain intervals this signal was interrupted by single cells extending broad 
lamellipodia into the wound void. The frequency of these salient cells was seemingly 
random. Images taken at the highest magnification (Figure 3.2.14E-F.), further highlight 
the organisation of parallel stress fibres at the leading edge. Differentiating the 
organisation between mono- and co-culture was not possible. However, these images 
describe a mode of migration in which adherent HBECs move in unity, led by individual 
cells on the leading edge that determine directionality by extending processes into the 
wound void. The continuous leading edge is maintained by parallel actin stress fibres 
but, further back, actin is re-orientated to enable the stretch of the epithelial sheet over 
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the wound void. The 9 hr time-course of these experiments limited the effect of HBEC 
proliferation and this understanding of sheet migration is concurrent with previous 
literature (Intro.1.1.3.3.) 77,78. It could therefore be postulated that the 
microenvironment created in co-culture accelerates migration, possibly via the 
fibroblastmediated secretion of chemotactic proteins in response to epithelial injury,   
  
Finally, the effect that epithelial wounding and the re-epithelialisation process had on 
the RNA levels of NHLF inflammatory wound signals was assessed by RT-qPCR. NHLF RNA 
was extracted 72 hrs after co-culture, either before wounding (0 hrs) or 9 hrs after 
wounding. It was unclear if 9 hrs would be long enough to have significant transcriptional 
effects on inflammatory markers but it was hypothesised that with wounding they would 
be increased. Though senescence is important in wound healing, literature evidence 
would suggest that this response occurs later in repair and that the senescence 
phenotype takes many days to develop in vitro. Therefore, levels of CDK inhibitors were 
not expected to change. The growth factors HGF and KGF (encoded by FGF7) were also 
assessed, as they are known to be important in promoting epithelial repair, and it was 
thought that they would be elevated 83,273. The results found levels of CXCL8, IL1B and 
CXCL1 to be significantly elevated, however levels of IL6, IL1A and IL33 were unchanged. 
Levels of HGF and CDKN1A were both significantly decreased and there was no change 
in levels of FGF7 or CDKN2A (Figure 3.2.15.). The results suggest a limited increase in 
inflammatory signalling with wounding yet an ability of the damaged epithelium to 
signal to basolateral fibroblasts and alter their behaviour.   
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3.2.3. Discussion  
  
This section set out to investigate the effect of co-culturing NHLFs with HBECs, with the 
aim of establishing a model of secretory crosstalk that could be used to uncover the role 
of FHLFs in IPF. NHLFs in co-culture have a lower cell number and display a more 
inflammatory phenotype. They do however promote HBEC development and 
reepithelisation. This is concomitant with reduced HBEC proliferation and decreased 
inflammatory gene expression. Taken together this suggest that, though more 
inflammatory than mono-culture, co-culture is nevertheless beneficial to HBEC function.   
  
Maintaining homeostasis?   
An aim of establishing this model was to recapitulate the secretory communication 
found in the lung airways. Epithelial-mesenchymal crosstalk plays an important role in 
maintaining homeostasis in the adult lung and therefore the reduction in cell number 
could be viewed as a reflection of homeostatic maintenance, a process that goes wrong 
in IPF. However, all other aspects of the results produced in this section would point 
towards much more active and dynamic processes occurring in co-culture. Therefore, 
though proliferation results are consistent with the idea of homeostasis, it is more likely 
that the model of crosstalk actually recapitulates processes of development and repair.   
  
Epithelial development or an epithelial response to injury?  
One of the important measurements employed in this investigation was RTE. Initially, 
measurements of RTE were seen as indicative of epithelial development, a measure of 
the processes that occur to establish the adult airways and processes that are also 
pertinent to the pathology of IPF. However, this investigation was not able to fully 
appreciate the role of developmental pathways in co-culture. WNT3A expression was 
assessed at an RNA level but found to be unreliably expressed and other key signalling 
proteins such as FGF10 and BMP4 were not investigated. This could be investigated in 
future experiments, initially by assessing RNA levels of developmental genes (including 
the broad range of other WNT genes) and then by measuring protein concentrations in 
the CM. This would add another dimension to this investigation and it would be 
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hypothesised that, as IPF is characterised by an aberrant reactivation of developmental 
signalling pathways, that these proteins would be elevated when investigating FHLFs in 
co-culture. Instead however, due to the focus of this study, these experiments found the 
co-culture microenvironment to be dominated by pro-inflammatory, wound-associated 
signalling mediators.   
  
Inflammatory micro-environment   
This pro-inflammatory micro-environment was of interest, potentially reflecting a more 
injury-associated environment. However, the proteins upregulated were also strongly 
associated with the SASP and NHLFs in co-culture were also less proliferative. This 
suggested that more cells could be beginning to enter a state of senescence. 
Morphologically though, these cells appeared normal and, at an RNA level, there was a 
decrease in expression of senescence regulators, making this possibility unlikely. 
Therefore, viewing the increase in inflammation from the perspective of wound healing 
was deemed to make more sense.  At 0 hrs, when HBECs were introduced into coculture, 
the cells were not confluent; they were dispersed in colonies across the insert 
membrane Appendix (Figure 6.1.3). This starting point may itself recapitulate a 
wounding event in the lung. Numerous forms of lung injury can occur that result in a 
denuding of the epithelial basement membrane and, though the stimulus of epithelial 
cell death was not present in this system, in essence, HBECs were put into a system in 
which they were required to repopulate a denuded membrane. Arguably this 
recapitulates injury and would begin to explain the increase in inflammatory signalling 
from the underlying fibroblasts. Therefore, in this study, it is more suitable to view RTE 
experiments in the context of epithelial injury.   
  
Epithelial regeneration  
When viewing the co-culture system as a response to injury, RTE, instead of a measure 
of development, can be described as a useful measure of the latter stages of epithelial 
regeneration. Airway denudation leads to epithelial migration and proliferation, which 
forms a permeable epithelial layer. This ‘leaky’ epithelium becomes more impermeable 
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with time. RTE quantifies ionic permeability and can therefore be used to describe the 
process of HBEC regeneration in co-culture.   
  
Arguably, regeneration elicits the use of many of the signalling pathways found in 
development, and it is a limitation of this study that they were not fully investigated, 
with a focus instead on immune-modulating signalling factors. However, the results 
from this section can support the concept of an epithelial response to injury, whereby 
the factors upregulated throughout this response are elevated. Understanding how 
coculture increases RTE does remain partially unclear and, although HBECs express 
receptors for many of the signalling factors investigated, to gain a better understanding 
of how co-culture promotes regeneration, interrogation of regenerative growth factors, 
such as HGF and KGF, in the basolateral CM could be performed. This isn’t without 
complication however as a simple increase in growth factors may not identify the cause 
of increased RTE. In co-culture, HBECs proliferate less, which is related to an increase in 
RTE. Therefore, co-culture is not beneficial due simply to an increase in growth 
factorinduced proliferation. Instead crosstalk is modulating HBEC phenotype and 
functionality in other ways, perhaps by enhancing differentiation.   
  
The decrease in HBEC VIM expression could suggest this and the possibility of increased 
differentiation could be measured by staining for various differentiation markers such 
as KRT5, MUC5AC and FOXJ1. Preliminary experiments were previously performed using 
confocal microscopy, which allowed 3D assessment of the relatively thick, 
pseudostratified epithelial layer, and some of these markers were investigated in 
monocultured HBECs (Appendix Figure 6.1.4.). These experiments could be repeated 
after coculture. However, it is unlikely that full differentiation to mucosal and multi-
ciliated cell types would be observed by 72 hrs. Previous investigations have extended 
cultures up to 28 days in order to evaluate this effect and cells were cultured without 
apical media, exposing them to the air 274. Therefore, co-culture experiments would have 
to be similarly extended and adjusted. However, it would be hypothesised that secretory 
factors produced by these cells would enhance differentiation of HBECs, resulting in 
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observation of increased numbers of mucosal and multi-ciliated cells via confocal 
microscopy.   
  
Better understanding this HLF secretory signalling could also be achieved by taking a 
more global approach to NHLF gene expression. HLFs could be isolated 72hrs post mono 
or co-culture and microarray experiments performed, allowing gene expression 
profiling. By utilising gene ontology, enrichment for specific secretory pathways could 
be identified. It would be hypothesised that co-culture would result in enrichment for 
pathways relating to regeneration / development, the end products of which could be 
targeted via neutralising antibodies, attenuating improvements in RTE. Similarly, factors 
up-regulated in co-culture but not mono-culture could be exogenously applied to 
monoculture in the form of recombinant proteins, subsequently enhancing RTE.   
  
Epithelial repair  
If measurements of RTE represent the latter stages of airway repair, then wound healing 
assays represent those stages at the start. These assays investigated re-epithelialisation, 
the process that precedes regeneration and NHLF co-culture was again found to be more 
beneficial. This is important within the context of IPF, in which there is recurrent injury 
to the lung. Interestingly, how HBECs respond to recurrent injury remains unknown and 
it could be interesting to perform multiple scratch assays on the same epithelium, 
comparing changes in percentage closure with recurrent injury. However, the 
immortalised HBEC cell line may not be perturbed by repeated injury and it would 
therefore be useful to investigate using primary epithelial cells or an in vivo model, in 
which aspects such as progenitor cell exhaustion may become important and lead to a 
decline in repair with repeated injury. Also, by investigating the morphology of the 
migrating HBECs it was not possible to discern a reason for these observed 
improvements but it would appear that factors in the micro-environment could 
accelerate migration. NHLFs further upregulated several inflammatory mediators but, 
interestingly, factors such as HGF and KGF were downregulated or unchanged. The 
enhancement of HBEC repair may be due to a whole range of other secretory factors not 
investigated thus far.   
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In conclusion, the co-culture of NHLFs and HBECs promotes the ability of HBECs to 
function in response to injury. The felicity of co-culture, however, remains to be 
underpinned by a more thorough, mechanistic understanding. Despite this, this 
investigation has established a series of useful assays and endpoints for future 
investigation into the nature of FHLF-mediated wound repair in the lung airway, which 
may further uncover the role of these cells in IPF.    
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 3.3  Fibrotic Human Lung Fibroblasts in a Model of Crosstalk  
  
3.3.1. Introduction  
  
With the establishment of an in vitro model of epithelial-mesenchymal crosstalk, and an 
understanding of the behaviour of NHLFs and HBECs in this system, the next step was to 
utilise FHLFs in this model. When investigating FHLFs in mono-culture, the differences in 
RNA and secretory protein levels were minimal. NHLF co-culture experiments have, 
however, highlighted that the presence of an overlying epithelium can significant alter 
fibroblast behaviour. This system better recapitulates how HLFs function in their native, 
airway environment and demonstrates how they can interpret signals from a 
regenerating or wounded epithelium to reciprocate signalling via protein secretion. 
Since NHLFs promote epithelial regeneration and promote re-epithelialisation after 
wounding, the following investigations aimed to understand how FHLFs perform in these 
assays.  
  
As evidenced from both the literature and the previous co-culture experiments with 
NHLFs, crosstalk is extremely important for epithelial repair and regeneration. Fibroblast 
secretions accelerate wound closure, in both AECs and HBECs, and also co-ordinate the 
regenerative process 41,82,83. IPF, however, is characterised by an aberrant repair 
response, in which there is a breakdown of the relationships governing these processes 
275. Though inflammation is critical for repair, in IPF there is evidence for an elevated 
background of inflammation 166. This may contribute to a defective repair process by 
altering the epithelial response to injury. It was therefore envisaged that co-culture with 
FHLFs may reveal an altered microenvironment, in which there is increased 
inflammation that impairs epithelial repair.   
  
FHLFs in co-culture  
There have been previous investigations into the role of epithelial-mesenchymal 
crosstalk in IPF. Primarily these have focused on the role of the epithelium in influencing 
fibroblast expansion and matrix deposition. For example, after mechanical epithelial 
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injury to cells isolated from healthy guinea-pig, fibroblast to myofibroblast 
differentiation and collagen deposition are observed in vitro 276. Similarly, experiments 
have been performed to investigate the effect of epithelial-associated protein signalling 
on fibroblasts in mono-culture. The healthy epithelium produces PGE2, which has 
antifibrotic effects, inhibiting fibroblasts proliferation and matrix deposition 277,278. 
Receptors for this ligand are, however, downregulated in isolated primary FHLFs and the 
cells are refractory to this signalling in mono-culture 279. This would suggest that FHLFs 
in a model crosstalk would be highly proliferative, ignoring direct epithelial signalling.  
Investigating this in co-culture with primary FHLFs has yet to be performed.   
  
Likewise, little research has been conducted on the effect that IPF fibroblasts have on 
epithelial function however. Epithelial cell death co-localises with aberrant fibroblast 
expansion in IPF tissue sections and treatment of an alveolar, transformed epithelial cell 
line with the CM from isolated FHLFs decreases cell number and the quantity of 
recoverable AEC DNA after 20 hrs 127,280. Likewise, TGF-β stimulated primary FHLFs 
produce H2O2 in a NOX4 dependent manner, which induces co-cultured, primary 
epithelial cell death 281. Exogenously applied H2O2 also inhibits AEC wound repair 282. 
How FHLFs facilitate epithelial re-epithelialisation and regeneration via secretion in 
coculture has yet to be established. Therefore, this study aims to provide a novel 
understanding of the role that FHLFs can play in the epithelial response to injury.   
  
Hypotheses:  
1. FHLFs in co-culture would create a micro-environment that fails to recapitulate 
the augmentation of epithelial regeneration and re-epithelialisation observed 
with NHLF co-culture.   
  
    
3.3.2. Results  
  
3.3.2.1. FHLFs show reduced cell number in co-culture, altered morphology and express 
higher levels of inflammatory signalling factors.  
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NHLFs in co-culture show attenuated cell number over 72 hrs, as measured by cell 
counting and viability staining, a characteristic that could be attributed to resource 
competition or epithelial signalling that impedes growth. IPF is a disease dominated by 
fibroproliferation and therefore it could be hypothesised that FHLFs in co-culture would 
proliferate significantly more than NHLFs and have a greater cell count. However, this 
was not evident. After 72 hrs, co-cultured FHLF RCN was calculated and compared to 
NHLF RCN. The RCN of FHLFs in co-culture was less than 1.00 and significantly lower than 
NHLFs, suggestive of proliferative arrest (Figure 3.3.1A.). Interestingly, this was 
complicit with prior morphological and proliferative characteristics observed in these 
cells under normal conditions. NHLFs had an archetypal, spindle morphology when 
cultured on plastic and population doublings occurred in around 3-4 days. Anecdotally, 
FHLFs under the same conditions often displayed a much larger, flattened morphology, 
population doubling was slower. When assessed via β-galactosidase staining, many of 
the cells displayed markers of proliferative arrest (Figure 3.3.1B.).   
  
In a separate series of experiments and after 72 hrs of co-culture, FHLF and NHLF RNA 
levels were measured via RT-qPCR. FHLF fold changes were calibrated against NHLF 
values and a significant elevation in FHLF levels of CXCL8 was observed (Figure 3.3.2.). 
There were no significant differences between levels of other transcripts, but there was 
a trend towards an increase in IL1B. At the protein level, however, the differences were 
much more dynamic. The CM from NHLF and FHLF co-culture was collected at 72 hrs and 
analysed via multiplex ELISA (Figure 3.3.3.). As in previous experiments, a broad range 
of immune-modulating cytokines, chemokines and growth factors were detected. 11 
analytes were detected at concentrations of greater than 100 pg/ml and of these, six 
were quantified at significantly higher concentrations in FHLF CM compared with NHLF 
CM. Protein concentrations of VEGF, GM-CSF, IL-6, CXCL8, CXCL1 and G-CSF were all   
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significantly greater in FHLF co-culture CM.  CCL7, CX3CL1, TNF-α, CCL2 and CXCL10 were 
also detected at concentrations >100 pg/ml but there no significant differences between 
co-culture conditions. This indicates that, though not necessarily evident at an RNA level, 
FHLFs upregulate a series of inflammatory secretory proteins that alter the composition 
of the co-culture micro-environment.   
  
3.3.2.2. FHLFs in co-culture impair re-epithelialisation and do not enhance epithelial 
barrier regeneration.  
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The next steps in this investigation were to evaluate what effect this altered 
microenvironment had on epithelial function in co-culture. NHLF and FHLF co-cultures 
were maintained over 72 hrs, along with HBEC mono-cultures, and, at 0 hrs, 
mechanically wounded via pipette scratch. Phase contrast images were taken across a 9 
hr time window and percentage wound closure quantified (Figure 3.3.4A.). 
Representative images of 0 and 9 hr wound sizes, with corresponding binary images, are 
also shown (Figure 3.3.4B.). 9 hrs post-wounding, HBEC re-epithelialisation was 
significantly less in co-cultures with FHLFs than in NHLF co-culture or HBEC mono-culture 
(Figure 3.3.4C.). Unlike in prior experiments (Figure 3.2.13.), there was no difference in 
closure between NHLF co-culture and HBEC mono-culture, with closure averaging at 
80.24% and 77.64% respectively. However, it was concluded that the environment 
created by FHLFs, and the relationships between these cells and the HBECs, is 
detrimental to re-epithelialisation, with closure averaging only 66.11%.   
  
The second aspect of epithelial function to be investigated was the development of 
epithelial ionic barrier integrity, as assessed by RTE. Cells were seeded at -24 hrs and 
brought into their respective cultures at 0 hrs. RTE was measured at 24 hr intervals from 
0 to 72 hrs (Figure 3.3.5A.). There were no significant differences in resistance at 0 and 
24 hrs. The mean increase in RTE across all culture types between these timepoints was 
0.036 KΩcm2. At 48 hrs there were significant differences between the mean RTE of each 
culture type, with resistance in NHLF co-culture significantly higher than FHLF co-culture  
(p<0.01, 2-way RM ANOVA). By 72 hrs, NHLF co-culture RTE was still significantly greater 
than HBEC mono-culture and FHLF co-culture (Figure 3.3.5B.). At this timepoint 
however, there was now no significant difference in resistance between FHLF co-culture 
and HBEC mono-culture, averaging at 0.43 and 0.57 KΩcm2 respectively. The mean 
resistance for NHLF co-culture was 0.90 KΩcm2. NHLFs augment HBEC regeneration over 
72 hrs. FHLFs, although not detrimental to HBEC regeneration, fail to recapitulate this 
benefit.    
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3.3.3. Discussion   
  
This series of experiments aimed to investigate FHLFs in an in vitro model of secretory 
crosstalk; investigating their behaviour in co-culture, the micro-environment they 
contribute to, and their effect on HBEC repair. FHLFs do not proliferate in co-culture and 
create a more pro-inflammatory environment, which concomitantly impairs 
reepithelialisation and fails to promote epithelial regeneration. This highlights the 
pathological attributes of this cell type and re-affirms their importance in the pathology 
of IPF.   
  
FHLF phenotype  
It was interesting that FHLFs had a lower cell count in co-culture. IPF is a disease 
characterised by excess proliferation and it would be expected that this would be 
observed in vitro with an increased RCN 120. That it wasn’t may reflect the dynamics of 
disease progression with time. Patients presenting with symptoms are likely to 
demonstrate a pathology that has been in action for many years, a period in which such 
proliferation predominates. The cells isolated from patients may display proliferative 
arrest due to isolation at later stages of the disease, when other characteristics of IPF 
become more salient. The strong signal does however corroborate the RCN results, 
suggesting that FHLFs were non-proliferative. It was also consistent with previous 
findings in mouse, in which the active regions of disease pathology, the fibrotic foci, have 
a non-proliferative core when investigated in aged mice, challenged with BLM 242. 
Though proliferation could be more accurately investigated with Ki67 or BrdU staining, 
taken together these results add to an overall picture of the FHLF phenotype in vitro in 
which they are characterised by a lack of proliferation.    
  
The results from RT-qPCR and multiplex ELISA showed that FHLFs could contribute to a 
more inflammatory micro-environment. However, the differences in RNA levels 
between 24 hr mono-culture and 72 hr co-culture were intriguing. The differences in 
time-point and culture type mean that these results were not directly comparable but it 
was interesting that IL1A levels were not increased (on average) and that there was no 
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statistical difference between levels of CDKN2A (Figure 3.1.1.). There are several 
possibilities for this. The loss of difference in CDKN2A could be due to NHLFs becoming 
more senescent in co-culture after 72 hrs, with increased expression of CDKN2A. 
Conversely, FHLF expression at an RNA level may be under temporal regulation, with 
levels at 72 hrs becoming less elevated when compared to normal cells. Not only this, 
but in terms of methodology, the primer used to assess CDKN2A (Table 2.3.3.) probed 
for the full complement of gene products. As the p16 protein was most pertinent to this 
investigation, it may perhaps be more appropriate to probe for this specific transcript. 
Likewise, experiments at an RNA level potentially miss the important effects of 
translational regulation of proteins, a mechanism of control that is important in the 
pathological characteristics of IPF fibroblasts 283. Consequently, a more robust approach 
to investing expression of this senescence marker would be to perform experiments at 
the protein level, performing western blot and immunostaining for p16. This could be 
achieved in future studies.   
  
Though not always reflected at an RNA level, there were significant increases in 
production of several pro-inflammatory proteins in the CM of FHLF co-cultures. These 
experiments were performed using all available cell lines. It remains difficult to delineate 
the cellular origin of proteins in the basolateral compartment, and the changes could be 
the result of increased HBEC production. Regardless, these results demonstrate that 
coculture with epithelial cells can expose significant differences in inflammatory protein 
production between NHLFs and FHLFs, results that were not obtained in mono-culture. 
This further highlights the importance of recapitulating elements of cell-cell signalling in 
vitro environment. It also raises questions about what other secretory factors could be 
differentially produced in this system and what would happen if additional stimuli were 
utilised, such as co-culture with immune cells or exposing the epithelium to the air.   
  
Impact on the epithelium  
However, in this system, the result of the environment created by FHLFs was that HBEC 
re-epithelialisation was impaired and that there was an attenuation of the regenerative 
benefits of NHLF co-culture. IPF is a disease characterised by an aberrant and 
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dysfunctional wound healing response, linked to epithelial dysfunction and 
fibroproliferative activation of a heterogenous population of fibroblasts. These results 
begin to implicate that, as well as the interstitial destruction described in the literature, 
FHLFs also mediate the loss of epithelial function, an ability elicited by the creation of a 
pro-inflammatory micro-environment that impairs their ability to respond to injury. That 
FHLFs can contribute to both of these disease characteristics further points towards the 
heterogeneity of this population, suggesting that different subsets of fibroblasts may 
elicit different pathological activities. This understanding firmly places the FHLF at the 
heart of IPF pathology, identifying them as the key orchestrator of disease progression.   
  
FHLFs and senescence  
One of the interesting features of the inflammatory environment generated by FHLFs in 
co-culture is its strong resemblance to the SASP, the key hallmark of senescence. IL-6, 
CXCL8, CXCL1, GM-CSF and VEGF are all core SASP components 213 and all were elevated 
with FHLFs. Growth arrest and SA-βgal activity have also been identified in FHLFs, as well 
as in increase in CDKN2A expression when mono-cultured. These features collectively 
imply a senescent, or at least a senescent-like / pre-senescent, phenotype in FHLFs, 
which is associated with impaired epithelial function.   
  
There is much evidence for a role of senescence in the pathology of IPF. It is implicated 
in all of the driving forces of IPF, playing a role in developmental signalling, wound repair 
and ageing. Fibroblasts from IPF patients have previously been found to display 
senescent characteristics in vitro and there is evidence for senescence in the IPF 
epithelium in vivo 239,246. Most recently, research has shown that senescent cells 
accumulate in mice treated with BLM and that the selective clearance of these cells 
reduces fibrosis-associated physiological impairments 247. Likewise, mice treated with 
ionising radiation develop fibrosis over the course of several weeks. This fibrosis is 
understood to be mediated by senescence, which, after treatment with the senolytic 
compound ABT263, can be resolved via the specific clearance of senescent cells 284. 
Therefore, the results from this section, coupled with current literature, suggest that 
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FHLFs are important in the pathology of IPF through a propensity to acquire a 
senescentlike phenotype that alters epithelial-mesenchymal crosstalk.  
  
How senescence is mediated in FHLFs is thus far unclear. However, the elevation in 
CDKN2A expression in mono-cultured FHLFs would suggest mediation through the 
p16pRB pathway. This pathway is most strongly associated with OIS and ROS-induced 
senescence 197. A role for ROS-induced senescence would comply with previous evidence 
highlighting a ROS imbalance in FHLFs that contributes to aberrant fibroblast activity in 
IPF 119. Better understanding of senescence in epithelial-mesenchymal crosstalk and its 
relevance to FHLFs will require further investigation and will be the focus of the next 
section of this work.   
  
In conclusion, FHLFs display a senescent-like phenotype in culture, associated with the 
generation of a more pro-inflammatory micro-environment. The detriment of this 
phenotype is evidence by a concomitant impairment of HBEC re-epithelialisation and an 
impairment of epithelial regeneration, further implicating the FHLF as a key mediator of 
the pathology of IPF.   
  
    
 3.4  Stress Induced Premature Senescence in Normal Human Lung Fibroblasts  
  
3.4.1. Introduction  
  
Senescence in IPF  
FHLFs impair epithelial function, a result associated with increased production of several 
core SASP proteins. As well as an altered morphology, FHLF also display a poor 
proliferative capacity. Taken together, this points towards a senescent-like phenotype 
in these cells. In aged mice, senescence inhibits the resolution of BLM-induced mouse 
fibrosis, with senescent fibroblasts chronically accumulating in the lung 242. Within 
fibroblastic foci of these aged mice, a combination of staining for p16, p21, Ki67 and 
αSMA, along with TUNEL staining, reveals a largely non-proliferative, myofibroblastic 
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core, positive for markers of senescence. On the periphery, there are regions of 
fibroblast proliferation and the foci are covered by a highly apoptotic epithelium. 
Elevated Nox4 activity in isolated FHLFs drives increased H2O2 production and its 
inhibition reduces SA-βgal activity. Coupled with a deficiency in fibroblast Nrf2 activity, 
an intrinsic redox imbalance in aged mice leads to this senescence and non-resolving 
fibrosis 242. Crucially, senescence can be observed in the HLFs of IPF tissue sections and 
the clearance of senescent cells can alleviate many of the detrimental effects of 
BLMinduced fibrosis in mouse 247. It is therefore conceivable that in the lungs of IPF 
patients there is an increased burden of senescent cells. The relationship between 
senescent fibroblasts and the epithelium in the context of IPF has yet to be elucidated.   
  
Stress induced premature senescence  
To better explore the impact of fibroblast senescence on the epithelium, and to establish 
a benchmark for the senescent-like FHLFs (whereby the degree to which they conform 
to the archetypal senescence phenotype could be compared), it was appropriate to 
generate a model of senescence in vitro. Senescence can be induced via numerous 
methods. As reported by Leonard Hayflick many decades ago, serial passage can induce 
senescence and this replicative senescence has been utilised in a wide range of 
published studies. The constitutive activation of oncogenic pathways, such as Kras, 
typically via viral transfection, can also induce senescence, a form of senescence termed 
OIS (oncogene-induced senescence). As well as this, stress, in varying guises, can be used 
to induce cellular senescence. This stress-induced, premature senescence (SIPS) can be 
caused by genotoxic agents such as ionising radiation, high glucose or H2O2.  All three of 
these agents cause DNA damage 285–288.   
  
DNA damage that causes double-strand breaks (DSBs) leads to ataxia telangiectasia 
mutated (ATM) activation and signal transduction, phosphorylating H2AX and p53 as 
part of a DDR. H2AX transitions to γH2AX, a classical marker of DNA damage, which 
promotes the recruitment of several DNA repair factors. p53 is stabilised via its 
phosphorylation, and cell cycle progression is inhibited. When DNA damage cannot be 
resolved, senescence is induced by activation of CDK inhibitors 289. p21 is upregulated, 
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promoting both growth arrest and also inhibiting apoptosis, via pleiotropic activity in 
which mitochondrial cytochrome c release and caspase-9 activation is prevented 290. 
Oxidative stress caused by genotoxic agents also leads to phosphorylation of p38 MAPK. 
p38MAPK causes TGF-β1 and caveolin-1 transcriptional upregulation 291,292. Caveolin-1 is a 
scaffold protein that can promote cell cycle arrest via activation of the p21-p53 pathway 
293. TGF-β1 induces mitochondrial dysfunction that results in the endogenous production 
of H2O2, creating more oxidative stress and causing further DNA damage 200. All of these 
pathways create a cyclical feedback loop, in which exogenous genotoxic insults, 
oxidative stress and mitochondrial dysfunction coalesce to either initiate or maintain 
commitment to a programme of cellular senescence.   
  
To prematurely induce senescence in NHLFs it was decided to use exogenous treatments 
of sub-lethal concentrations of H2O2. SIPS was favoured over replicative senescence due 
to the ability of it to be induced at any stage of the NHLFs replicative lifespan, speeding 
the process of induction and enlarging the pool of cells that could be made senescent. It 
could be argued that because IPF is a disease of old age and that because the senescent 
cells in fibrotic foci are likely to have been previously involved in excessive proliferation, 
replicative senescence is more relative to the disease. However, there is also a strong 
rationale for utilising SIPS, especially via induction with H2O2. IPF is characterised by 
recurrent injury and with epithelial injury there is H2O2 release 81. In the exhaled breath 
condensate of IPF patients there are elevated concentrations of H2O2 and isolated FHLFs 
display increased NOX4 activity, which produces H2O2 118,294. There is also increased TGF-
β1 activity that can cause mitochondrial H2O2 production and induce senescence 93,295. 
Therefore, exogenous, sub-lethal H2O2 treatment may in fact begin to recapitulate the 
environmental exposures relevant to the IPF lung.   
  
Phenotypic changes in SIPS  
The changes associated with SIPS in vitro are diverse and irreversible. The most obvious 
changes are those to morphology, with cells becoming flattened and enlarged 296. This 
occurs in concurrence with growth arrest, in which DNA synthesis is inhibited and cells 
fail to respond to exogenous growth factor signalling. These irreversible changes are, 
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however, not associated with loss of cell viability 297. The arrest in growth is mediated 
by classical senescence pathways, with a transient increase in p53 and long-term 
elevation of p21, which can be assessed by western blotting and IMF. Cells are arrested 
at the G1 phase of the cell cycle, which can be analysed via flow cytometry 298. The most 
widely used marker for senescence induction is an increase in SA-βgal activity 299. In both 
replicative and cellular senescence, there is an increase in lysosomal activity, occurring 
as part of a compensatory mechanism, elicited to assist the degradation of damaged 
organelles in secondary lysosomes 300. GLB1, a gene encoding lysosomal β-
Dgalactosidase, is upregulated and the resultant enzymatic activity can be detected by 
Xgal, a chromogenic substrate that produces a blue compound when enzymatically 
cleaved 301. Lysosomal enzymes optimally function in acidic conditions (pH 4.0). The 
significantly greater lysosomal activity in senescence, however, allows detection at a 
sub-optimal pH of 6.0. By using a citric acid/sodium phosphate buffer at pH 6.0, SA-βgal 
activity can be distinguished from normal lysosomal β-gal activity 249. SA-βgal has been 
robustly established as a marker of senescence, with activity limited to only senescent 
cells, not quiescent, proliferative or terminally differentiated cells.  Finally, another key 
alteration that can be detected in SIPS is the establishment of SASP. SASP encompasses 
a broad range of cytokines, chemokines and growth factors, which can differ between 
cell types. For fibroblast SIPS, the core SASP repertoire consists of IL-6, CXCL8, CXCL1, 
CCL2 and GM-CSF 212,213. Elevation of these factors is widely used as evidence of 
senescence induction, especially IL-6 and CXCL8 (Figure 1.3.3.).   
  
SIPS in co-culture  
The effect of fibroblast SIPS in co-culture have been investigated before, although not in 
the context of IPF. Senescent tracheal HLFs, co-cultured with HBECs (the BEAS-2B cell 
line), promote EMT in the presence of the carcinogen, hexavalent chromium. After 4 
weeks of transwell co-culture, almost 80% of HBECs display enlarged nuclei, a loss of 
cobblestone morphology and a fusiform morphological alteration, as well as a significant 
increase in vimentin expression. This is indicative of malignant transformation, part of 
the initial stages of tumourigenesis 302. Other studies, using different approaches to 
paracrine signalling, have also found senescent lung fibroblasts to promote malignant 
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epithelial growth 303,304. Interestingly, the epithelium of honeycomb lesions and cysts in 
IPF is also characterised by a hyperplastic epithelium, suggesting a similar mechanism 
could be at play. Using Matrigel-coated transwell inserts, the secretome of senescent 
fibroblasts promotes epithelial invasion, evidenced in both breast mammary epithelium 
and pancreatic cancer cells 231,305. An inability to differentiate also occurs under the 
influence of SASP but the establishment of epithelial barrier integrity, as measured by 
RTE, has yet to be assessed. Likewise, though studies have investigated the role of 
senescence in wound healing via other methodologies, how the secretory factors of 
senescent cells impact re-epithelialisation remains to be elucidated.   
  
Taking all these aspects into consideration, the following experiments set out to 
establish a robust method of SIPS induction, utilising classical senescence markers. An 
understanding of how these cells function in co-culture and their effect on the overlying 
epithelium was also a principal aim, achieved by assessing re-epithelialisation and ionic 
permeability. The rationale for these experiments was that SIPS cells would represent 
the extremity of the FHLF phenotype, acting as a positive control for their behaviour in 
co-culture.   
  
Hypotheses  
1. Sub-lethal treatment with H2O2 will induce SIPS in NHLFs, leading to numerous 
phenotypic changes.    
2. HBEC co-cultures with SIPS will fail to promote RTE and impair re-epithelialisation.  
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3.4.2. Results   
  
3.4.2.1. H2O2 treatment can prematurely induce senescence in NHLFs.    
  
As previously discussed, treatment with sub-lethal concentrations of H2O2 can induce 
senescence via irreparable DNA damage. The concentration of peroxide is extremely 
important as too much can cause cell death and too little can have no effect. Various 
concentrations of H2O2 have been used in prior studies 295,298 and ultimately trial and 
error was adopted to identify a concentration suitable for this investigation. The literary 
nuance regarding SIPS protocols was further complicated by the heterogenous response 
of different NHLF lines to equivalent treatment regimes. For example, treating the NHLF 
line TB0917 for 5-days with 200 μM H2O2 resulted in 90% cell death, the same treatment 
in the line TB0932 however resulted in cells reaching confluence. Accommodating for 
these discrepancies was complicated but, through tailoring treatment protocols to each 
cell line, a uniform induction of senescence was achieved. The best suited concentration 
was found to be 200 (±100) μM peroxide, given recurrently over 5 days to NHLFs seeded 
at an initial density of 1.0 x106 cells/T75 flask. After treatment, the key step to achieving 
senescence was passage and recovery. On day 6, 1 day after final treatment, cells were 
passaged and left to recover for a further 6 days. During this time cells acquired the 
classical senescence morphology, in what appeared to be a time-dependent process. In 
total, 12 days was deemed to be a suitable period for senescence induction, offering 
robust increases in SA-βgal activity alongside morphological changes. This SIPS protocol 
was used throughout the following experiments.   
  
The SIPS protocol and the assessment of senescence hallmarks was achieved in 
monoculture. After protocol completion, H2O2-treated NHLFs had undergone extensive 
morphological changes, as assessed by IMF (Figure 3.4.1.). NHLFs have a typical 
fibroblast morphology, with an oblong or triangular shape and size (length) of around 
100 μm. Cytoskeletal actin was present, with a strong signal, and it was observable in its 
polymerised form, with stress fibres running throughout the cells. SIPS displayed striking 
morphological alterations with many of the cells displaying an enlarged morphology.   
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There was still heterogeneity within these populations but in general there was a 
frequent enlargement, with cells reaching widths of 400 μm in some instances. 
Polymerised actin was still present in these cells, again forming stress fibres, yet, due to 
  
193  
  
the increase in size, these fibres were more dispersed. The nuclei themselves were also 
of interest. With the exception of cells such as megakaryocytes and 
tuberculosisassociated giant cells, cells do not routinely have multi-nucleation. Across 
multiple cell lines however, numerous SIPS cells displayed a multi-nucleated phenotype 
as seen via DAPI. This was not observed in NHLFs.   
  
H2O2 treatment also robustly increased senescence associated lysosomal activity, as 
evidenced by chromogenic staining for SA-βgal activity. After the SIPS protocol, cells 
seeded at 30,000 cells/well of a 12-wall plate and allowed to adhere overnight. They 
were then fixed in 4% PFA and stained overnight with X-gal staining solution. 
Phasecontrast images were then taken revealing extensive SA-βgal activity in SIPS, but 
not NHLFs (Figure 3.4.2.). Donor matched images are shown, with the majority of SIPS 
displaying a blue staining, located primarily around the nucleus. This was concomitant 
with the morphological changes previously seen although, interestingly, even cells that 
were not enlarged also stained positive for SA-βgal, suggesting that either senescence 
can be induced independently of morphological alterations or that SA-βgal precedes 
these changes, with fixation occurring before they had time to develop.    
  
To elucidate the pathway that was facilitating these changes and establishing 
senescence, p21 protein expression was assessed. NHLFs and SIPS seeded at a density 
of 45,000 cells/well of a 6-well plate and culture for 72hrs. Cells were then lysed with 
RIPA buffer and the protein content quantified via BSA assay. Equal concentrations of 
protein were loaded onto a gel and run with subsequent antibody staining for p21 and 
the loading control β-actin (Figure 3.4.3A.). p21 banding was considerably more intense 
in SIPS than NHLFs. Relative densitometric analysis quantified this intensity, highlighting 
a significant increase in p21 expression in SIPS (Figure 3.4.3B.). To further corroborate 
this finding and identify the intracellular location of p21 activity, NHLFs and SIPS were 
stained for p21 and imaged by IMF (Figure 3.4.4.). In NHLFs there was exceptionally little   
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p21 expression but in SIPS, p21 was observable in numerous cells. By merging p21 and 
DAPI signal this expression was found to be localised within the nuclei, consistent with 
physiological p21 activity. p53 was not investigated but, given the strong expression of 
p21, it could be postulated that the senescence induced by peroxide treatment is 
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mediated through the p21-p53 pathway, consistent with other evidence regarding 
DNAdamage induced senescence.   
  
Changes in RNA levels were also assessed via RT-qPCR. After the SIPS protocol, cells were 
seeded at a density of 30,000 cells/well of a 12-well plate, in mono-culture and cultured 
for 24 hrs prior to RNA isolation. RNA levels for a range of senescence associated 
proteins were assessed, as well as CDKN1A, the gene encoding p21. As expected from 
the western blot and IMF analysis, CDKN1A levels were significantly higher in SIPS than 
in NHLFs (Figure 3.4.5.). This was also evident for levels of CXCL8, IL1A, IL1B and HGF, 
genes upregulated in senescence and indicative of cellular stress. IL6, IL33, CXCL1, FGF7 
and CDKN2A were also expected to be elevated but were not and, as in previous 
experiments, CSF3 was not reliably expressed at this timepoint. The lack of CDKN2A 
transcript elevation begins to suggest that the p16-pRB pathway is not heavily involved 
in this form of senescence or not involved at this stage of the induction process, in 
contrast to FHLFs, which display elevated CDKN2A RNA levels (Figure 3.1.1.).  
  
These results ostensibly highlight a robust induction of senescence upon recurrent 
treatment with sub-lethal concentrations of H2O2, evidenced by classical morphological 
alterations, increased SA-βgal activity and p21 expression, and an elevation of RNA levels 
encoding for several genes relating to senescence.   
  
3.4.2.2. SIPS in mono-culture produce altered concentrations of secretory proteins.  
  
To assess the secretory factors produced by SIPS and how their composition changes in 
relation to NHLFs, the CM of mono-cultured cells was analysed via Multiplex ELISA. Cells 
were mono-cultured for 72 hrs prior to CM collection. In this experiment the percentage 
of SA-βgal positivity differed between cultures. By quantifying the percentage positivity,   
  
198  
  
   
  
199  
  
two SIPS populations were identified: a low burden population, with a mean positivity 
of 39%, and a high burden population, with a mean of 85% (Figure 3.4.6.). The secretory 
factors produced by these populations were detected at differing concentrations (Figure 
3.4.7.). As with previous multiplex ELISA experiments, many secretory proteins were 
detected yet only a select few were found at meaningful concentrations. Of these 
proteins, the pattern of concentration can be broadly grouped into four categories: (1) 
with a low burden of senescence there is no elevation of protein concentration, but 
when high there is significant elevation. This was evident for the factors: CX3CL1, CXCL1, 
CXCL10, IL-6 and CXCL8. (2) Both low and high burdens of senescence resulted in 
elevated protein concentrations, evident in bFGF and CCL3 concentrations. (3) Both 
populations of senescent cells produced decreased protein levels compared to NHLFs, 
evident only for CCL2. (4) A low burden of senescence resulted in a significantly 
decreased protein concentration but at a high burden, concentrations were significantly 
elevated. This was evident in concentrations of VEGF, INFα2, G-CSF and GM-CSF. 
Therefore, the percentage burden of senescence is important for determining the local 
micro-environment.   
  
3.4.2.3. SIPS have an altered mitochondrial morphology and increased mitochondrial 
membrane potential.  
  
Mitochondrial function and membrane potential are important components in the 
pathways mediating senescence and, in IPF, dysmorphic mitochondria can promote the 
process of fibrosis. Therefore, as with FHLFs, experiments designed to elucidate 
mitochondrial phenotype were performed in SIPS. NHLFs and SIPS were mono-cultured 
prior to fixation and IMF staining for ATP5B (Figure 3.4.8A.). As previously, using ImageJ 
the ATP5B signal was converted to a skeletonised image, allowing quantification of 
mitochondrial morphology (Figure 3.4.8B.). NHLFs showed a highly-interconnected 
network of mitochondria. SIPS in contrast, as well as being much larger, showed a more 
extensive mitochondrial network with more numerous mitochondria. This network was 
less well connected, and the mitochondria were typically smaller and more isolated 
within the cytosol. Analysing these images by ImageJ quantified these differences   
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(Figure 3.4.9A.). The average number of mitochondria per cell was significantly 
increased in SIPS, although there was no difference in the area of this network. The 
average size of each mitochondrion within each cell was significantly less in SIPS, as was 
the average number of branches that each mitochondrion had. The average length of 
these branches was no different, nor was average maximum length of each branch. The 
average number of branches per mitochondrion was, however, significantly decreased 
in SIPS. The mean copy number of mtDNA was also measured via RT-qPCR. Isolated DNA 
was analysed, revealing that the mean copy number for SIPS fell within the range of that 
measured in NHLFs, with no significant difference between the two (Figure 3.4.9B.). 
Therefore, SIPS do display a less interconnected mitochondrial network, composed of 
smaller and less branched organelles.   
  
In an attempt to understand mitochondrial membrane polarity, Δψm was measured in 
NHLF and SIPS, after 24 hrs of mono-culture. TMRE and FCCP were again used (Figure  
3.4.10.). The fluorescence intensity of coupled mitochondrial was significantly higher in 
SIPS when compared to NHLFs. FCCP also significantly reduced this intensity in SIPS and 
there was no statistical difference between the uncoupled intensity of these cell types. 
In summary, this suggest that SIPS mitochondria, as well as being more fragmented and 
punctate, have hyperpolarised membranes in comparison to NHLFs. This potentially 
indicates increased ATP production and increased mitochondrial activity; however, it 
would be worth using an extracellular flux analyser to investigate this further.   
  
3.4.2.4. SIPS RCN is decreased in culture and SIPS express greater levels of 
inflammatory and senescence-associated markers.  
  
Senescence is defined by proliferative arrest. To begin to understand this in SIPS, cells 
were counted using a haemocytometer at 24 hr intervals, over a period of 72 hrs, to 
quantify RCN. SIPS were seeded at -24 hrs in either mono- or co-culture. Cell counts are 
shown relative to the initial seeding density. With the exception of a small drop at 0 hrs,  
RCN remains flat for 72 hrs, never significantly elevating above 1.0 for any culture   
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condition. At 72 hrs post co-culture, there was no significant difference between the RCN 
of either condition (Figure 3.4.11A.). When comparing the values of SIPS in mono- or co-
culture to equivalent data from NHLFs, RCN failed to rise in SIPS yet increased over 72 
hrs for both NHLF conditions. At 72 hrs, NHLF mono-culture RCN and NHLF co-culture 
RCN were both significantly higher than the corresponding RCN of SIPS. Though not a 
measure of proliferation these results suggest a potential proliferative arrest in SIPS, 
under any culture condition, consistent with the underlying principles of the senescence 
phenotype (Figure 3.2.11B.).   
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Though not increasing in cell number, after 72 hrs of co-culture there were significant 
changes to levels of SIPS RNA and protein secretion. RNA was isolated from SIPS and 
NHLFs at this time point and RT-qPCR performed. SASP and inflammatory wound 
associated RNA levels were quantified, as well as the regulators of senescence CDKN1A 
and CDKN2A. Average fold change was calculated in comparison to NHLF levels. There 
was a significant elevation in RNA levels of all factors, with the exception of CDKN2A, for 
which there was no significant change (Figure 3.4.12.). The most significant increase was 
in levels of IL33, with an average change of 14.8-fold. IL6, CXCL8 and IL1B were all 
increased on average over 5-fold. The smallest increase was in HGF levels, which 
increased 2-fold on average. The concentrations of secretory proteins were also 
measured, again via multiplex ELISA. The concentrations of proteins detected above 100 
pg/ml are shown in (Figure 3.4.13.). There were no significant differences in 
concentrations of VEGF and GM-CSF and concentrations of CCL2 and CXCL10 were 
significantly reduced. Concentrations of IL6, CXCL8, CXCL1 and GCSF were significantly 
increased. In SIPS co-culture CM concentrations of these proteins more than doubled 
when compared to their NHLF counterparts. The concentration of CXCL8 in SIPS CM was 
also the highest detected across all ELISA experiments, averaging at a concentration of 
roughly 14,000 pg/ml. As in previous experiments, the concentrations of IL-1α, IL-1β and 
IL-33 (measured via standard ELISA) were exceptionally low and there was no difference 
between CM types. These results highlight that with robust, p21-dependent senescence 
induction, cells experience severe stress, with upregulation of alarmin expression, 
concomitant with the upregulation of numerous SASP proteins that are secreted into 
the micro-environment.  
  
These results describe the characteristics of SIPS in mono- and co-culture, the following 
experiments were aimed at understanding how these characteristics influence HBEC 
function.   
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3.4.2.5. The regeneration of HBEC barrier impermeability is impeded by both coculture 
with SIPS, or treatment with SIPS CM.  
  
Firstly, the effect of SIPS co-culture on RTE and the regeneration of epithelial ion 
impermeability was investigated. RTE was measured over 72 hrs, at 24 hr intervals, in 
either HBEC mono-cultures or NHLF/SIPS co-cultures (Figure 3.4.14A.). RTE values did not 
significantly differ over the first 24 hrs. By 48 hrs, values for both co-culture types were 
significantly greater than mono-culture, although there was no difference between 
them. By 72 hrs there were significant differences between all three culture conditions 
(Figure 3.4.14B.). RTE values for both co-culture conditions were still significantly greater 
than those of mono-culture but the values for SIPS co-culture were significantly less than 
those for NHLF co-culture.   
  
To investigate this further, an experiment was devised utilising an important aspect of 
SIPS induction. The period of recovery after H2O2 treatment is key to allowing the 
senescence phenotype to establish itself and the longer cells are left to recover, the 
greater the percentage of SA-βgal positivity. This property of SIPS induction was used to 
create SIPS mono-cultures of varying burdens of SA-βgal positive cells (Figure 3.4.15A.). 
By taking cells at either recovery day 2, 4, or 6, a culture of increasing senescence burden 
could be created (Figure 3.4.15B.). These populations of cells were then seeded at a 
density of 12,000 cells/well of a 24-well plate and subsequently given fresh medium and 
maintained for 72 hrs to produce CM. NHLFs were also cultured for 72hrs creating 
control CM. The CM, generated by differing levels of senescent HLFs, was then used to 
treat HBEC mono-cultures. As a further control, HBEC mono-cultures were also treated 
with CM, generated over 72 hrs but in the absence of cells. Treated HBECs were then 
cultured for 72 hrs and RTE was measured (Figure 3.4.15C.). When compared to the 
values of control CM, RTE was significantly higher in NHLF co-culture and significantly   
  
    
  
210  
  
   
  
211  
  
  
  
212  
  
lower in HLF-free CM, consistent with earlier experiments investigating CM and RTE 
(Figure 3.2.7.). With an increasing burden of senescent cells, the subsequent CM has an 
increasingly attenuated ability to elevate RTE, to the extent that, when the range of 
SAβgal positivity is between 48-59%, the CM fails to increase RTE to a level significantly 
greater than that of control CM. SA-βgal activity was quantified prior to CM-production 
and therefore, over the 72 hr culture period, the senescence burden was likely to 
increase in all cultures. However, linear regression analysis of the data in Figure 3.4.15B. 
highlights a linear relationship between time and percentage positivity (r2 = 0.93).  
Therefore, though the percentage burden will have changed by the end of CM 
production, the differences between cultures are likely to be maintained. Taken 
together, these results indicate that the microenvironment generated by SIPS is unable 
to promote epithelial regeneration.  
  
3.4.2.6. In co-culture, SIPS reduce HBEC cell number and alter HBEC RNA levels.    
  
To try and understand the cause of these differences, HBEC cell number was 
investigated. HBEC RCN was calculated over 72 hrs, following the protocol previously 
used to assess HBEC proliferation in NHLF co-culture. HBEC cell number was counted 
every 24 hrs in either mono-culture or co-culture with SIPS and RCN calculated (Figure 
3.4.16A.). HBEC RCN in mono-culture was significantly greater at 72 hrs than in 
coculture. This effect of co-culture was, however, not observed in SIPS co-culture, with 
no significant difference in RCN between co-culture conditions. Comparing the results 
of SIPS co-culture to those of NHLF co-culture and HBEC mono-culture, it can be seen 
that, at 72 hrs, HBEC RCN is significantly less in SIPS co-culture (Figure 3.4.16B.). As 
found previously, there was an inverse relationship between HBEC RCN and RTE, with a 
smaller RCN equalling a greater RTE. The results from SIPS co-culture, however, do not 
fit this trend. Although there is a smaller RCN in this condition, RTE is not greater (Figure  
3.4.17.).   
  
SIPS co-culture also has an effect on HBEC RNA levels, as measured by RT-qPCR at 72 hrs 
post co-culture (Figure 3.4.18). RNA levels of VIM, KRT5, IL1A, CXCL1 and TNFA were all   
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significantly elevated. There was no significant difference between levels of CDH1, IL1B, 
IL6, CXCL8 or CSF3. This suggests a more inflammatory HBEC phenotype in SIPS coculture 
and also a potential resemblance to the epithelial phenotype found in IPF, with an 
increase in VIM and KRT5 suggesting a more mesenchymal and a more basal epithelial 
phenotype.   
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3.4.2.7. SIPS in co-culture impair HBEC re-epithelialisation after wounding, associated 
with altered levels of inflammatory RNA transcripts.   
  
Co-culture with SIPS fails to promote epithelial regeneration, decreases HBEC 
proliferation and increases mesenchymal and inflammatory RNA levels. The effect of 
SIPS on re-epithelialisation was next evaluated. Co-cultures were maintained for 72 hrs 
prior to mechanical wounding via scratch. Phase-contrast images were then taken at 0, 
6 and 9 hrs, allowing quantification of wound closure with ImageJ (Figure 3.4.19A). 
Representative images are shown in Figure 3.4.19B. By 6hrs there was a significant 
decrease in the percentage wound closure of HBECs co-cultured with SIPS, when 
compared to both HBEC mono-culture and NHLF co-culture. At 9 hrs these differences 
were maintained (Figure 3.4.19C.). Re-epithelialisation was significantly impaired in SIPS 
co-culture over the course of 9 hrs, further highlighting the detriment of the 
SIPSgenerated micro-environment to epithelial function.   
  
The effect that epithelial wounding had on SIPS RNA levels was also quantified. After 72 
hrs of co-culture, NHLF or SIPS RNA was collected, prior to and 9 hrs after wounding. 
Though already significantly elevated compared to NHLFs, RNA levels of IL1A, HGF, FGF7, 
CDKN1A, IL6, CXCL8 and IL33 did not significantly change with wounding (Figure 3.4.20). 
The average fold change of HGF levels remained greater than NHLFs but this did not 
reach significance after wound. Levels of CDKN2A were not elevated either pre- or 
postwounding. RT-qPCR did, however, reveal that wounding lead to an increase in RNA 
levels of IL1B, CXCL1 and CSF3. The average fold change of both IL1B and CXCL1 more 
than tripled and the average fold change of CSF3 went from 3.9 to 42.7 in response to 
wounding, highlighting that SIPS are responsive to epithelial wounding and able to   
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further increase expression of certain pro-inflammatory factors. IL1B is potentially 
elevated in response to epithelial cell death occurring during wounding, with necrotic 
cells releasing damage-associated molecular patterns that stimulate upregulation. 
Likewise, CXCL1 and CSF3 are secretory factors associated with wound repair and 
therefore expected to be elevated 306. It is interesting however that the other key 
wound-associated factors, such as IL-6 and CXCL8, were not elevated and perhaps this 
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is demonstrative of the SIPS phenotype at baseline recapitulating the that of normal 
fibroblasts responding to epithelial injury.   
  
3.4.2.8. SIPS CM can alter RNA levels of COL3A1 in NHLFs.   
  
The primary focus of this section of experiments was to induce SIPS and to understand 
their relationship with HBECs in co-culture. Another area of intrigue however was the 
effect that SIPS could have on otherwise normal NHLFs. Hecker et al. described fibrotic 
foci in the aged, BLM-treated mouse as being comprised of an internal core of 
nonproliferative, senescent myofibroblasts surrounded by proliferative fibroblasts, with 
the suggestion that senescent fibroblasts promote proliferation and fibrogenic 
processes in their neighbours 242. Schafer et al. have since been able to demonstrate that 
the CM from senescent fibroblasts can promote an increase in the relative expression of 
the collagen encoding genes COL1A1 and COL1A2, genes important for matrix deposition 
and this fibrogenic process (Figure 1.3.7B.) 247. Therefore, the effect that SIPS had on 
fibrotic processes in NHLFs was also of interest and it was hypothesised that the CM 
from SIPS would up-regulate expression of ECM producing genes. Consequently, an 
experiment was setup in which mono-cultured NHLFs were treated with SIPS CM or 
NHLF CM for 72 hrs, with RNA collected at this time point. SIPS CM was generated after 
72 hrs of mono-culture, with cells seeded in 12-well plates at a density of 30,000 
cells/well. Treated NHLFs were also seeded in this format. RT-qPCR was performed for 
the collagen encoding transcripts COL1A1 and COL3A1, and the elastin encoding 
transcript ELN, key components of the ECM deposited in fibrosis. As a positive control, 
NHLFs were also treated with 1ng/ml of recombinant TGF-β1 (PrepoTech, USA), which 
is known to robustly increase expression of these ECM encoding genes. TGF-β1   
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treatment significantly elevated levels of all three RNA transcripts when compared to 
untreated cells (Figure 3.4.21.). NHLF and SIPS CM treatment had no significant effect 
on levels of either COL1A1 or ELN, although the average fold change was greater in 
COL1A1 levels and smaller in ELN levels. Treatment with NHLF CM had no significant 
effect on levels of COL3A1 but treatment with SIPS CM led to a significant increase, 
matching the effect of TGF-β1 treatment. Though only evidenced at an RNA level, this 
result could also begin to suggest that SIPS can stimulate collagen type-3 α-1 production 
in non-senescent, neighbouring HLF. It is interesting that the CM could modulate NHLF 
gene expression and this further exemplified a role for senescence in the pathology of  
IPF.   
  
3.4.2.9. SIPS recapitulate the functional behaviour of FHLFs, acting as a positive control 
and highlighting the senescence-like phenotype of these cells.   
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This section has thus far considered senescent cells, their characteristics and effects, in 
their own right. The rationale behind investigating this cellular phenomenon was, 
however, to understand how they relate to the previously described results concerning 
FHLFs. SIPS were designed to act as a positive control for FHLFs, under the hypothesis 
that FHLFs display a senescent-like phenotype that causes their pathological attributes. 
Due to an equivalence of experimental set ups and conditions, a direct comparison of 
data generated from FHLFs and SIPS can be made, allowing this hypothesis to be tested.   
  
When comparing mitochondrial morphology, it is evident that both SIPS and FHLFs share 
similar characteristics (Figure 3.4.22.). In comparison to NHLFs, both had an increased 
average number of mitochondria per cell whilst the mitochondria themselves were 
smaller and less branched. Mitochondrial junctions were also less prevalent in both. 
Therefore, both cell types have an altered mitochondrial phenotype, characterised by a 
high prevalence of mitochondria, but which are more punctate and part of a less 
wellconnected network.   
  
Both cell types also have significantly smaller RCNs after 72 hrs of compared to NHLFs 
(Figure 3.4.23A.). Both also significantly impaired re-epithelialisation (Figure 3.4.23B.). 
SIPS were on average more detrimental to the process but there was no significant 
difference between the effect of them and the effect of FHLFs. Likewise, both also 
attenuated the beneficial effect of NHLF co-culture on RTE development and epithelial 
regeneration (Figure 3.4.23C.). RTE, after 72 hrs of co-culture, was significantly less than 
in co-culture with NHLFs, with no statistical difference between the RTE of monocultured 
HBECs, and again there was no difference between FHLFs and SIPS. Together these 
results highlight that SIPS and FHLFs are a detriment to epithelial function.   
  
After 24 hrs of mono-culture and RT-qPCR, the evidence for similarities in phenotype 
was less robust (Figure 3.2.24.). Both cell types showed a non-significant and modest 
increase in IL6 expression, with no statistical difference between the two. FHLFs showed 
a non-significant increase in CXCL8 expression but this was significantly less than the 
expression in SIPS. This was also true for expression of IL1B. IL1A was again 
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nonsignificantly upregulated in FHLFs, whereas in SIPS it was, but this time there was no 
statistical difference between the two. CDKN1A was upregulated exclusively in SIPS 
whereas, conversely, CDKN2A was upregulated exclusively in FHLFs. Therefore, only a 
trend of similarity can be described at an RNA level, although it is evident that changes 
in RNA levels are likely to be mediated by different pathways.   
  
Protein concentrations in the CM, after 72 hrs of co-culture, can also be compared 
(Figure 3.2.25.). Regarding IL-6 and CXCL8 protein secretion, both SIPS and FHLFs 
produce a higher concentration of these products than NHLFs. The average protein 
concentration was greatest in SIPS co-culture, significantly so for CXCL8, suggesting that 
SIPS represent a more pro-inflammatory phenotype than FHLFs. CCL2 and CXCL10 were 
both produced less by SIPS whereas there was no difference in FHLFs, indicating that 
this phenotypic alteration is unique to SIPS. There was a non-significant trend towards 
an increase in FHLFs CXCL1 production, with SIPS producing a significantly greater 
concentration. Conversely, for GM-CSF and G-CSF, FHLFs produced a significantly higher 
concentration than controls whereas SIPS did not. Taken together, these results suggest 
that, when looking at IL-6 and CXCL8, SIPS serve as a benchmark for a senescent-like 
phenotype in FHLFs. This is non-significantly evident for CXCL1 production as well and, 
in terms of GM-CSF and G-CSF, both cell types share a trend towards increased 
production. Overall, the comparison of data from these different experiments highlights 
how SIPS recapitulate many of the phenotypic characteristics of FHLFs.    
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3.4.3. Discussion  
  
This section set out to induce senescence in NHLFs, ultimately allowing an investigation 
of their phenotype in co-culture and how they alter HBEC function. Senescence was 
robustly induced, as evidenced by several markers, and SIPS upregulated expression of 
a range of inflammatory signalling factors, concomitant with impaired HBEC 
reepithelialisation and an attenuation of HBEC regeneration.   
  
Characterising SIPS in mono-culture  
The successful and repeatable induction of SIPS was only achieved by providing each 
NHLF cell line with a tailored regimen of H2O2 treatments. The idiosyncratic response of 
differing cell lines was unanticipated and has not been discussed in previous literature. 
Why such differences existed was not specifically investigated in this study but 
numerous reasons may be relevant. H2O2 is a ROS that acts as a genotoxic agent, causing 
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DNA damage. Cells have several intrinsic mechanisms capable of responding to both ROS 
and DNA damage. These may be differentially regulated in the NHLF cell lines used. For 
example, the enzyme catalase is capable of decomposing H2O2 to form O2 and H2O. This 
may be differentially expressed, allowing some lines to tolerate much greater 
treatments with exogenous H2O2 than others. Secondly, DSBs created by genotoxic 
agents are repaired via homologous recombination and non-homologous end joining. A 
complex repertoire of nuclear machinery is required to facilitate these processes, all of 
which may also be differentially expressed. This could allow some lines to better repair 
DNA damage during treatment intervals and better respond to subsequent damage. 
γH2Ax is a marker of DNA damage and could be used in future to assess the severity of 
damage in differing cell lines, indicating how well they tolerate peroxide treatment. This 
could be achieved by both IMF imaging and flow cytometry.   
  
The results from this section have demonstrated that SIPS induction is robust, with cells 
undergoing classical morphological alterations, acquiring SA-βgal activity and 
undergoing proliferative arrest. p21 was upregulated at both the RNA and protein level 
and this protein has been implicated as a key mediator of DNA damage induced 
senescence 197. It was interesting that CDKN2A was not upregulated in SIPS whereas it 
was in FHLFs. Although its expression was only assessed by RT-qPCR, this would begin to 
suggest a different pathway for phenotype induction, an area for future 
experimentation.  
  
Expression of classical SASP factors were upregulated in mono-cultured SIPS, further 
confirming the induction of senescence. These included IL-6, CXCL8, CXCL1, GM-CSF and 
VEGF, which have been previously identified in SASP 213. It was interesting however that 
the levels of VEGF and GM-CSF were found at lower concentrations with a low burden 
of senescence in mono-culture. Though the reason for this is unclear, it further highlights 
that senescence is likely to play differing physiological roles dependent on the number 
of senescent cells present in the local environment, something that may be important 
for the role of senescence in IPF. Another point of interest was that the concentrations 
of certain proteins cold be so dramatically elevated in SIPS compared to NHLFs. Due to 
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the 72 hr culture period, and due to cell cycle arrest being concurrent with senescence, 
the number of NHLFs and SIPS is likely to be very different, with more cells available to 
produce the proteins analysed in NHLF cultures. Protein concentration was not 
corrected to cell number but it is therefore intriguing that with fewer cells, SIPS can 
produce significantly greater protein concentrations in the CM, further highlighting that 
senescence is not a state of dormancy but one of intensive activity.    
  
The results from investigating SIPS mitochondria were in some instances consistent and 
in some instances inconsistent with the current literature. Peroxide induced senescence 
causes mitochondrial network fragmentation in immortalised mouse auditory cells, as 
assessed by skeletonised mitochondrial analysis 307, an observation also found in this 
study. However, shRNA knockdown of mitochondrial fission proteins in Chang cells 
(HeLa derived epithelial cell line) leads to extensive mitochondrial fusion and increased 
connectivity, causing senescence 262. This is in agreement with other studies in which 
senescence is associated with increased mitochondrial mass, number and volume 
fraction, taken to mean an increase in mitochondrial biogenesis 201. This investigation 
did find an increase in mitochondrial number but this was due to increased 
fragmentation and a greater dispersal throughout the enlarged cell cytoplasm. The 
network area was no different in SIPS suggesting that biogenesis has not occurred and 
increased fusion was not apparent. Adding further inconsistency were the results from 
assessing mitochondrial membrane potential, which revealed an increase in polarity 
when compared to NHLFs. Senescent cells exhibit a depolarised mitochondrial 
membrane when analysed via JC-1 IMF 200,307. However, though further experimentation 
is required, it is clear that there are significant differences in mitochondrial morphology 
after SIPS induction.   
  
The effect of SIPS in co-culture  
SIPS in co-culture displayed upregulation of a range of inflammatory, SASP related 
proteins that, as hypothesised, occurred concomitantly with both an impairment of 
HBEC re-epithelialisation and an attenuation of regeneration. The experiments 
performed to uncover this effect have thus far been unreported in the literature.   
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That SIPS were of no benefit to the epithelium in co-culture is reflective of the persistent 
nature of these cells in the assays used. An acute, short acting induction of senescence 
is beneficial to development, wound repair and regeneration. This benefit however is 
dependent on immune-mediated clearance and no such clearance was facilitated in 
these experiments. This, coupled with the typically high burden of SA-βgal positive cells 
in culture is the likely reason for the concomitant reduction in epithelial function. 
Regarding wound healing, the parallels between SASP proteins and wound-associated 
inflammatory proteins is intriguing. Indeed, initially the panel of proteins investigated in 
this study were viewed under the guise of wound repair. The argument could be put 
forward that SIPS, and senescent cells in vivo occurring as a result of injury, re-enforce 
micro-environmental wound signalling, promoting repair. it would be interesting to see 
if having a lower burden of senescent cells in co-culture promotes re-epithelialisation 
and whether transient epithelia exposure to SIPS CM promotes RTE development.   
  
In an attempt to understand why SIPS impair these aspects of HBEC function, 
proliferation and RNA expression were assessed. Regarding proliferation, it was 
interesting that SIPS co-culture led to a decrease in growth. Previous literature would 
suggest that the interaction of senescent cells with their local environment is 
protumourigenic, causing epithelial cells to undergo full malignant transformation: 
proliferating excessively and becoming more invasive, in association with 
dedifferentiation 231,303. This would also agree with the previously described, inverse 
relationship between proliferation and RTE. That it did not was interesting. The reduction 
of growth may again be related to resource competition, in which SIPS out-compete the 
HBECs. Although senescent cells remain metabolic active, this activity would disagree 
with prior literature highlighting mitochondrial dysfunction in senescence. Any other 
reason for decreased proliferation could be related to the non-cell autonomous effects 
of SASP, whereby its components are able to induce senescence in neighbouring cells 
191. This would reduce HBEC growth by causing them to senesce. Assessing this via 
SAβgal staining after co-culture is difficult though, as it is hard to distinguish individual 
cells in the densely packed, pseudostratified epithelial layer. However, p21 / p16 
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expression could be assessed, by either IMF staining and imaging via confocal 
microscopy or via western blotting.   
  
Regarding RNA expression, clues from this investigation were derived to suggest that the 
attenuation of function was related to a change in cell phenotype. RT-qPCR revealed 
that SIPS co-culture led to an upregulation of HBEC VIM and KRT5. VIM upregulation 
indicates that the cells are adopting a more mesenchymal phenotype and KRT5 
upregulation suggest a more basal-like phenotype. Re-epithelialisation is facilitated my 
epithelial sheet migration, in which the cells migrate as a unit. Cells of a more 
mesenchymal phenotype would be less conducive to this form of migration, potentially 
impeding the process. Their more basal nature may also limit the ability to form an 
impermeable ionic barrier. To further understand phenotypic changes in co-cultured 
HBECs, IMF experiments could be utilised to look at the protein expression of these RNA 
transcripts. Similarly, other epithelial markers could be analysed. Because ZO-1 
expression was previously found not to be associated with changes in RTE it was not 
assessed in HBECs after SIPS co-culture. To make sure that it is not playing a role in this 
scenario it could again be analysed via western blot.   
  
Overall the results from these experiments highlight the detrimental role of senescent 
fibroblasts on the local epithelium. This is important in the context of IPF, in which 
recurrent injury requires the epithelium to be able to adequately respond. An epithelial 
niche dominated by senescent HLFs that contribute to a highly pro-inflammatory 
microenvironment would be detrimental to repair and regeneration, thereby 
accentuating the pathogenesis of the disease.   
  
Comparing SIPS and FHLFs  
An important aspect of this section was to understand how the phenotype of SIPS relates 
to that of FHLFs. This was achieved by comparing data from previous experiments. It was 
interesting that, by treating NHLFs with hydrogen peroxide, many of the characteristics 
of FHLFs could be recapitulated. SIPS and FHLFs shared a similar mitochondrial 
morphology, had lower cell counts, impaired HBEC re-epithelialisation and regeneration, 
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and also expressed elevated levels of several pro-inflammatory proteins. These results 
substantiate the hypothesis that the characteristics of senescence are an important 
driving force in the pathology of IPF.   
  
The mitochondrial morphology of SIPS and FHLFs were similar across several 
parameters. In terms of SIPS, these results point towards a stress-induced, 
senescenceassociated mitochondrial morphology. If this morphology is a result of 
senescence induction, occurring after the establishment of senescence pathways, or if 
these changes actually drive the process of induction remains unclear. Oxidative stress 
causes greater, more persistent DNA damage in mitochondria and therefore it is possible 
that the mitochondria represent a weak spot in the capacity of HLFs to respond to H2O2 
mediated stress 308. Subsequently, loss of mtDNA integrity may lead to the increased 
production of ROS, accentuating DNA damage in the nucleus, aligning with the current 
paradigm that mitochondria are the key drivers of senescence 201. Though based more 
on speculation than evidence, it would be tempting to hypothesise that the apparent 
mitochondrial fragmentation observed in these cells is part of a cellular response aimed 
at mitigating the impact of mtDNA damage, quarantining mitochondria with damaged 
DNA (which can result in deleterious mutations) and allowing mechanisms such as 
mitophagy to alleviate the burden of defective organelles. What is more important 
however, is that the equivalent morphology in FHLFs would suggest that these cells have 
also been previously exposed to similar insults. It suggests that in the lung, oxidative 
stress is also in abundance, capable of causing the same changes as found in SIPS.    
  
That both FHLFs and SIPS display comparative cell cycle arrest is also indicative of the 
activation of similar, senescence-associated pathways in both. Unfortunately, as 
previously discussed, the data regarding FHLF proliferation is limited. However, it is still 
of interest that FHLFs, a cell type isolated from patients with a disease characterised by 
excess fibroproliferation, are non-proliferative, even in the presence of numerous 
growth factors, suggesting that this is also their behaviour in the IPF lung.   
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SIPS also recapitulate the effect of FHLFs in co-culture, impairing re-epithelialisation and 
attenuating regeneration. This again suggests that FHLFs have a senescence-like 
phenotype, one that is a detriment to the overlying epithelium in the IPF lung. Likewise, 
though at an RNA level the pattern is less clear, the proteins secreted by both cell types 
share many similarities, indicative of a common phenotype, characterised by an 
increased production of pro-inflammatory proteins that alter the local 
microenvironment. IL-6 and CXCL8 are the best examples of this shared phenotype, 
being significantly elevated in both co-cultures. These factors are elevated in IPF and in 
SASP and this direct comparison of results provides novel evidence for a role of SASP in 
IPF.    
  
Gaining a better understanding of the phenotype of FHLFs within the context of 
senescence would be useful in further substantiating this hypothesis. RT-qPCR results 
would suggest that the phenotype, contrary to SIPS, is mediated by the p16-pRB 
pathway. However, it would be appropriate to establish this further by investigating 
protein expression and considering the roles of other senescence-regulating pathways. 
For example, western blotting and IMF imaging of p16, p53 and p38 would be suitable 
as all contribute to regulating the DNA damage response. Furthermore, as ROS is a key, 
upstream initiator of the p16-pRB pathway, it would be interesting to investigate ROS 
production these cells. Linking with hypotheses concerning the mitochondria, this could 
be achieved with dyes such as MitoSox, which highlight mitochondrial ROS. Interestingly, 
the redox imbalance and subsequent H2O2 production previously described in FHLFs 
could be a cause of the phenotype observed in this study 119.   
  
In conclusion, it is evident that FHLFs and SIPS share similarities of phenotype, both of 
which are ultimately detrimental to the overlying epithelium in co-culture. This is 
indicative of an exposure of FHLFs to sub-lethal, yet recurrent, oxidative stress in the 
lung, which leads to the acquisition of a pro-inflammatory phenotype. Though much 
more could be done to understand these similarities and the mechanisms driving them, 
it is also worth attempting to understand if this phenotype can be modulated, with an 
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aim to attenuating the epithelial impairments caused by these cells. The next section of 
this study will investigate such questions.   
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 3.5  Targeting the Senescence Associated Secretory Phenotype in Fibrotic and  
Senescent Human Lung Fibroblasts  
  
3.5.1. Introduction  
  
Co-culture with SIPS and FHLFs impairs post-wound re-epithelialisation and attenuates 
epithelial regeneration in vitro. In this model, this is due to an altered microenvironment 
generated by the secretory factors of these cells. Significantly elevated proteins, 
detected in both co-culture types, included IL-6, CXCL8, CXCL1, and G-CSF, all of which 
are strongly implicated in SASP and inflammation. These collective results led to the 
question, “can the secretome of SIPS and FHLFs be either suppressed or altered to better 
promote epithelial function?”.   
  
Pathways regulating inflammation  
NF- B is an important regulator of senescence induction and SASP production 214,309,310. 
It is the archetypal, transcriptional regulator of inflammation and is implicated in both 
the ageing process and in tumourigenesis 174,311. The pathways mediating NF- B 
signalling are interconnected with those of STAT signalling, most notably STAT-3 312. 
NF B-initiated IL-6 production is maintained by activated STAT-3 and, in cancer, direct 
interaction between the two prolongs NF- B nuclear retention, increasing inflammation 
313,314. Direct STAT-3 signalling also leads to upregulation of proteins such as IL-6, CXCL8, 
CCL2, PAI-1, IL-1β and VEGF 236,312,315.    
  
Role of the IL-6 / JAKs1-2 / STAT-3 signalling pathway   
STAT-3 lies downstream of a signalling pathway involving IL-6 and JAKs 1 and 2. 
Activation of this pathway is initiated with IL-6 binding to its receptor IL-6R. IL-6R is a 
dimerised complex of two IL-6Rα subunits, which are either expressed on the cell surface 
or, more typically, found in a soluble form (sIL-6Rα). The receptor-ligand complex binds 
to, and dimerises, cell-surface bound gp130 molecules, which are associated with JAKs. 
Dimerisation of gp130s activates these JAKs, which in turn phosphorylate the cytosolic 
domains of gp130, allowing recruitment and activation of STAT-3. STAT-3 subsequently 
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becomes phosphorylated, forming a homodimer (or heterodimer with STAT1) and 
translocating to the nucleus where it can bind to enhancer sequences in numerous 
target genes 316.    
  
JAK/STAT signalling in disease and age  
Underpinned by increased inflammation, the result of JAK/STAT signalling can be 
diverse. It plays a role in tumourigenesis, it reinforces the senescence phenotype and it 
contributes to ageing 218,236,317–319. It is also prominent in fibrosis in general. Via IL-6 
signalling, STAT-3 activation mediates an indirect enhancement of TGF-β signalling that 
promotes collagen production. Subsequently, blocking JAK 1/2 signalling with the 
molecular inhibitor, Ruxolitinib, reduces dermal fibroblast COL1A1 expression 320.   
  
JAK/STAT signalling has also been investigated in the context of pulmonary fibrosis.  
Treatment of primary AEC2s in vitro with an inhibitor of STAT-3 phosphorylation, C-1889 
321, decreases TGF-β and IL-6/sIL-6Rα induced expression of injury and EMT associated 
markers, including Pai1, Hif1a, Twist and Snail. Likewise, nuclear-located 
phosphorylated STAT3 (pSTAT-3) is highly enriched in IPF derived fibroblasts, alveolar 
macrophages and epithelium 322. In BLM-induced mouse fibrosis, soluble IL-6Rα is 
elevated and neutralising this signalling with a gp130 recombinant Fc fragment reduces 
pulmonary inflammation and attenuates pathology 323. Similarly, genetically reducing 
systemic STAT-3 expression, prior to BLM instillation, decreases the susceptibility of 
mice to fibrosis 324. Blocking the phosphorylation of STAT-3 with C-188-9, from days 1530 
post-BLM, also attenuates fibrotic development 322. In human patients, there are also 
increases in soluble IL-6Rα in tissue protein lysates, and pSTAT-3 is excessively abundant 
in the IPF lung, located primarily in non-epithelial parenchymal cells 323,324.  
  
The drug Ruxolitinib (INCB18424) has also been used in the suppression of SASP 
production. Preadipocytes, induced to senescence by irradiation in vitro, produce 
elevated levels of secreted IL-6, CXCL8, CXCL1, CCL2, CXCL10, VEGF, GM-CSF, G-CSF and 
CCL5. At an RNA level, IL1A and IL1B are also elevated. With the exception of VEGF, JAK  
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1/2 inhibition (with an unnamed, alternative inhibitor) significantly decreases 
production of these proteins. Ruxolitinib, after a 72 hr treatment at a concentration of 
1.0 μm, also reduces RNA levels of IL6, CXCL8, CCL2 and PAI1. The result of this inhibition 
in vivo is a reduction in age-associated systemic inflammation. It also enhances physical 
activity in aged mice, suggesting that SASP is a key driver of the ageing phenotype, 
mediated by JAK/STAT signalling 236.  
  
The implications of over-active signalling in both IPF and ageing, coupled with the 
increase in inflammatory proteins in FHLF and SIPS co-cultures, make inhibition of this 
pathway an attractive answer to the question of secretome suppression. Ruxolitinib was 
identified as a potential compound to achieve this.   
  
Ruxolitinib  
Ruxolitinib is a small, molecular compound that functions as an ATP mimetic, selectively 
inhibiting JAK 1 and 2. This leads to a decrease in STAT-3 phosphorylation and inhibition 
of IL-6 signalling. As well as inhibition at the RNA level, it also reduces circulating levels 
of IL-6 and TNF-α, evidenced in a mouse model of myelofibrosis, and it is currently used 
to treat patients with this disease 325. Myelofibrosis is a myeloproliferative neoplasm, in 
which there are abnormal blood cell counts and systemic inflammation, resulting from 
scarring of haemopoietic centres in the bone marrow. Ruxolitinib has improved survival 
rates across several clinical trials 326,327. Only modest histological improvements in bone 
marrow fibrosis were identified in these trials, but a case report of a patient treated for 
three years with the drug found that treatment lead to fibrosis resolution 328.   
  
Taken together, this evidence suggested Ruxolitinib may be an appropriate treatment for 
suppressing the production of inflammatory proteins evident in FHLF and SIPS coculture.   
  
Hypotheses  
1. Ruxolitinib will reduce production of inflammatory cytokines in FHLFs and SIPS, 
improving epithelial regeneration and re-epithelialisation.   
  
  
236  
  
3.5.2. Results  
  
3.5.2.1. Treatment with Ruxolitinib is non-toxic to HBECs or HLFs.  
  
Prior to investigating the effects of Ruxolitinib treatment in co-culture, the effect of the 
drug on mono-cultured HLFs was assessed. First the toxicity of the drug was evaluated 
across all cell types used, with cells initially seeded in 96-well plates at a density of 2,000 
cells/well. For HBECs, it was important to understand the effects of the drug on 
proliferation, since HBEC cell number is related to RTE in co-culture. HBECs were treated 
with Ruxolitinib at 0.0, 0.1, 0.5 and 1.0 μM, diluted in media containing 0.1% DMSO, 72 
hrs prior to proliferative assessment via Alamar Blue staining. No effect on HBEC cell 
number was observed following treatment (Figure 3.5.1A.). Extending this to HLF 
cultures revealed that the drug also had no detrimental effects on either NHLFs, FHLFs 
or SIPS, with no significant differences in cell number between any treatment 
concentrations (Figure 3.5.1.). Also, in accordance with prior experiments, the cell 
numbers of both FHLF and SIPS were significantly lower than those of NHLFs after 72 
hrs. Taken together, it is unlikely that any effect of the drug in co-culture is related to 
increased cell toxicity or increased proliferation.   
  
3.5.2.2. Ruxolitinib does not alter SA-βgal activity in SIPS but does reduces STAT-3 
phosphorylation.   
  
Whether Ruxolitinib reverses the senescence phenotype has thus far been unreported. 
Conceivably, the reduction in cytokine and chemokine production could act as a brake 
on paracrine mediated senescence, preventing non-senescent cells from adopting this 
phenotype. However, in cells that are chronically senescent, Ruxolitinib is unlikely to 
interfere with already established senescence pathways and the state of senescence is 
understood to be irreversible. To test this, SIPS were treated for 72 hrs with Ruxolitinib 
prior to fixing and SA-βgal staining. Representative images highlight staining across 
NHLFs and three SIPS cell lines (Figure 3.5.2.). The staining suggests that the drug has no 
effect on SA-βgal activity over this time course, with the majority of SIPS staining blue   
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across all four drug concentrations. Therefore, treatment is unlikely to be mediating 
effects by reducing the burden of senescence.   
  
To test whether Ruxolitinib was inhibiting JAK 1/2 activity and thereby preventing STAT3 
phosphorylation, western blotting was performed on NHLF and SIPS lysates. Cells were 
seeded at a density of 60,000 cells/well in 6-well plates and treated for 72 hrs prior to 
protein isolation. The resulting blot was probed for total STAT-3 (tSTAT-3), pSTAT-3, p21 
and β-actin (as a loading control) (Figure 3.5.3.). Ostensibly, all cells expressed similar 
levels of tSTAT-3. SIPS however displayed much stronger expression of p21 and 
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untreated SIPS also displayed increased expression of pSTAT-3. Treatment with 1.0 μM 
Ruxolitinib abrogated STAT-3 phosphorylation in all three SIPS lines, whilst having no 
effect on the levels of p21. Therefore, it is evident that Ruxolitinib reduces STAT-3 
phosphorylation in SIPS, and a 1.0 μM concentration was sufficient to achieve complete 
inhibition.   
  
3.5.2.3. Treatment with Ruxolitinib promotes post-wound re-epithelialisation and 
epithelial regeneration in both FHLF and SIPS co-cultures.   
  
The effect that Ruxolitinib had when used to treat co-cultures was next examined. NHLF, 
FHLF and SIPS co-cultures, as well as HBEC mono-cultures, were established in which 
cells were treated with Ruxolitinib at 0 hrs, concurrent with the change of media. Drug 
was only added to the basolateral compartment of co-cultures and all culture types were 
treated with a range of drug concentrations. Re-epithelialisation was first assessed 
(using the methods previously described). A treatment of 0.0 μM and 1.0 μM of drug 
was used in mono-cultured HBECs (Figure 3.5.4A.) and HBECs co-cultured with NHLFs 
(Figure 3.5.4B.). Treatment lead to a significant improvement in mono-cultured 
reepithelialisation, increasing wound closure by roughly 10%. Interestingly, treatment 
had no additional benefit in NHLF-HBEC co-cultures, with both conditions displaying a 
higher percentage closure when compared to mono-culture. Therefore, despite the lack 
of proliferation noted in Results 5.2.1., Ruxolitinib can directly alter HBEC function to 
promote re-epithelialisation in mono-culture following wounding. The effect of drug   
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treatment was subsequently assessed in SIPS co-cultures, using 0.0 μM treated HBEC 
mono-cultures and NHLF co-cultures as controls. Representative phase-contrast images, 
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and corresponding 9 hr binary images, are shown Figure 3.5.5A. The results, 9 hrs 
postwounding are shown in Figure 3.5.5B. Wound closure in both 0.0 μM and 0.1 μM 
treated SIPS co-cultures was significantly less than in NHLF co-cultures, as previously 
observed in Figure 3.2.19. Treatment with 0.5 μM and 1.0 μM of drug increased 
percentage wound closure to the extent that there were no significant differences when 
compared to NHLF controls. 1.0 μM Ruxolitinib also significantly improved wound 
closure when compared to 0.0 μM SIPS co-culture. Therefore, Ruxolitinib is able to 
promote reepithelialisation, attenuating the impairment of closure found in SIPS co-
culture.   
  
This experiment was repeated using FHLFs, with phase contrast images and 9 hr 
postwounding results shown in Figure 3.5.6. As with SIPS, wound closure was 
significantly less in 0.0 μM and 0.1 μM treated FHLF co-cultures but improved with 0.5 
μM and 1.0 μM treatments. The improvement in closure was non-significant between 
0.0 μM and 1.0 μM treatment but was significantly elevated between 0.1 μM and 1.0 
μM treated cultures. Therefore, Ruxolitinib is able to promote re-epithelialisation in 
both SIPS and FHLFs co-cultures, an effect that, could in part, be mediated through the 
drug influencing the epithelium.   
  
Epithelial regeneration was next investigated, assessed via RTE measurement over 72 hrs 
with a full range of Ruxolitinib concentrations. At 72 hrs, treatment had no effect on 
mono-cultured HBEC RTE (Figure 3.5.7A.) but, with an increase in drug concentration, 
there were significant increases in RTE in NHLF-HBEC co-cultures (Figure 3.5.7B.), 
suggesting that Ruxolitinib does not directly influence the epithelium but does elicit 
changes in the basolateral NHLFs. The effect of treatment on SIPS and FHLF co-cultures 
was assessed, in comparison to 0.0 μM treated HBEC mono-cultures and NHLF 
cocultures. At 72 hrs, the RTE of 0.0 μM treated SIPS co-cultures was significantly less 
than that of NHLF co-cultures, consistent with previous experiments (Figure 3.5.7C.). 
Treatment with 0.1 μM and 0.5 μM increased SIPS RTE making these differences 
nonsignificant. Treatment with 1.0 μM resulted in a significant increase in RTE, greater 
than   
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both controls and 0.0 μM treated SIPS co-culture. Therefore, Ruxolitinib improves the 
regenerative potential of HBECs, attenuating the detrimental effect of co-culture with 
SIPS. The same was also found to be true for co-culture with FHLFs (Figure 3.5.7D.). 0.0 
μM treated FHLF RTE was significantly less than NHLF co-culture but again RTE was 
increased with drug treatment, making this attenuation non-significant. Treatment with 
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1.0 μM did not increase RTE to a level greater than that of NHLF 0.0 μM co-culture but 
did significantly improve upon 0.0 μM treated FHLF co-cultures. In summary, Ruxolitinib 
promotes HBEC regeneration when in co-culture with SIPS and FHLFs.   
  
3.5.2.3. Treatment with Ruxolitinib does not alter RNA levels of inflammatory factors in 
SIPS.   
  
Ruxolitinib was shown to reduce STAT-3 phosphorylation in SIPS and promote HBEC 
reepithelialisation and regeneration. It was hypothesised that this was due to a 
suppression of the inflammatory mediators secreted by SIPS into the microenvironment. 
Therefore, RNA levels for proteins previously assessed were quantified after Ruxolitinib 
treatment. This was performed in both SIPS mono- and co-culture, with RNA analysed 
72 hrs after treatment in each (Figure 3.5.8.). In both set-ups treatment with Ruxolitinib 
had no effect on SIPS RNA levels. All transcripts were elevated in SIPS when compared 
to NHLFs, with the exception of CDKN2A, which was not upregulated. A 1.0 μM 
treatment in co-culture did significantly increase RNA levels of CXCL1 but this was the 
only observable effect of treatment. These results, as well as being inconsistent with 
previous literature, strongly suggested that Ruxolitinib had no effect on transcriptional 
regulation in SIPS, at least at this timepoint. Though treatment had positive effects on 
RTE, measurable at 72 hrs, it was thought that, in terms of RNA levels, by 72 hrs any 
transcriptional changes may have reverted to baseline. Inhibition of STAT3 
phosphorylation was measured only 1 hr after treatment and therefore it was deemed 
that a shorter treatment period may allow transcriptional changes to be observed. 
Consequently, RT-qPCR was again performed, this time in mono-cultured cells treated 
for only an 8 hr period (Figure 3.5.9.). As before, treatment with 1.0 μM of Ruxolitinib 
had no effect on SIPS RNA levels. These results strongly suggest that Ruxolitinib does not 
improve epithelial function by reducing gene expression of SIPS inflammatory proteins. 
Subsequently, the mechanism by which functional improvement is attained remains 
undetermined and requires further investigation. Experiments such as multiplex ELISA 
on the CM could offer a more definitive answer.  
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3.5.3. Discussion  
  
As a result of previous experiments, this section set out to investigate whether epithelial-
mesenchymal crosstalk could be modulated via pharmacological intervention, in an 
attempt to suppress the secretion of the numerous inflammatory proteins that were 
found to be elevated in co-culture with SIPS and FHLFs, under the assumption that they 
were detrimental to epithelial function. The results from this investigation found that by 
targeting the JAK/STAT signalling pathway, HBEC re-epithelialisation and regeneration 
could be improved. These results also provide rationale for a range of further 
investigations.   
  
Firstly, though STAT-3 phosphorylation was assessed in SIPS, it would be interesting to 
understand if there was also an increase in phosphorylation in FHLFs. As SIPS reflect the 
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phenotype of FHLFs it would be hypothesised that there is an increase and that 
treatment with Ruxolitinib could also reduce this. Likewise, it would be interesting to 
better elucidate the effect of Ruxolitinib on the  wider JAK/STAT signalling pathway, 
identifying alterations in other signalling proteins, most notably by identifying the 
phosphorylation status of JAKs 1 and 2 and also the intracellular localisation of STAT-3 - 
which should localise to the nucleus when activated 316.  It would also be appropriate to 
revisit these experiments using structurally different, but functionally equivalent JAK 1 
and 2 inhibitors. For example, the compounds Baricitinib and Tofacitinib which also 
inhibit these kinases 329,330. Finding similar results with these drugs would reduce the 
likelihood of the effects of Ruxolitinib being non-specific and off-target, further 
supporting the validity of targeting this pathway.    
  
That re-epithelialisation in mono-cultured HBECs is improved with Ruxolitinib is a point 
of interest, reflecting a difficulty of co-culture in which selective treatment of one cell 
type is not straightforward. One way to gain a more discriminate understanding of the 
role of JAK/STAT signalling in co-culture would be to silence JAKs 1 and 2, or STAT-3, via 
the use of siRNA knockdown – or similar approaches. This would evade the issue of  
Ruxolitinib directly effecting the epithelium. If this method of signalling inhibition was 
also found to promote re-epithelialisation it would more conclusively demonstrate its 
importance, further validating the use of this treatment.   
  
Regarding RTE and HBEC regeneration, results found that drug treatment did not effect 
HBEC mono-cultures. It was interesting however that it did have an effect on NHLF 
cocultures. From previous experiments with mono- and co-cultures it is evident that 
NHLFs produce significantly more inflammatory factors when co-cultured (Figure 3.2.4.), 
the same factors that are produced at even greater levels in SIPS and FHLFs. This 
upregulation is understood to be due to a post-wounding, regenerative process 
occurring in co-culture, in which the epithelial cells repopulate a denuded basement 
membrane. That regeneration is also improved in both SIPS and FHLF co-cultures 
suggests that treatment may be useful in targeting crosstalk in IPF and attenuating the 
pathological impact of recurrent lung injury. It would be interesting to test the effects of 
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treatment in more complex systems, such as in vivo models of lung injury. The most 
obvious of these would include the mouse model of BLM-induced fibrosis, in which BLM 
causes widespread AEC1 death, however other approaches could include mechanical 
de-epithelialisation in vivo, using an intra-tracheal probe to mechanical remove upper 
airway epithelium 76.     
  
When attempting to understand why treatment with Ruxolitinib promotes 
reepithelialisation and regeneration, analysis of RNA expression offered limited 
assistance. It was expected that treatment would decrease expression of IL6 and CXCL8, 
as observed by Xu et al. 236. That it did not could be interpreted as there being a temporal 
disconnect between intracellular RNA levels and protein production, or it could be due 
to other, compensatory pathways, upregulating this inflammatory signalling. This could 
be identified by a repeat of the multiplex ELISA assays on Ruxolitinib-treated CM. The 
results could also reflect the more salient importance of other secretory proteins in 
mediating HBEC function, again suggesting the potential for investigating changes in 
global gene expression. Predominantly immune-modulating proteins were assessed in 
this study but a whole range of other proteins may be relevant to the effects seen in 
coculture, the expression of which may also be modulated by Ruxolitinib. Because of 
this, it can only be stated that the elevation of inflammatory proteins, observed with 
SIPS and FHLFs, correlates to the functional alterations found in HBECs, with their 
elevation in the micro-environment not a causal reason for impairment. To establish a 
causal relationship, it would be worth attempting to more directly target some of the 
key secretory proteins elevated. The use of neutralising antibodies, targeted to proteins 
such as IL-6 and CXCL8, could be used. It would be hypothesised however that their 
effect would not be as significant as treatment with Ruxolitinib.  Part of the rationale for 
targeting an upstream signalling pathway is that IPF is a complex disease. An imbalance 
in expression of a single secretory protein is unlikely to be the cause and it therefore 
makes sense to pharmacologically suppress a range of proteins. Indeed, the success of 
Nintedanib and Pirfenidone has been attributed to their pleiotropic effects. However, 
the use of neutralising antibodies would be useful in vitro to validate targeting this 
pathway.   
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One other consideration to make, regarding targeting this pathway, is that although 
evidenced to play an important role in SASP and IPF, JAK/STAT signalling is also an 
important mediator of BC airway regeneration, with pathway activation critical for the 
regeneration of differentiated ciliated cells 88. This differentiation occurs after epithelial 
barrier establishment in BC cultures exposed apically to the air, a phase of regeneration 
not investigated in this study. It highlights however the complexity of cytokine signalling 
in the lungs response to injury and suggests that an over-reduction of this signalling 
would be detrimental to regeneration if sustained into the period of differentiation.   
  
In summary, this section represents an attempt at modulating HLF secretion, providing 
some rationale for investigating the use of SASP suppressing drugs in further in vitro 
experiments, with the hope of continuation in in vivo models of IPF. That the current 
therapeutic options for IPF are somewhat limited (Intro 2.2.) and that Ruxolitinib is 
already used clinically mean it remains an attractive and viable option. Though it would 
be premature to offer the appellation of therapeutic candidate to Ruxolitinib, it is worth 
furthering our understanding of how this drug functions within the context of IPF and 
how it may be used to potentially treat the disease.    
  
  
  
  
  
  
  
  
  
  
  
4. Discussion  
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 4.1  Summary of Results  
  
The results from this thesis have demonstrated several important and interesting 
aspects of IPF biology, revolving around the human lung fibroblast and its relationship 
with the epithelium. Understanding this relationship has focused most prominently on 
the role of inflammatory secretory signalling, investigating production of a broad range 
of immune-modulating cytokines, chemokines and growth factors. When normal and 
diseased HLFs were cultured on their own, without exogenous stimulation, it was 
difficult to discern any substantial pathological differences (Results.3.1.). There were 
significant alterations in mitochondrial morphology, yet fully understanding the 
importance of this requires extensive experimentation. The lack of differences in 
monoculture did not necessarily conflict with current literature; in which studies 
typically apply some form of stimulant to their cultures, such as patient derived matrix 
or profibrotic stimuli, but it did suggest that in order to develop a more profound 
understanding of the role of HLFs in IPF, an in vitro system would have to be established 
that better recapitulated specific cell-cell interactions in the lung.   
  
This was achieved by a method of co-culture (Results.3.2.). Utilising an epithelial cell line 
and semi-permeable transwell inserts, a system was established that allowed cocultured 
cell types to communicate via secretion. The simple addition of an epithelial layer to 
fibroblast cultures had interesting effects and facilitated the investigation of epithelial-
mesenchymal crosstalk along with several of the key characteristics and driving forces 
of IPF. Co-culture with NHLFs created a micro-environment that promoted epithelial 
function. Though postulated to reflect epithelial development ab initio, coculture 
experiments were re-evaluated as a model of injury, in which epithelial cells are required 
to repopulate a denuded basement membrane (in this case, the transwell insert). This 
was coupled with scratch assays that aimed to recapitulate the process of re-
epithelialisation, in sum allowing an in vitro investigation of the airways response to 
injury. NHLFs were found to enhance both of these processes, signifying that healthy 
fibroblasts are supportive of their epithelial neighbours and promote their function 
through secretory communication. FHLFs, by contrast, failed to demonstrate such 
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abilities. Reluctant to proliferate and pro-inflammatory, these cells impaired the process 
of re-epithelialisation. Not only this, but they could not match the ability of NHLFs to 
enhance regeneration (Results.3.3.). These results better aligned with the current 
understanding of IPF, complying with a paradigm in which pathological fibroblasts 
contribute to aberrant and dysfunctional epithelial repair. Importantly, such was the 
repertoire of secretory factors produced by these cells and its similarity to the secretory 
phenotype of cells in a state of senescence, that it was thought that this phenotype could 
be important in unlocking the detrimental role of fibrotic fibroblasts in IPF. There was 
much evidence for this, from both the literature and prior experiments with these cells. 
As well as displaying a reduced proliferative capacity, FHLFs were also shown to 
upregulate expression of CDKN2A, an important regulator of senescence. It was 
therefore hypothesised that a senescent-like phenotype was in operation in these cells.   
  
To further understand this, NHLFs were recurrently treated with hydrogen peroxide, an 
agent used to cause DNA damage and an important signalling factor in airway injury. The 
treatment regimens adopted were able to reproducibly and robustly induce a state of 
cell cycle arrest, typified by the acquisition of numerous senescence-associated 
hallmarks (Results.3.4.). Critically these cells recapitulated many of the functional 
effects of FHLFs in co-culture, impairing re-epithelialisation and failing to promote 
regeneration. Indeed, even the mitochondrial morphology of both cell types was found 
to be defined by similar characteristics. The implications from these results were that 
the secretory factors, produced by both cell types, were an appropriate target for 
pharmacological intervention. The nature of SASP, and the elevation of several of its 
core proteins in FHLFs and SIPS, led to the decision to target its regulation upstream, 
inhibiting the JAK/STAT signalling pathway, a pathway important to IPF, senescence and 
ageing. Inhibition of this pathway did yield success, restoring re-epithelialisation and 
reinstating the regenerative process, yet this was not without several limitations, and 
the creation of several unanswered questions (Results.3.5.). Whether Ruxolitinib is a 
viable therapeutic option for IPF cannot be confidently stated, yet these results, and this 
body of work, have opened up the potential for further investigation that may offer 
future success. In sum, this investigation has highlighted important characteristics of 
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FHLFs and how these cells alter the function of the epithelium. A resulting question 
however is, what can these results suggest about the activity of FHLFs in vivo, and what 
do these results mean regarding the pathobiology of IPF?      
  
 4.2  Implications for Disease Pathobiology  
  
4.2.1. Senescence in the context of IPF  
  
The inability of FHLFs to facilitate epithelial repair and regeneration reflects one of the 
defining characteristics of the disease, an aberrant and dysfunctional wound healing 
response, and implicates the FHLF as the central mediator of this defect. That they are 
detrimental to these processes is of real significance in a disease characterised by 
recurrent injury 164,275. Because injury is seemingly frequent, it makes the importance of 
adequate repair all the more salient and focuses the implications of fibroblast pathology 
onto their paracrine abilities to dictate airway repair, as well as their ability to excessively 
deposit extracellular matrix. This investigation has attributed the pathological effects of 
FHFLs to senescent-like properties, a phenotype highly relevant against the backdrop of 
the ageing lung in which this disease arises 174,229,242. Fibroblast senescence does 
however present somewhat of a paradox in the context of a disease also characterised 
by excessive fibroblast proliferation and matrix deposition. The two phenotypes of 
senescence and fibroproliferation are however not mutually exclusive in a population of 
cells defined by its heterogeneity. It may well be that the results of this investigation 
have struck upon a subset of fibroblasts in which the characteristics of senescence 
predominate.   
  
This does however raise the question of how these cells arise themselves, but it is 
possible to describe a narrative, that is novel yet complicit with the current literature, 
which describes the endowment of these senescent-like properties. Firstly, injury to the 
lung airways would induce activation of a series of homeostatic repair pathways, which 
encompass signalling via developmental pathways and the use of hydrogen peroxide  
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41,81,86. These pathways ultimately result in the induction of an acute senescence 
response, whereby previously activated fibroblasts enter a state of cell cycle arrest, 
signalling to the immune system for clearance 220,223. Senescent cells come and go during 
normal, infrequent repair yet in the IPF lung recurrent injury and the recurrent activation 
of these pathways would create a sustained burden of senescent cells. Though these 
cells could and would normally be cleared by immune cells, the decline of this system 
with age would lead to their accumulation 234, reaching a threshold in which the burden 
of senescent cells becomes detrimental to epithelial repair, as evidenced in this 
investigation. The micro-environment created by these senescent cells would have 
detrimental ramifications for both the epithelium and the mesenchyme. The secretome 
of these cells limits the differential potential of epithelial progenitors 222 and, coupled 
with an over-compensatory attempt at regeneration, could result in the AEC2 
hyperplasia and distal BC colonisation observed in the disease 128,130. The 
proinflammatory elements of the secretome also stimulate pro-repair responses in 
neighbouring, normal fibroblasts. However, because this signalling is chronic, it would 
result in an overexuberant response, associated with fibroproliferation and matrix 
deposition 247. Through these effects, it is feasible that senescent-like fibroblasts could 
orchestrate the demise of normal lung physiology, acting as central mediators in the 
pathogenesis of IPF (Figure 4.1.1.).   
  
That FHLFs are representative of senescent cells has interesting implications for IPF in 
terms of research and therapeutics. Clinically, IPF is beset by the issue of a lack of 
therapeutic options that reverse pathology 103. Likewise, the only two currently available 
treatments are promiscuous in their activity, having a broad range of effects on 
numerous cell types with several side-effects. Investigations into senescence however 
have thus far been able to produce strategies that selectively target and clear senescent 
cells 235,237,238. Therefore, if senescent-like fibroblasts are indeed the key to IPF pathology 
then they present a viable pharmacological target that can utilise already existing 
therapeutic strategies, such as treatment with D+Q or ABT263.      
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4.2.2. Modelling secretory crosstalk in the context of IPF  
  
The model system used throughout this investigation involved the use of primary human 
lung fibroblasts in co-culture with a human, bronchial epithelial cell line, in system that 
restricted cell-cell contact but facilitated secretory communication. This model allowed 
investigation of epithelial-mesenchymal crosstalk, focusing on the role of secretory 
proteins in an attempt to better recapitulate airway physiology. However, it is worth 
identifying how this model fits into the wider concepts of IPF cell biology, as well as the 
other types of secretory communication prominent in the lung and the more complex 
interactions that drive the disease.   
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4.2.2.1. Patient-derived HLFs  
Patient-derived HLFs were an extremely important element of this investigation, as such 
it is important to consider the way in which they were used. One of the limitations of 
this study was that more patient information was not available. For a variety of reasons 
information pertaining to smoker-status, weight, co-morbidities, and outcome 
postdiagnosis was not available. This information would have been both useful and 
interesting, providing a potential explanation for any large variations in in vitro data. 
Ideally, future experiments would use a greater number of patients stratifying them 
along clinical outcome and patient history.   
  
Another possible limitation was that population doublings were not thoroughly 
accounted for, instead relying on the assumption that passage of cells upon roughly 80% 
confluency would maintain broadly equivalent population doublings between differing 
populations. This assumption creates the potential that certain populations of cells used 
in an experiment could be considerably more biologically ‘aged’ than passage matched 
counterparts, a potential pitfall when investigating senescence. Future experiments 
could be made more robust by passaging cells on the basis of population doublings and 
using kinetically matched populations of cells for experiments.   
  
Regarding IPF cell biology, one of the merits of the normal and diseased fibroblasts used 
in this investigation was that they were all derived from patients of older age. This meant 
two things: firstly, that when comparing FHLFs to these cells, differences in phenotype 
and behaviour were less likely to be the result of age-associated alterations and more 
likely to be the result of pathology-associated changes; secondly, it meant that these 
age-related changes were likely to affect both cell types and that these cells were likely 
different to those from young patients. This means that differences, especially relating 
to senescence, may have been harder to distinguish between cell types, as even in 
NHLFs, senescent-like alterations could have begun to develop as part of the natural 
process of ageing.     
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Another important consideration, especially when focusing on senescent-like 
properties, is the method by which primary HLFs were derived (Methods 2.1.4.). 
Explantation requires fibroblasts to migrate and proliferate from their resident lung 
environment onto a tissue culture environment, which vastly differs. Only a select subset 
of cells would achieve this, and it was these cells that were used in subsequent 
experiments. Consequently, this process acted to select for fibroblasts that had a 
sufficient migratory and proliferative capacity to allow them to leave their native 
environment and grow on plastic. Previous work from this lab has shown that because 
of this, the yield of cells is dramatically less than if lung tissue is enzymatically digested 
(removing matrix to leave all cells on plastic). Therefore, cells in the lung that are either 
in a senescent or pre-senescent state are not likely to be found in the cohort of cells 
derived from explantation. This has meant that the ability of this investigation to assess 
senescence has most likely been restricted, but it has also meant that the senescent-like 
properties identified in FHLFs could reflect a phenotype that is in fact much more 
prominent in the IPF lung. The FHLF phenotype and its relationship to senescence may 
therefore be more accentuated in vivo and makes future investigation into this 
phenomenon even more worthwhile.   
  
  
  
4.2.2.2. The use of the HBEC cell line  
Turning now to the epithelium, this investigation utilised a bronchial epithelial cell line. 
This was preferred as it provided consistency and avoided issues of inter-donor 
variation. Results using this line in co-culture were interesting and allowed investigation 
into aspects of re-epithelialisation and regeneration. However, although these cells have 
been widely evidenced to recapitulate many of the in vivo characteristics of primary 
HBECs across multiple passages, they are still a transformed line and some aspects of 
HBEC biology may be lost. The use of primary HBECs would therefore more faithfully 
represent the lung epithelium in vitro. Primary HBECs could be obtained either by 
isolation from human tissue samples or by purchasing from commercial sources. 
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Regardless, experimenting with these cells is a viable option for future experiments that 
could further corroborate the findings of this investigation.   
  
Similarly, using one epithelial cell type raises questions about the effect of HLF coculture 
on other types of epithelial cell in the lung. HBECs, in particular BCs, are implicated in 
the pathology of IPF, inappropriately propagating in a distal direction and colonising 
both the small airways and honeycomb cysts (Intro 1.2.3.2.). However, there are also 
substantial alterations to AEC2 cells, which hyperpolarise and overlay fibrotic foci, and 
AEC1s, which appear to be lost through injury. Subsequently, how HLF secretory 
crosstalk influences these two cell types could also be considered, with similar 
experimentation creating a more complete picture of epithelial-mesenchymal 
interactions in the lung.   
  
Finally, one of the unique characteristics regarding epithelial cells in the lung is that their 
apical surface is exposed to the air. Though, fluids such as ASL in the airways or 
surfactant in the alveoli form a barrier to direct contact, this exposure is important in 
epithelial function, providing a cue for the establishment of polarity and influencing 
airway homeostasis. Interestingly, during development airway epithelium does not 
experience this environmental stimulus but it is important to consider that the HBECs in 
this study were kept in submerged culture. Exposing them to the air would have allowed 
a potentially better recapitulation of the in vivo airway and again could be performed in 
the future using standard air-liquid interface cultures.  
  
4.2.2.3. Different types of crosstalk  
This investigation has focused specifically on the role of secretory crosstalk in the 
pathology of IPF, using a method of co-culture that restricts cell-cell contact and 
cellmatrix interactions. Though secretory crosstalk is fundamental to the numerous 
processes of development, homeostasis and repair, how cells communicate via direct 
contact, both with other cells and the ECM are also very important. For example, the 
AEC2 niche is maintained by basement membrane fenestrations that allow AEC2 foot 
processes to make contact with pericytes (Figure 1.1.8.). Similarly, the invasive 
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properties of IPF fibroblasts are mediated, in part, by an increase in integrin signalling 
that interacts with stiffened ECM (Figure 1.2.5.). Not only this, but epithelial and 
mesenchymal cell types also communicate with a broad range of other cells in the lung. 
Interactions with endothelial cells, lipofibroblasts, pericytes and an extensive repertoire 
of immune cells are also important in both disease and health. Indeed, additional 
dialogue with these cell types may have important ramifications for 
epithelialmesenchymal crosstalk. Therefore, understanding these interactions would 
also add to the overall understanding of crosstalk in IPF and, in sum, it is clear that the 
model utilised in this investigation, although well-suited to assess secretory 
communication, doesn’t fully capture the complex interactions between differing cell 
types, using differing modes of communication, that are likely to have a significant 
influence on IPF pathology.   
  
  
 4.3  Future experiments  
  
An appreciation of where the model of secretory communication sits within the complex 
pathology of IPF raises possibilities for a whole range of future experiments, aimed at 
corroborating the results from this investigation whilst also widening its scope.   
  
4.3.1. Understanding HLF mitochondrial function  
  
This investigation attempted to assess mitochondrial phenotype in isolated HLFs by 
looking at mitochondrial morphology and membrane potential. These two parameters 
however, though in some cases highlighting interesting differences between cell types, 
provided an incomplete picture of mitochondrial function and what this meant for cell 
activity. As previously alluded to, further understanding membrane potential and how it 
relates to ROS production could be achieved by both repeating the TMRE experiments 
with the dyes JC-1 and MitoSox, and also by investigating their fluorescence via 
microscopy (Results 3.1.3.). Mitochondrial function itself could also be assessed using 
an extracellular flux analyser (Seahorse). This machine allows investigation of glycolytic 
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function and mitochondrial respiration, by measuring extracellular acidification rate and 
oxygen consumption rate respectively. It would be hypothesised that FHLFs and SIPS 
would display more mitochondrial stress, indicative of increased oxidative stress, which 
could then be attributed to changes in mitochondrial morphology. With SIPS, it would 
also be interesting to measure changes in glycolytic function and mitochondrial 
respiration, over the time-course of senescence induction. Coupled with further 
morphological quantitation, this would highlight if changes in mitochondrial function 
occur before or after fragmentation, answering the question of whether changes in 
morphology are a cause of a consequence of altered function.   
  
4.3.2. Epithelial differentiation at air-liquid interface (ALI)  
  
Results 3.2.2.2. began to suggest that NHLF co-culture promoted epithelial function not 
through increased HBEC proliferation or tight junction formation but through potentially 
modulating differentiation. This was not investigated further but could prove an 
interesting avenue of future research. Fully examining epithelial differentiation requires 
a more complicated approach to maintaining co-cultures but is possible, allowing 
determination of how mono-culture and co-culture with NHLF, FHLF and SIPS alters 
differentiation. Ideally, a primary HBEC line would be utilised for these experiments as 
these cells have greater potency and more readily differentiate under appropriate 
conditions. These cells could be seeded in conjunction with HLFs in adherence with the 
method used in this study (Method 2.1.6.), allowing formation of a confluent and 
integral epithelial barrier by 72 hrs. At this time point, the cells would then be moved to 
ALI by removing the apical media. This exposes the polarised epithelium to the 
atmosphere, and can provide contextual cues for differentiation whilst the basolateral 
surface remains in contact with the media and retains the ability to communicate with 
fibroblasts. Evaluating differentiation is best achieved after periods of culture up to 3 
weeks. To avoid fibroblast overcrowding or apoptosis, ALI HBEC inserts would have to 
be transferred to fresh HLF cultures every 72 hrs. Across varying time intervals, 
extending up to 3 weeks post-ALI, HBEC cultures could be fixed and stained, using 
primary antibodies for BCs (KRT5), mucosal cells (MUC5AC) and multi-ciliated cells 
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(FOXJ1). Via confocal microscopy, z-stack images would be produced allowing a 3D 
reconstruction of the epithelial layer. By counting the numbers of different cell types 
present, the ratio of basal to mucosal or ciliated cells could be calculated providing a 
quantitative score of differentiation that could be compared across differing co-culture 
types. It would be hypothesised that, compared to mono-culture, NHLF co-culture 
increases differentiation, indicative of these cells creating a micro-environment that 
benefits the epithelium. It would also be hypothesised that both FHLFs and SIPS would 
fail to provide this support. In fact, it could be expected that the epithelium would be 
densely packed with undifferentiated BCs, reminiscent of the distal BC colonisation 
observed in IPF.   
  
4.3.3. Effect of senescence on NHLFs  
  
A preliminary attempt was made at understanding how the secretory factors of SIPS 
influence fibrogenic processes in NHLFs, a question that remains extremely important in 
understanding the role of senescence in IPF. To test the hypothesis that SIPS promote 
ECM deposition in NHLFs, RNA levels of COL1A1, COL3A1 and ELN were measured in cells 
treated for 72 hrs with SIPS CM (Figure 3.4.22.). This however provided only a limited 
answer and future experiments could be performed to better understand this 
interaction. Firstly, as the cells in this experiment were pre-treated with media 
containing factors that assist in matrix deposition, protein levels could also be measured 
post-treatment. Protein would be extracted with RIPA buffer and western blot 
performed, staining for the different collagen proteins, allowing investigation of 
differential expression. Similarly, collagen levels could be determined by utilising 
highperformance liquid chromatography (HPLC). After 72 hrs, treated cells would be 
incubated at -80 oC for 24 hrs and then defrosted and scraped to disrupt the cell layer 
and ECM. Protein would then be precipitated in 67% (v/v) ethanol at 4 oC overnight, then 
hydrolysed via a 16 hr incubation in 6M hydrochloric acid at 110 oC. Hydrolysates would 
then be evaporated to dryness under vacuum in a centrifuge and re-dissolved in 
HPLCgrade H2O. Further derivatisation would be achieved, ultimately allowing samples 
to be run on HPLC. Collagen content would be quantified by measuring hydroxyproline 
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content (a component of collagen that makes up 12.2% w/w) with the hypothesis that 
both SIPS CM treatment and recombinant TGF-β1 treatment would significantly increase 
collagen deposition in NHLFs, providing further evidence that the characteristics of 
senescence play a central role in IPF pathology. Similarly, this series of experiments could 
be repeated using the CM from FHLFs, operating under the same hypothesis.   
  
4.3.4.  Interactions with the immune system  
  
One other area of substantial interest, that it was not possible to study in this 
investigation, is how epithelial-mesenchymal crosstalk links with the cells of the immune 
system. The immune system is extremely important in facilitating the pathology of IPF 
and understanding how fibroblasts mediate its function would be of interest. Firstly, it 
would be interesting to investigate how the CM of various culture conditions influences 
chemotaxis of macrophages, neutrophils or NK cells, with the hypothesis that there 
would be greater migration towards CM from FHLF and SIPS cultures, indicative of these 
cell types producing elevated levels of chemoattractant. As a preliminary study, this 
could be achieved by investigating the simple migration of THP-1 cells (a human, 
monocytic cell line) in Boyden chemotaxis chambers. Varying CM types would be placed 
in the basolateral chamber and immune cells seeded into the apical chamber. As a 
control for chemotaxis, certain chambers would also contain varying concentrations of 
recombinant CCL2, an archetypal chemoattractant, or volumes of unconditioned media. 
Similarly, to control for the effects of chemokinesis, pelleted THP-1s would also be 
resuspended in CM or chemoattractant-containing media. Across a period of 2-3 hrs, 
and at intervals of 30 min, the basolateral media would be extracted and the number of 
THP1s counted, providing information on chemotaxis.   
  
Extending investigations into the role of the immune system could also be performed, 
with IPF patient derived immune cells providing a good platform for investigation. When 
using these cells (for example circulating monocytes derived from IPF blood samples) in 
a similar chemotaxis experiment it may be expected that these cells fail to respond to 
chemotactic signals in the CM, indicative of immune alterations. Likewise, with patient 
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and control immune cells it would be interesting to investigate their ability to clear 
senescent cells. An inability of the immune system to clear senescent cells is potentially 
important in both the process of ageing and the pathology of IPF. Understanding 
clearance in vitro could be achieved by incubating SIPS with patient derived monocytes 
and counting SIPS cell number after incubation. It could also be achieved by transfecting 
the cells with fluorescent proteins. Immune cells that perform phagocytosis would then 
acquire a degree of fluorescence that could be measured via spectroscopy or 
microscopy. Again, it would be hypothesised that IPF derived cells lack the capacity for 
senescence mediated clearance and together this could provide another reason for the 
accumulation of senescent-like cells in IPF.  
  
4.3.5. Investigating senescence in vivo  
  
As discussed previously, the model of crosstalk used in this investigation doesn’t fully 
recapitulate the complex interactions between cell types of the human airways. The use 
of an in vivo model of fibrosis would provide a better opportunity to understand the 
significance of the fibrotic fibroblast phenotype and the role of senescence in IPF.  The 
classical method of investigating fibrosis in vivo involves the treatment of mice with BLM, 
either via intra-tracheal or intra-nasal instillation, or by intraperitoneal injection. In this 
model, a period of inflammation occurs with subsequent fibrosis establishing itself by 
around 21 days post-treatment. This method is normally performed using young mice (2 
– 3 months-old), however, as already discussed, age is an important driving force in IPF 
(Intro 1.2.4.4.), which is also underpinned by senescence (Intro 1.3.3.1.). Therefore, the 
use of aged mice (>18 months-old) would better suit this investigation. Developing a 
model of established fibrosis in aged mice would provide a useful platform for studying 
the involvement of senescence-like hallmarks in IPF. This could be achieved 
histologically, by comparing sections of normal and fibrotic lung (from both young and 
aged mice) for the classical markers of senescence such as p16 and p21, as well as 
performing staining for SA-βgal activity. Importantly it would be interesting to 
understand the cellular localisation of these markers, if expressed, hypothesising that 
they would be found most prominently in fibroblasts. Markers of SASP could also be 
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assessed, focusing in particular on IL-6 and CXCL8 expression, as well as the 
phosphorylation status and intracellular localisation of STAT-3, again hypothesising that 
there will be an enrichment for nuclear located pSTAT-3 in fibroblasts of aged, fibrotic 
mice. Taking a more global approach to gene expression could also yield interesting 
findings, giving a broader overview of senescence and fibrosis-associated pathways. This 
could be achieved by performing microarray analysis on whole lung homogenates from 
these mice. Though this restricts discrimination between cell types, subsequent gene 
ontology analysis could further identify pathways of interest.   
  
As well as investigating these aspects in animal models, it would also be interesting to 
repeat these histological and gene expression analyses on sections of human tissue, 
comparing sections from IPF patients and normal controls. Evidence for elevation of 
senescence markers, SASP proteins and JAK/STAT enrichment would provide a more 
compelling rationale for attempting to target senescence in vivo.   
  
4.3.6. Targeting senescence in in vivo models of IPF   
  
With an established model of BLM-induced fibrosis in aged mice, and the identification 
of hallmarks of senescence in both this model and patient samples, subsequent 
investigations would focus on pharmacological intervention, to either slow the 
progression of fibrosis or even reverse the pathology. The choice of therapeutic would 
primarily revolve around targeting the JAK/STAT signalling pathway, utilising Ruxolitinib. 
Other JAK inhibitors could also be used, such as Baricitinib and Tofacitinib, to validate 
the on-target effects of Ruxolitinib. Treatment could be administered via oral gavage or, 
following the method of Xu et al., administered in the animal feed 236. The regimen 
adopted by this study utilised a 60 mg/kg treatment for 10 consecutive days and this 
approach could be adopted in preliminary experiments. Inhibition of JAK/STAT signalling 
would be assessed via the same histological analysis as previously discussed. The effect 
of drug treatment would then be assessed across several parameters. Blood oxygen 
levels would be measured at multiple timepoints, with decreases in pO2 indicative of 
declining lung function. Post mortem, whole lungs would be digested and protein 
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expression of αSMA assessed via western blot, with increased expression indicative of 
myofibroblast propagation and a worsening of fibrosis. Similarly, whole lung collagen 
content could be quantified via HPLC, highlighting the extent of matrix deposition. 
Likewise, all of these markers of fibrotic progression could be corroborated by 
histological staining. Finally, survival curves could be plotted. It would be hypothesised 
that, compared to vehicle-treated animals, treatment with JAK inhibitors would lead to 
an attenuation of fibrotic progression across all of these parameters, ultimately resulting 
in increased survival rates in Ruxolitinib-treated mice. As well as controlling for drug 
vehicle, it would also be appropriate to compare the effects of these treatments to 
equivalent mice treated with Nintedanib and Pirfenidone. As these are the current 
therapeutic options for IPF patients it would be important to demonstrate that JAK/STAT 
inhibition has a greater effect on fibrotic progression than either of these drugs.   
  
 4.4  Concluding remarks  
  
In summary, this investigation into the role of epithelial-mesenchymal crosstalk has 
resulted in: the successful isolation, propagation and experimentation with primary 
HLFs, from both fibrotic and non-fibrotic patients; the establishment of a method of 
coculture, creating a system with which to test the direct effects of HLFs on epithelial 
cells; the successful induction of premature senescence in NHLFs and has proposed a 
new potential option for the treatment of IPF. This investigation has also opened up 
many novel avenues of research, providing rationale for the further investigation of 
senescence in vivo, both in mouse and human, and for the further investigation of 
JAK/STAT signalling and its role in the disease. Overall, the concluding point of this work 
is that key to the pathology of IPF is a breakdown in the relationship between fibroblast 
and epithelial cells, the result of fibroblasts acquiring a secretory phenotype that is 
proinflammatory and reflective of the characteristics of cellular senescence. Ultimately, 
this investigation has highlighted the complexity of IPF pathology, yet regardless, there 
is much promise for future research.     
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